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iAbstract
In 2008 Anthony Nolan opened the UKs first public umbilical cord blood (CB) bank
(Anthony Nolan Cell Therapy Centre, ANCTC) in which CB is stored for haematopoi-
etic stem cell (HSC) transplantation. Due to strict quality thresholds, the majority of
units are not suitable for transplantation. Therefore, ANCTC aims to create a Biobank
allowing these units to be stored for other purposes. To ensure cell products retained
high levels of viability and potency, this study optimised banking processes starting with
assessing the effects of transport conditions.It is essential that units are of the highest
possible quality upon arrival at ANCTC, yet there is no consensus as to the optimal
transport conditions of HSCs. Therefore, different fresh storage temperatures and the
effect of delaying cryopreservation was assessed on three sources of HSCs. Cells were
found to be better maintained at refrigerated temperatures and to avoid significant losses
in potency, delays in cryopreservation should be minimised to <24 hours for bone mar-
row and <48 hours for CB and mobilised peripheral blood stem cells. Based upon these
observations, ANCTC maintains all fresh samples at refrigerated temperatures and aims
to cryopreserve them within 24 hours of collection.
Banking cells involves cryopreservation and potentially long term storage of samples,
however, suboptimal cryopreservation conditions can result in reduced cell viability.
Cryoprotectants are used to reduce damage during the freeze and thaw stages of cry-
opreservation but they have been linked to toxic effects observed in cells. Dimethyl
sulphoxide (DMSO) was found to exhibit a dose-dependent toxic effect on CB and op-
timal concentrations were found to be between 7.5% and 10% (v/v). This study also
highlights the importance of minimising exposure to DMSO to <1hour prior to freezing
and <30 minutes post-thaw. In addition, the presence of 1% (w/v) dextran-40 in the
cryoprotective solution was found to be crucial to maintaining cell potency.
The Biobank would require the storage of specific pure cell populations. Tregs are vital
for the homeostasis of the immune system and have the potential to be used therapeu-
tically in autoimmunity or transplantation, thus making these cells an ideal candidate
for the Biobank. CB Tregs were found to have reduced suppressive abilities compared
ii
to their adult counterparts, due to lower levels of FoxP3 intensity and CD39 expression.
However, their higher frequency and a more defined CD25+ population facilitates the
isolation process. Two banking strategies were assessed, using both research and GMP
grade methods. Firstly banking an isolated pure Treg population which, post-thaw, the
cells maintained their phenotype but viability and suppressive ability was reduced. Al-
ternatively, mononuclear cells were banked and Tregs isolated post-thaw. This strategy
resulted in comparable isolation yields and purities compared to fresh cells, however,
improved viabilities and higher suppressive abilities were observed compared to the cry-
opreserved pure Treg samples (p=0.0012). Therefore, this banking strategy was found
to be more efficient.
Overall, this study has optimised banking procedures from the transport of fresh samples
to isolation and cryopreservation of pure cell populations. Therefore, this study has
laid the foundations for the creation of a Biobank within the ANCTC allowing the
distribution of cell products not only for research purposes, but also potentially for their
use in immunotherapeutic interventions.
I wish to dedicate this thesis to my parents,
for their love and endless support
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CHAPTER 1
INTRODUCTION
1.1 Haemopoiesis
Blood is highly regenerative; in an adult approximately one trillion (1012) cells are gen-
erated daily.1 Haemopoiesis (from the Greek αι˜µα (haima): blood and pioιι˜υ (poiein):
to make) is the process in which blood cells are formed. This process is continuous and
responds rapidly to haemorrhage, infection or hypoxia.2 The location of haemopoiesis
changes during foetal development; initially in the foetal yolk sac, six weeks after concep-
tion it moves to the foetal liver and spleen, after six months and onwards haemopoiesis
occurs in the bone marrow (BM).3
The haematopoietic system can be divided into four sections: haematopoietic stem cells
(HSC), progenitor cells (HPC), precursor cells and fully differentiated cells with spe-
cialised functions. During haemopoeisis HSCs divide, one daughter cell remains a HSC,
whilst the other daughter cell becomes a multipotent HPC committed to differentiation
along a specific lineage. Haemopoiesis continues along one of two lineages, myeloid or
lymphoid (shown in Figure 1.1).
1
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Figure 1.1: Overview of haemopoiesis through the common myeloid and lym-
phoid progenitors. CMP, common myeloid progenitor; CFU-GEMM, granulocyte-
erythrocyte-macrophage-megakaryocyte colony forming unit; MEP, megakaryocyte-
erythroid progenitor; CFU-Mk, megakaryocyte colony forming unit; BFU-E, ery-
throcyte burst forming unit; CFU-E, erythrocyte colony forming unit; CFU-GM,
granulocyte-macrophage colony forming unit; CFU-G, granulocyte colony forming unit;
CFU-M, macrophage colony forming unit; CLP, common lymphoid progenitor; NK,
natural killer cell. Figure created using SmartDraw and adapted from Stirewalt et al.4
1. Myeloid lineage
The common myeloid progenitor (CMP) is a granulocyte-erythrocyte-macrophage-
megakaryocyte colony forming unit (CFU-GEMM) which differentiate into a range
of different cells such as megakaryocytes which produce platelets; anucleated ery-
throcytes; monocytes which circulate the peripheral blood producing macrophages
and dentritic cells at the site of infection, and granulocytes, a collection of granu-
locytic cells with a lobed nucleus.
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Granulocytes consist of: short lived phagocytic neutrophils which are the most
abundant leucocyte (50 to 60%); eosinophils which have cytotoxic properties par-
ticularly against parasites (1-3% of leucocytes); basophils which play a role in the
inflammatory response and are the least common leucocyte (<2%); and mast cells
which function in a similar manner to basophils and play an important role in the
development of allergy.
2. Lymphoid lineage
The common lymphoid progenitor (CLP) differentiate into natural killer (NK) cells
which are cytotoxic cells essential for innate immunity, B cells which mature in
the BM and on activation form plasma cells which secrete antibodies and T cells
which mature in the thymus into CD8+ cytotoxic T cells or CD4+ helper cells
with the ability to differentiate further upon activation (described in §1.6.2.3).
1.2 Haematopoietic stem and progenitor cells
The concept of stem cells arose from studies by Till and McCullogh on the irradiation
of BM in mice.5 Stem cells are defined as undifferentiated cells with the capacity to
divide and self-renew indefinitely. More explicitly, upon cell division stem cells produce
an identical daughter stem cell (self-renewal) and a progenitor cell with a more limited
differentiation potential. Whereas cells cultured in vitro can divide only a finite number
of times (40-60 times depending on telomere length) prior to senescence,6 stem cells
are able to divide indefinitely due to the expression of telomerase.7 Stem cells can be
classified depending on the numbers of different cells they can differentiate into. This is
defined as cell potency and stem cells can be divided into four different groups.
1. Totipotency
These are the most versatile of the different stem cells and only include the fertilised
egg (zygote) and the first few divisions in embryonic development. These cells
have the potential to divide and differentiate into any cell type found within the
body including extra-embryonic tissues such as the placenta. Beyond the first few
divisions the cells specialise into pluripotent stem cells.
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2. Pluripotency
Like totipotent stem cells, these cells can give rise to all three germ layers (endo-
derm, mesoderm and ectoderm) and therefore, can form any cell found within the
body, however, they do not have to potential to differentiate into the cells required
to form the placenta and are therefore, not totipotent.
3. Multipotency
Descendants of pluripotent cells, these cells are less plastic and can only differen-
tiate in to cells along a certain lineage, for example HSCs which produce all the
different types of blood cells.
4. Unipotency
These cells have to ability to differentiate into only one specific cell type and are
often referred to as progenitor cells. For example the erythroid progenitor cells
(BFU-E and CFU-E) have only the potential to differentiate into erythrocytes.
1.2.1 Characterisation of HSC and HPCs
The cluster of differentiation (CD) are a series of protein molecules that are used as
markers to identify specific cell populations. CD molecules are often functional and can
be receptors or ligands or involved in cell adhesion and homing.8,9 No single marker for
identifying all HSCs has been identified. This is made difficult as markers are gained
and lost as the cell differentiates. CD34 was the first marker to be identified on HSCs
and is currently the most commonly used marker for their identification and during
enrichment protocols.10 CD34 is believed to play a role as an adhesion molecule through
the attachment of HSCs to the BM extracellular matrix or to stromal cells.11 The CD34+
population include the majority of cells with the ability to repopulate the haematopoietic
system, all of the long-term culture initiating cells (LTC-ICs) and many of the Colony
Forming Units (CFUs).10 This CD34+ population contains a mixture of HSCs and HPCs
which can be differentiated by their different levels of expression of other markers. There
is however, evidence of primitive CD34− cells with HSC properties which can generate
CD34+ in vitro and in vivo.12,13 These CD34− cells can be further characterised through
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expression of CD133 and absence of CD38 and lineage-specific markers. CD133 (AC133)
expression patterns in HSCs overlap with the expression of CD34; CD133 is expressed
on the majority of CD34+ cells including the more primitive stem cells and the CD34−
HSCs.14,15 HSC and HPCs do not express the markers associated with differentiated
blood cells (lineage markers or lin). These markers can include CD2, CD3, CD4, CD7,
CD8, CD10, CD11b, CD14, CD19, CD20, CD56, CD235a and identify T cells, B cells,
NK cells, monocytes and granulocytes.
1.2.2 Sources of HSCs
1.2.2.1 Bone Marrow as a source of HSCs
In an adult human haemopoiesis occurs within the bone marrow (BM), this is a soft
spongy highly vascularised tissue located in the interior of bones. There are two types
of BM; the medulla ossium rubra (red marrow) in which the haematopoietic cells reside
and medulla ossium flava (yellow marrow) which consists mainly of fat cells. At birth
all BM consists of red marrow, the proportion of yellow marrow increases with age and
the ratio between the two is roughly half and half in adults. However, at times of severe
blood loss, the yellow marrow can convert back to red marrow to increase blood cell
production through haemopoesis. Schofield in 1978 proposed the concept of a stem
cell niche within the BM, this is compromised of stromal cells which associate with the
HSCs and provide specific signals that help maintain their function.16 The location of
the HSCs within the niche remains controversial and it has been suggested that there is
more than one niche between which the HSCs migrate between in response to injury or
certain migration signals.17
HSC harvests from BM are performed under general anaesthetic, the cells are taken
from the red marrow in the iliac crest of the pelvis. The needle can be repositioned after
each aspiration in order to isolate the required number of cells. CD34 has been found
to be expressed in 1-4% of the nucleated cells extracted from this site.10
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1.2.2.2 Peripheral blood as a source of HSCs
In response to specific signals HSCs can migrate from the BM to the blood stream
(mobilisation) and back to the BM (homing). CD34 is expressed in approximately
0.06% of nucleated cells found within the blood periphery.18 However, it is possible
to mobilise HSCs from the BM into the peripheral system. This is achieved through
administering the cytokine granulocyte colony-stimulating factor (G-CSF) over three or
four days. This increases the percentage of CD34+ cells to >1%, these cells can then be
harvested by leukapheresis.
1.2.2.3 Cord blood as a source of HSCs
CB has been found to contain similar CFU-GM numbers compared to BM and is con-
sidered to be a good source of HSC and HPCs.19 CB can be collected either in utero
(during the third stage of labour prior to delivery of the placenta) or ex utero from
vaginal or caesarean deliveries. A large needle is inserted into the umbilical vein and the
blood drains into an attached collection bag containing anticoagulant. The procedure is
non-invasive and there is no harm to the mother or baby. From each placenta a volume
of ∼100ml can be collected. As the volume of blood collected is limited to what remains
in the placenta and cord after it has been clamped, CB collections tend to yield lower
cell counts compared to BM and PBSC collections.
1.3 HSC Transplants
HSC transplants (HSCT) have routinely been used to reconstitute the haematopoietic
system after high dose chemotherapy.20,21 Patient conditioning treatments originally
involved high doses of chemotherapy and total body irradiation leading to BM ablation
destroying tumour cells and creating space in the stem cell niches within the BM for the
transplanted HSCs to home to. Since a graft-versus-leukemia (GvL) effect was observed
during autologous transplants,22 the intensity of the pre-transplantation conditioning
has been reduced. Levels are high enough to avoid rejection of the transplanted cells,
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but allow the GvL effect to eliminate the tumour cells. This new conditioning regime
may lead to higher rates of relapse, but the mortality associated with transplantations
has been reduced significantly.23
The first HSCTs were reported in 1959 in which two patients with leukaemia received
BM cells from identical twins.24 HSCTs are currently used to treat a range of malig-
nant haematological diseases and congenital BM disorders. According to the Worldwide
Network for Blood and Marrow Transplantation (WBMT) the one millionth HSCT was
performed in December 2012.25
HSCTs can be performed using cells from the patient (autologous) or from a donor
(allogeneic). Autologous transplants involves the harvesting of HSCs from the patient’s
own BM or PBSCs; these cells are cryopreserved and stored until the patient completes
the pre-transplantation conditioning regime, at which point the cells are thawed and
re-infused. Allogeneic transplants require a volunteer to donate their HSCs to a patient.
High levels of human leukocyte antigen (HLA) matching is required between donor and
patient to avoid graft-versus-host-disease (GvHD). As all the HLA genes are located on
one chromosome there is a 25% chance a sibling will be a match, therefore, many patients
will not find a suitable donor within their family. In the UK alone there are currently
1,800 patients searching for a match.26 The first successful HSCT from an unrelated
donor occurred in 1973 in New York. This led to the creation of the first register of people
willing to donate their HSCs to strangers in 1974 called the Anthony Nolan Bone Marrow
Register∗. There are currently over 22,000,000 donors from 72 different registers across
52 countries registered with the Bone Marrow Donors Worldwide (BMDW).27 With these
large numbers of volunteers willing to donate, caucasians have a 60% chance of finding
a donor with suitable levels of HLA matching.28 However, patients with uncommon
HLAs or those from ethic minorities have a reduced chance of finding a suitable donor.
In these cases, a haploidentical sibling or mismatched unrelated donor may be used.
These transplantations are associated with an increased risk of GvHD and samples are
∗Anthony Nolan was born in 1971 with the rare condition Wiskott-Aldrich syndrome for which
the only cure was HSCT. With no suitable match found within his family his mother, Shirley Nolan,
established the first BM register which she named after her son. Sadly a suitable donor could not be
found for Anthony Nolan who died in 1979 aged eight.
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often depleted of T cells prior to infusion leading to increase risk of graft rejection, and
disease relapse as the GvL effect is reduced.29,30
The European Group for Blood and Marrow Transplantation (EBMT) conducted a
survey between 1990 and 2010 in 654 transplant centres.31 Over this time period, 30,012
patients received HSCTs, 59% were autologous and 41% allogeneic. The EBMT reported
that the overall survival 5 years after HSCT is approximately 53%, and 44% after 10
years.
1.3.1 Graft-versus-host-disease
GvHD is a major complication that can arise during HSCT. GvHD is initiated when
donor T cells raise an immunological response against the host and is a significant cause
of mortality and morbidity following allogeneic HSCTs. GvHD occurs in approximately
60% fully HLA matched HSCTs,28 but the frequency and severity increases greatly if
there is an HLA mismatch between donor and host.32,33 There are two forms of GvHD
with distinct clinical manifestations:
1. Acute GvHD
Usually observed within 100 days after transplantation as the HSCs engraft, but
can occur later if a reduced intensity conditioning regime is used prior to HSCT.
Acute GvHD (aGvHD) targets the skin resulting in a maculopapular rash, liver,
gastrointestinal tract and occasionally the eye and oral mucosa.34 Severity of
aGvHD is graded (0-IV) based on factors such as the levels of bilirubin and diar-
rhoea and the percentage of the body surface covered by the rash.35 Patients with
grade I-II aGvHD have a long term survival rate of >80% patients with grade III
or IV aGVHD tend to have poor outcomes with long term survival probability of
30% and <5% respectively.36 Patients are treated with a combination of immuno-
suppressive drugs such as cyclosporine and methotrexate.37 Approximately 50%
of patients with aGvHD will also develop chronic GvHD (cGvHD).38
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2. Chronic GvHD
Occurring more than 100 days post-HSCT, there may be some overlap period
between aGvHD and cGvHD occurrence. However, cGvHD is a distinct syndrome
with features similar to autoimmune disorders and can develop even when the
patient did not have aGvHD. Many organs can be affected by cGvHD including
the skin, liver, eyes, gastrointestinal tract and the lungs. cGVHD is a major cause
of long term morbidity and mortality in patients and has a significant effect on
the quality of life after HSCT. However, cGvHD can also lead to an increase in
GvL. As in aGvHD, cGvHD is also treated with immunosuppressive drugs, but
these drugs are required for much longer periods of time extending over months
to years.
1.3.2 The use of CB in HSCT
The use of CB to treat cancer was first reported by Ende in 1963. The patient suffered
from lymphangiosarcoma and had previously been treated with surgery, chemotherapy
and radiation. With no further treatment options, 17 CB units were infused (untested
for HLA compatibility) with the hope that ‘youth factors’ could inhibit the sarcomas.
Although the patient initially showed improvement, she died within a year of the trans-
plant.39 In 1966 a patient with myelogenous leukaemia was given 500ml CB, assessment
of the patients blood after the transplant discovered only the donors cells remained,
which without the knowledge that CB contained HSCs was not thought to be feasible.40
CB was used to treat leukaemia again in 1970 on a 16 year boy with acute lymphoblastic
leukaemia. The patient received eight CB units untested for HLA compatibility. The pa-
tient also received continued treatments with chemotherapy and remained in remission
for nearly one year.41
In 1989 it was discovered that CB was a source of CFU-GM, BFU-E and CFU-GEMM
and could be used as an alternative to BM for HSCT.19 The first successful cord blood
transplantation was performed the same year in Paris by Gluckman et al :42 Haematopoi-
etic reconstitution was achieved in a 5 year old boy with Fanconi anaemia through a
cord blood transplant from his HLA-identical sister. This patient remained in remission
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and is still alive today. In 1996, the first unrelated mismatched CB transplantation was
performed in a child43 and in an adult.44 Since then thousands of HSCTs using CB have
been performed.45
The main advantage of using CB over adult sources of HSCs is the almost immediate
availability of a unit, due to CB banks which store samples at cryogenic temperatures.
On average the transplant centre can receive a CB unit 25-36 days earlier than a do-
nation from an adult donor.46 These units are HLA typed and tested for bacterial
and viral contaminations prior to freezing. Therefore, CB units are available when the
patient requires them without inconveniencing a donor. A reduction in the frequency
and severity of GvHD has been noted when using CB for transplants rather than adult
sources of HSCs. However, the GvL effect remains. This allows units with only partial
HLA matching of 4/6 to be tolerated after transplantation, making it more likely to find
a suitable match for a patient.47 Other advantages include the ease of procurement with
no risk to the donor, a reduced likelihood of viral infections being transmitted and no
need to maintain databases of potential donors who may become untraceable or unable
to donate for medical or personal reasons.
The CD34+ cell count of a unit being transplanted has been linked to time to engraft-
ment.48 Therefore, as CB units contain lower cell doses compared to BM and PBSC,
the major disadvantage of using CB in transplants are the increase in time to platelet
and neutrophil engraftment.49 In an attempt to overcome this, two CB units from dif-
ferent donors can be simultaneously infused into a patient.50,51 Engraftment is usually
achieved by only one infused unit, the reason why one CB unit dominates over the
other is unknown.52 However, there is one reported case of long term haematopoietic
reconstitution with substantial contributions from both CB units infused.53
1.4 CB banking
In 2009 it was reported that over 20,000 CB transplants have been performed45 and
there are currently over 600,000 CB units in the BMDW database from 47 CB banks in
33 countries.27 The first CB bank (CBB) was created in New York in 1993.54,55 This
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involves the long term storage of CB samples under cryogenic temperatures. Broxmeyer
et al reported that to avoid cell losses, in CB which already has reduced counts compared
to BM, samples should be cryopreserved as whole samples.19 However, Rubinstein et
al suggest reducing the volume and increasing the cell concentration would allow for
more efficient storage and avoid the high costs for liquid nitrogen usage.55 This group
developed a protocol involving the addition of hydroxyethyl starch (HES) to the blood
causing the erythrocytes form a rouleaux which along with some plasma can be removed
after centrifugation to reach the required volume.
Two types of CB banks exist; private banks in which the stored CB is for exclusive use by
the family who pay for the service, or public banks in which CB samples are stored with
the potential to be released to any patient that requires them. The odds of requiring
an autologous transplant has been reported to be between 1 in 1000 and 1 in 200,000.56
In addition to this, autologous transplants are often unsuitable as most conditions that
require a transplant would already exist in the patient’s CB unit. Therefore, many
physicians who perform paediatric HSCTs recommend against the private storage of
cord blood for autologous use.57
1.4.1 CB bank regulations
Three European Union directives (2004/23/EC,58 2006/17/EC59 and 2006/86/EC60)
were established to ensure the quality and safety of human tissues and cells is maintained
from collection to their use in therapy. The relevant countries have added these directives
to national legislation, designating competent authorities to implement them.61 Within
the UK, the collection and banking of CB (regarded as a tissue) is regulated by the
Human Tissue Authority (HTA) under the Human Tissue (Quality and Safety for Human
Application) Regulations 2007.62 The HTA has produced guidance documents for the
procurement, processing, storage and distribution of CB.63 This document states that
processing procedures must be validated either by the establishment or based on data
from published studies and these validated methods must be documented in Standard
Operating Procedures (SOPs).
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CB banks also have the opportunity for voluntary accreditation programs by adhering
to standards developed by consensus of world-renowned experts within the field. The
Foundation for the Accreditation of Cellular Therapy (FACT) is a non-profit corporation
co-founded by the International Society for Cellular Therapy (ISCT) and the American
Society of Blood and Marrow Transplantation (ASBMT). FACT establishes standards
for high quality medical and laboratory practice in cellular therapies and promotes
continued progress within this field. In 1997, FACT collaborated with The International
NetCord Foundation (NetCord), a non-profit international organisation of the largest
CB banks, and together published the first NetCord-FACT International Standards for
Cord Blood Collection, Processing, Testing, Banking, Selection and Release with new
editions published approximately every three years. These NetCord-FACT standards are
universally recognised by transplant programs and are based upon published medical
evidence whenever possible. When published data is not available, requirements are
based upon accepted scientific theory.
1.4.1.1 Good Manufacturing Practice
Good Manufacturing Practice (GMP) systems ensure products are consistently produced
and controlled in accordance to relevant quality standards.
Within the EU, there are two directives describing the principles and guidelines of GMP
for medicinal products: 2003/94/EC applies to medicinal products for human use64 and
Directive 91/412/EEC for veterinary use.65 GMP guidelines are not a series of instruc-
tions on how to manufacture products, instead they are a series of general principles
which must be applied to the manufacturing process. GMP guidelines are regularly
revised and therefore, GMP is often referred to as current GMP or cGMP.
GMP covers all aspects of both production and quality control. Production should be
clearly defined, controlled and performed in accordance with pre-established instruc-
tions and procedures. These procedures should be validated to ensure consistency and
compliance with pre-defined specifications and critical process regularly re-validated.
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GMP facilities are regularly inspected by competent authorities using Quality Risk Man-
agement principles. Failure to comply with GMP standards whilst making a medical
product can result in product recall, fines and even custodial sentences.
1.4.2 Biobank
CB is being increasingly used over BM and PBSC in haematopoietic stem cell trans-
plants. Once considered to be a waste product from birth, CB is now collected from the
umbilical cord and placenta and sent to cord blood banks where it is processed (involv-
ing a volume reduction procedure), cryopreserved and stored until it is required for a
transplant. One such cord blood bank was established at Nottingham Trent University
by Anthony Nolan, the charity that established the worlds first bone marrow register.
Anthony Nolan’s Cord Blood Bank (Anthony Nolan Cell Therapy Centre, ANCTC)
has instigated high quality thresholds for CB units in order to be banked for potential
HSCT. Examples of these quality thresholds include a minimum total nucleated cell
(TNC) count of 1.2×109 and a minimum CD34+ count of 3.2×106 cells. Units that do
not meet these requirements can be used for other purposes including research. An-
thony Nolan aims to create a research grade Biobank within the CB bank where the
research grade units can be cryopreserved and stored either as whole blood, isolated CB
mononuclear cells (CBMC) or pure isolated cell types. These CB cellular fractions can
be stored until they are required by researchers for their projects.
1.5 Cryopreservation
A Biobank requires the cryopreservation and long term storage of samples. Successful
cryopreservation of mammalian cells was first documented by Polge et al in 1949 when
they successfully revived bull spermatozoa which had been frozen in glycerol.66 The
techniques used in 1949 were used again by Barnes et al in 1955 in the cryopreservation of
mouse spleens which upon thawing were still viable and functional and could regenerate
the haematopoietic system in irradiated mice.67 Over the years the techniques of HPC
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cryopreservation were further developed through the assessment of different cooling and
thawing rates and the use of different cryoprotectants.68–79
1.5.1 Risk to the cells during cryopreservation
During the process of cryopreservation the highest risk to the cells are during freezing and
thawing; no further damage should occur during the storage period if the temperatures
are low enough to halt cell metabolism.80,81 This can be achieved through storing the
cells below temperatures of -130◦C which has been shown to solidify the storage medium
sufficiently to halt metabolism.82 As a result of this, lower storage temperatures of
-196◦C have resulted in higher post-thaw recoveries than samples stored at -70◦C.83,84
Despite the DNA-repair system being inactive, background radiation does not appear
to have any effect on cells undergoing long term storage.85
1.5.1.1 Risk to the cells during freezing
The rate of cooling during freezing can have a significant impact on cells (Figure 1.2).
Cooling the cells slowly favours extracellular ice formation where thermal exchange with
the freezing chamber is faster and the likelihood of a nucleation point is higher.82,86 The
removal of liquid water results in an increasing salt concentration in the extracellular
space, this increases the osmolality and pulls the water out of the cells resulting in their
shrinkage.87 However, cells can be cooled too slowly; if the cells are maintained at sub-
zero temperatures before freezing they are exposed to high concentrations of solutes for
prolonged periods of time. This can cause the cells to become dehydrated and shrink to
the point of damaging their membranes.88 This is known as the solutions effect87,89 and
leaves the cells more susceptible to thermal shock and mechanical stress caused by ice
formation.87,90,91 If cells are cooled rapidly, ice crystals will form in both the extra- and
intra-cellular regions as insufficient water is removed. This intracellular ice damages the
internal structure of the cells and membrane leading to cell death.92 A cooling rate of
1-3◦C minute−1 has been shown to be optimal when freezing BM.93
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Figure 1.2: The effect of water on cells during cryopreservation: Freezing (A) Rapid
cooling of cells results in the formation of ice in the extra- and intra-cellular regions.
Intracellular ice crystals cause damage to the membrane resulting in cell lysis. (B) Slow
cooling of the cells results in the formation of extracellular ice increasing extracellular
solute concentration leading to eﬄux of water and cell shrinkage. Diagram created
using SmartDraw.
The duration of the phase transition, when the water solidifies releasing its latent heat,
correlates with cell mortality.72,94 This is an important step of the freezing process which
needs to be controlled, especially when freezing larger samples.86 The first controlled
rate freezer (CRF) apparatus in which samples are placed inside a chamber and liquid
nitrogen pumped in intermittently to reach the required temperature was developed by
Hill et al.95 The use of a CRF ensures the freezing conditions are reproducible through
a series of defined temperature changes (the freezing protocol currently used at ANCTC
is shown in Figure 1.3). The chamber of the CRF (represented by the red line in the
graph) is cooled at a rate of 1◦C minute−1 until a temperature of -10◦C is reached,
at this point the heat of fusion is liberated from the sample. To compensate for the
release of heat and avoid rewarming the sample (represented by the green line) the
temperature of the chamber is reduced by -20◦C minute−1 reaching -50◦C and then
rewarmed back to -18◦C to prevent the sample from cooling too quickly once the latent
heat has been compensated for. The temperature of the sample is decreased further and
at an increasing faster rate down to the target temperature of -120◦C. At this point the
Chapter 1 Introduction 16
sample is removed from the chamber of the CRF and transferred to the vapour phase
of liquid nitrogen storage tanks (maintained at <-170◦C).
Figure 1.3: Control Rate Freezer (CRF) freezing program used at ANCTC
1.5.1.2 Risk to the cells during thawing
The speed of thawing of a sample has also been shown to be critical to the viability of
cells (Figure 1.4). A rapid thaw, involving immersing the sample into a water bath at
37◦C, has been shown to be less damaging to cells as ice crystals are thawed quickly
preventing them from joining into larger crystals leading to structural disruption.74 As
the ice crystals melt forming liquid water, the salt concentration in the extracellular
region is reduced resulting in an influx of water into the cells causing them to swell
which can lead to lysis.
1.5.2 Cryoprotectants
Cryoprotective agents are used during cryopreservation to prevent the damage caused
by the formation of ice and by changes in osmotic pressure.
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Figure 1.4: The effect of water on cells during cryopreservation: Thawing. (A) Slow
thawing of cells leads to ice crystals combining into larger crystals causing membrane
damage. (B) As the ice melts the salt concentration in the extracellular portion of the
sample decreases leading to the influx of water causing the cell to swell potentially to
the point of damage. (C) Rapid dilution of the cryoprotectant post-thaw exacerbates
the osmotic pressure, whereas slow dilution allows equilibrium to be reached. Diagram
created using SmartDraw.
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There are two types of cryoprotectants:
1. Intracellular or penetrating cryoprotectants - penetrate the cell preventing forma-
tion of ice crystals within the cell (e.g. glycerol, dimethyl sulphoxide (DMSO)).
2. Extracellular or non-penetrating cryoprotectants - work by further increasing the
solute concentration in the extracellular region to cause further removal of wa-
ter from the cells and reduce the possibility of intracellular ice formation96 (e.g.
hydroxyethyl starch (HES) and dextran).
1.5.2.1 The use of DMSO in cryopreservation
Initially glycerol was used as a cryoprotectant before DMSO was introduced as an al-
ternative option97,98 and shown to be superior in the cryopreservation of HPCs.99,100
DMSO is a naturally occurring polar aprotic solvent which acts by forming hydrogen
bonds with extracellular water, thereby slowing the formation of ice crystals and reducing
the osmotic pressure and solution effect.101 The ease at which a cryoprotectant can
pass through the cell membrane is important in cryopreservation. Cryoprotectants that
pass through the membrane slowly (e.g. glycerol) or rapidly (e.g. DMSO) bind to
the water molecules in the cytoplasm blocking the eﬄux of water preventing cellular
dehydration and shrinkage.102,103 These cryoprotectants can also prevent the formation
of intracellular ice by reducing the probability of its nucleation.96 It has also been
suggested that DMSO works by stabilising the tertiary structure of protein and lipid
complexes.72,104 The ability of a cryoprotectant to penetrate the membrane is also
important during the thawing of a sample. The melting of the extracellular ice crystals
causes an osmotic gradient, water enters the cell and the cryoprotectant needs to diffuse
out of the cell rapidly to avoid the cell from swelling.
1.5.2.1.1 Toxic effects of DMSO in patients
DMSO is believed to have dose-dependent toxic effects and has been linked to adverse
reactions during HSCT.105–107 Some of the minor side effects from transplantation such
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as nausea and abdominal cramps are believed to be caused by the intravenous infusion
of a chilled sample.105 A survey assessing current practices in the use of DMSO at
transplant centres found a wide range of different concentrations were used (2.2-20%),
with a trend of higher incidence and severity of adverse reactions in patients who had
been infused with larger doses of DMSO.102 DMSO and its metabolites dimethyl sul-
fide and dimethyl sulfone have been found in the plasma of patients for up to 48 hours
after infusion.108,109 These compounds have been linked to side effects including cardio-
vascular complications,106,110,111 respiratory problems,112,113 anaphylactic reaction,102
renal dysfunction114 and neurological toxicity.115–118 It has also been observed that the
odour of DMSO from patients has caused headaches and gastrointestinal reactions in
oncology nurses.109 Toren et al suggested DMSO may have some anti-tumour effects
upon infusion by inducing the differentiation of malignant cells,119 however there has
never been any further support for this concept. Despite the removal of DMSO prior to
infusion, adverse reactions can still occur.120 Therefore, other factors must contribute
to the adverse reaction and in this regard the number of granulocytes infused has been
found to correlate with the level of severity of the adverse reactions.121
1.5.2.1.2 Toxic effects of DMSO to the cells
As well as toxicity in patients, DMSO may also cause cellular injury. Douay et al
report a progressive loss of CFU in BM after exposure to 10% (v/v) DMSO at 4◦C with
a recovery of 24% after 30 minutes decreasing further to 10% after 3 hours.122 However,
Rowley et al found no toxic effects of 10% DMSO to BM HPCs at 4◦C or 37◦C, although
they observed a loss in HPCs when higher concentrations of cryoprotectant were used
or the exposure time extended.123 Branch et al found no significant losses in CFU when
BM remained in 8% (v/v) DMSO for up to 2 hours after thawing.124
DMSO has been shown to induce apoptosis by interacting with programmed cell death
receptors and their ligands.125,126Another suggested mechanism of DMSO toxicity is
via denaturation of proteins caused by the formation of hydrogen bonds with the cry-
oprotectant,127 in particular with fructose dehydrogenase resulting in the impairment of
glycolysis.128
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The effects of freezing and thawing may not affect all cells equally, as CD34+ cells have
been shown to be more resistant to the damage caused by cryopreservation than other
nucleated cells.129 It has also been observed that within the CD34+ population the
CD38− early progenitor cells demonstrate higher resistant to the effects of cryopreser-
vation than more mature CD38+ cells.130
Current CB cryopreservation protocols were established to maintain HPC viability.
Granulocytes are much more susceptible to cooling and freezing injury compared to other
cells and are not preserved efficiently under these conditions. Post-thaw they lyse releas-
ing nucleoprotein and lysosomal enzymes which promotes clumping of the sample.131,132
Different freezing protocols have been developed in order to successfully cryopreserve
granulocytes these involve combining DMSO with HES as cryoprotectants.133,134
Also, the toxic effects of DMSO may not be equal across different cells, as Douay et al
found higher levels of toxicity in the more mature BM precursor cells122 and Hiroshi Ara
et al also found the more mature BFU-E to be more sensitive than CFU-E.135
The speed of DMSO addition and removal is believed to be a contributing factor to cell
death, as rapid addition may cause the cells to shrink below their critical minimal volume
due to an abrupt increase in osmotic pressure.136,137 In order to avoid damage caused
by osmotic shock and the latent heat released, slow addition of a pre-cooled DMSO
solution has been suggested.55,122 However, this has been contradicted by Meyer et al
who report improved post-thaw quality after ‘fast’ addition of DMSO to CBMC.138 In
contrast, Radke et al found no difference in the percentage of apoptotic CD34+ cells
when comparing DMSO addition speeds in fresh CB.139
1.5.2.1.3 DMSO concentrations
A survey to EBMT (European Society for Bone and Marrow Transplantation) centres
on the various uses of DMSO for stem cell transplantation showed that a wide range
of concentrations were used when cryopreserving cells (2.2-20% v/v)with 10% being the
most commonly used.102 As DMSO has been shown to be toxic to patients in a dose re-
lated manner, the use of lower concentrations to prevent this has been suggested.105–107
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However, this will also have an effect on the ability to cryopreserve viable cells and
CFUs.
It has been reported that the use of 5% (v/v) DMSO is the optimal concentration and
results in higher post-thaw CFU recoveries.140–142 However, other groups have found no
significant difference in viable cell and CFU recovery between the use of 5% or 10%.143–145
The effect of a reduction in DMSO concentration on transplant outcomes was evaluated
by Akko¨k et al, and it was reported that the concentration of DMSO is independent
of the time to neutrophil and platelet engraftment.146 In addition, the proportion of
adverse reactions has been found to be higher when using 10% than 5% (19.1% versus
6.8% respectively).143
7.5% (v/v)DMSO has been reported to be the optimal concentration for CFU recovery in
PBSC samples, despite the TNC recovery being higher when using 10%.147 Donaldson et
al also report 7.5% (v/v) DMSO to be optimal concentration for cryopreservation with
higher CD34+ recoveries. They observed 5% to be as effective as 10%, and concentrations
below resulted in very low recoveries of CD34+.148 However, concentrations as low as
2.2% have been shown to engraft successfully in patients undergoing HSC transplants,
although the post-thaw cell recoveries are not reported.149
Combinations of cryoprotectants have also been used to reduce the concentration of
DMSO required. Adding the non-penetrating cryoprotectant HES along with DMSO
has been shown to reduce the post-thaw clumping caused by granulocytes.150 In PBSC
samples, the use of DMSO and HES together has been shown to result in similar151 if
not higher152,153 CFU recoveries. However, there is no apparent advantage in combining
the use of HES with DMSO when cryopreserving CB.148
1.5.2.1.4 Removal of DMSO post-thaw
Due to the toxic effects observed to cells and patients, the removal of DMSO through a
wash procedure has been suggested. This involves a slow dropwise dilution with an equal
volume of a dextran-40 and albumin solution to reduce osmolality (Figure 1.4C).55,154
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Washing DMSO from samples post-thaw is a time consuming procedure and can be tech-
nically difficult with large cell losses reported.55,155 Therefore, automated cell washing
devices have been developed to remove DMSO post-thaw under a closed system and
these include the Cytomate,156 SEPAX157 and Cobe.158
However, washing and spinning of thawed BM has been shown to result in cell clumping
leading to losses.159 To avoid clumping of the cells post-thaw, DNase is often added
to the washing solution to break down free DNA and disperse any clumps.148,160,161
However, Bayer et al however found that DNase did not help to prevent clumping.162
There are contradicting reports on the effect that washing samples has on engraft-
ment speed; some report no significant difference between washed and unwashed sam-
ples,163,164 Kurtberg et al found washing samples facilitated engraftment speed43 and
Akkok et al found washing led to an increase in platelet engraftment by two days and
recommend washing to be necessary only for patients with a high risk of DMSO tox-
icity.165 Therefore, some transplant centres will directly infuse thawed HPCs into a
patient86 despite documented evidence of toxic effects caused by infused DMSO,166 and
others administer the samples in fractions to prevent toxicity.167
1.5.2.2 The use of dextran-40 in cryopreservation
Dextran is a complex branched polysaccharide comprised of glucose units of varying
lengths. Dextran has multiple applications including its use in surgery,168 vaccines,169
ophthalmology170 and as a blood volume expander where it can be used to replace lost
blood when a donor is not available.171
Dextran is also used as a non penetrating cryoprotectant. Studies assessing the use of
dextran when cryopreserving erythrocytes observed that the optimal concentration was
dependent upon the rate of cooling during freezing, with 25-40% (w/v) dextran being
optimal for a drop of 1◦C second−1 whereas 15-21% (w/v) was found to be optimal for
a cooling rate of 4-8◦C second−1.172–174
Rubinstein et al state that in preliminary experiments the presence of 1% (w/v) dextran-
40, in combination with 10% (v/v) DMSO, improved the post-thaw viability of CB
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leucocytes by 3-10%.55 Based on this article, Dextran-40 has been commonly used in
combination with DMSO when cryopreserving CB. However, this data has never been
published.
Available is multiple molecular weights up to 2,000 kDa, larger dextran molecules of 60
kDa or more are poorly excreted from the kidney and remain in the blood until they are
metabolised into glucose and water.175 Although 70% of dextran-40 (molecular weight:
40 kDa) is excreted by the kidney within 24 hours of intravenous infusion, it has still
been linked to cases of toxicity during HSCT.176,177 Therefore, it has been suggested
that dextran-40 should be removed from the cryoprotective solution or that alternative
cryoprotectants should be considered.176
1.6 An overview of immunology
The role of the immune system is to protect from infectious microorganisms though
the recognition of pathogens and then react to eliminate them. The immune system
is composed of two components; the innate and adaptive response. The innate system
is non-specific, fast acting, but short-lived. In contrast, the adaptive system is highly
specific and generates immune memory which improves the capacity of the host to
eliminate subsequent infections from the same pathogenic challenge.
1.6.1 Innate immunity
Innate immunity provides the first line of defence against pathogens and consists of phys-
ical barriers (epithelial surfaces including the skin) and chemical substances (for example
the low pH within the stomach or microbial substances such as lysozyme in saliva). Con-
sidering the human body is exposed to high numbers of potentially infectious agents,
yet rates of infection are low, it can be assumed that these barriers prevent the vast
majority of pathogens from entering the body. Once an infectious agent passes into the
tissues, it is immediately recognised by phagocytes such as the macrophages, neutrophils
and dendritic cells (DC) which engulf and destroy the invading microorganism, along
with natural killer (NK) cells, through cytotoxic actions.178 Activation of these cells
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releases cytokines (such as IFN-γ, TNF-α, IL-1, IL-6, IL-8 and IL-12) which initiates
inflammation.178 Inflammation is characterised by calor (heat), rubor (redness), tumor
(swelling) and dolor (pain). These changes are due to the increased rate of blood flow to
the site and an accumulation of fluid, proteins and more immune cells from the blood.
An important component of the innate system are the Toll-like receptors (TLR) found
on phagocytic cells.179 Activation of the TLR stimulates the production of cytokines,
such as TNF-α and the expression of the co-stimulatory molecules B7.1 (CD80) and
B7.2 (CD86), thereby facilitating the adaptive response.178
1.6.2 Adaptive immunity
The innate immune system is non-specific, defending only against pathogens with cer-
tain molecular patterns that are not found on host cells, and its ability to defend against
the same pathogen repeatedly is unaltered. In contrast, the adaptive immune system,
although slower to respond, leads to a long-lasting memory of specific pathogens and
allows more rapid protection against repeat encounters.180,181 Induction of adaptive im-
munity begins when an antigen presenting cell (APC), such as a DC, ingests a pathogen
and displays small fragments of it’s peptides on the major histocompatibility complex
(MHC) on the cell surface.182,183 This activates the APC which up-regulates its ex-
pression of co-stimulatory molecules and migrates to the lymph node, where it may
come into contact with lymphocytes. The adaptive system can be separated into two
parts, humoral or cell-mediated immunity which are performed by B cells and T cells
respectively.
1.6.2.1 Humoral response
The humoral response involves B cells, so called because they are produced and mature in
the bone marrow. na¨ıve B cells circulate the secondary lymphoid tissues and peripheral
blood where they are activated after encountering a specific pathogen and a helper-T
cell activated by the same antigen.184 Upon activation, B cells mature into plasma
cells which secrete large quantities of antibodies or immunoglobulins (Ig) with a unique
structure specific to the presented antigen.185 The antibodies circulate the bloodstream
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until they come into contact with the antigen that stimulated their production. Antibody
binding inactivates viruses and marks pathogens, recruiting other cells to destroy them.
During activation memory B cells are also produced which have the ability of rapid
clonal expansion if the host is re-exposed to the same pathogen.185
1.6.2.2 Cell mediated response
The cell-mediated response involves T cells which are produced in the bone marrow,
but mature in thymus. These na¨ıve cells circulate between the blood and lymphoid
periphery until they come into contact with an APC displaying their specific antigen.
The T cell recognises the MHC presentation of the antigen through the T cell receptor
(TCR). In addition to the interaction of the TCR with the MHC, a second interaction
is required between CD28 on the T cell and B7.1 (CD80) or B7.2 (CD86) on the APC
(TCR from a CD4+ cell and MHC class II binding shown in Figure 1.5).186 If only the
TCR-MHC interaction occurs the cell becomes unresponsive and potentially anergic.187
Upon encounter with their antigen and binding of the co-stimulatory molecules, the
cell is activated and proliferation induced, thereby generating a population of antigen-
specific effector T (Teff) cells. CD8+ T cells are activated through the MHC class I
molecules to produce cytotoxic T cells (CTL) which induce apoptosis in their target
cells through the release of the lytic enzyme granzyme and perforin. CD4+ cells are
activated through MHC class II molecules and differentiate into different subsets with
different functions depending on the cytokines secreted by the APC.188,189
Major histocompatibility complex
The major histocompatibility complex (MHC) was first discovered during the rejec-
tion of transplanted tumours.191,192 In humans these genes are called human leucocyte
antigen (HLA) and are situated on the short arm of chromosome 6 (6p21.3).193 This
contains the genes for MHC class I (HLA-A, -B and C) and class II (HLA-DR, -DP and
-DQ). These two classes are composed of distinct subunits which fold to have similar 3D
structures. Both MHC class I and II molecules consist of two polypeptide chains forming
four subunits; three of the MHC class I subunits are formed from an α chain and the
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Figure 1.5: Binding of the TCR complex on a CD4+ cell to the MHC class II molecule
with co-stimulation by CD28 to B7. Figure created using SmartDraw and adapted from
Janeway et al.190
remaining subunit a β2-microglobulin.
194,195 The α1 and α2 subunits form the cleft and
binding site for the antigen whilst the α3 subunit spans the membrane. The MHC class
II molecule also consists of an α and a β chain folding to form four subunits.196 The
antigen binding cleft is formed of subunits α1 and β1 whilst α2 and β2 both span the
membrane.
The different classes present antigens to different T cells and have different levels of
expression on different cells. MHC class I binds to peptides from the cytosol and presents
them to CD8+ T cells which when activated, have the ability to kill any cell recognised.
These peptides are usually from viruses that have replicated in the cell and so MHC
class I molecules are expressed on all nucleated cells. MHC class II molecules presents
peptides, that have been internalised and degraded within vesicles to CD4+ T cells and
are expressed in cells that participate in the immune response.197
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T cell receptor
The antigens presented by APCs on the MHC molecules are recognised by T cells via
the T cell receptor (TCR). The TCR on the majority of T cells is composed of an α
and β chain† linked by a disulphide bond and similar in structure to the Fab fragment
of an Ig molecule.200 The two chains of a TCR consist of a constant (C) region which
spans the membrane and a variable (V) amino-terminal region. The ability of a T cell
to recognise a specific antigen and the wide variety of antigens recognised by different
T cells lies within the formation of the V region. The genes that encode this region
are split into different segments; V, D and J gene segments.201 Whilst the T cell is
maturing in the thymus, these genes rearrange themselves creating a variety of different
TCRs making each one unique and able to bind to a specific peptide on a given MHC
molecule.202,203 A failure to rearrange these genes, such as in SCID (severe combined
immunodeficiency) mice, removes the adaptive immune system and is fatal.204
The TCR recognises the antigen, but is unable to signal this to the cell, it is therefore,
associated with the CD3 complex consisting of γ, δ,  and ζ chains.200 Each CD3
chain contains an intracellular immunoreceptor tyrosine-based activation motif (ITAM)
which is phosphorylated upon antigen recognition by the tyrosine kinases Fyn and Lck,
initiating a signalling pathway leading to activation of the T cell.
1.6.2.3 Activated CD4+ cell lineages
Once activated, the CD4+ T cells differentiate into different subsets depending on the
type of antigen presented, the cytokines secreted by the APC and the strength of the
TCR-MHC interaction (Figure 1.6).188,189 If high levels of IL-12 are secreted, Th1 cells
are generated through the transcription factors STAT4 (signal transducer and activa-
tor of transcription) and T-bet.205 These cells produce high levels of IFN-γ, TNF-β
and IL-2 and play a role in activation of macrophages and development of CTLs.206,207
In the presence of IL-4, the activated CD4+ cell differentiates into Th2 cells requir-
ing the activation of GATA3 and STAT6. Th2 cells secrete IL-4, IL-5, IL-9 and IL-13
†The TCR on a small subset of T cells present at epithelial surfaces consists of γ and δ chains. These
γδ-cells are predominantly CD4−CD8− and can act as part of both the innate and adaptive immune
response with the capacity to function as APCs whilst also having anti-tumour properties.198,199
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supporting the development of the humoral response by stimulating B cells to differ-
entiate into plasma cells and produce antibodies.205,208 Th17 cells are distinguished
by their production of IL-17 and have a specialised developmental pathway, which is
distinct from Th1 or Th2 cells. The combination of TGF-β and IL-6 induce the dif-
ferentiation of Th17 cells through the activation of STAT3.209,210 This in turn induces
the expression of the transcription factor retinoic acid-related orphan receptor gamma
t (RORγt).209,210 Once induced, Th17 effector function and phenotype is maintained
by the presence of IL-23.209 As well as IL-17, Th17 cells also secrete IL-21, IL-22 and,
in humans, IL-26.211,212 Through these cytokines, Th17 cells play a role in the de-
fence against extracellular pathogens.211,212 Differentiation of follicular helper T (Tfh)
cells requires IL-21 and the transcription factor Bcl-6.213 These cells secrete IL-21 and
regulates B cell maturation.214 CD4+ T cell activation with high levels of TGF-β se-
cretion leads to the differentiation of an induced T regulatory (iTreg) population215–217
(discussed further in §1.7.3.1).
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Figure 1.6: After activation via the TCR CD4+ cells mature into Th1, Th2, Th17,
Tfh or iTregs depending on the type of antigen presented, the cytokines present and the
strength of the TCR-MHC interaction. Figure created using SmartDraw and adapted
from O’Shea et al.218
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1.6.3 Immunological tolerance
In the 1900’s Ehrlich and Morgenroth proposed that the immune system, whilst able to
mount a response against an antigen, has a mechanism of avoiding reactivity to itself.219
Lymphocytes with receptors that strongly bind self antigens are removed before devel-
oping into immunocompetent cells. This occurs as they mature in the bone marrow
and thymus for B and T cells respectively. Mechanisms for negative selection include
induction of anergy and deletion via apoptosis.
Tolerance through anergy
Tolerance can be achieved through the functional inactivation of T cells whilst main-
taining their viability, this is termed anergy. There are two mechanisms of initiating
anergy; clonal anergy and adaptive tolerance.220 Clonal anergy is induced through in-
complete activation of a T cell by antigen recognition minus the co-stimulation from the
APC required. This leads to downregulation of IL-2 preventing the cells from prolifer-
ating. This is observed mostly in T cells which have been previously activated and can
be reversed by IL-2 signalling. Adaptive tolerance occurs mostly in na¨ıve T cells and
can be induced in the presence of a persistent antigen. Adaptive tolerance differs from
clonal anergy in that as well as reduced IL-2 production, other cytokines such as IL-4
and IFN-γ are down regulated and the anergic state is maintained through persistence
of the antigen, and is not reversed by IL-2.221
Tolerance through deletion
In response to a pathogen, T cells are activated, undergo proliferation and differentiate
to form Teff cells. Once the infection has been cleared, large numbers of activated
Teff cells remain which are no longer needed. To prevent the accumulation of these
potentially harmful cells, they are removed through apoptosis.222 Apoptosis can be
initiated through different mechanisms, such as through the activation of caspase-8 via
increased expression of Fas and its ligand FasL.223 Another pathway leading to the onset
of apoptosis involves the pro-apoptotic protein Bim, which via the release of cytochrome
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c from the mitochondria, leads to the activation of caspase-9.224,225 Mice deficient
for both Fas and Bim accumulate T cells and develop autoimmunity,226,227 thereby
suggesting thaat these two pathways play important roles in lymphocyte homeostasis.
Dominant tolerance
The presence of a specific T cell population can actively suppress the actions of other
immunological cells through a variety of mechanisms.228 This population is known as
regulatory T cells (Tregs) and are the cells chosen to focus on within this project when
banking a pure isolated cell population.
1.7 Regulatory T cells
The concept of a cell capable of exerting suppressive activity was first suggested in 1970.
Gershon and Kondo demonstrated that lymphocytes derived from the thymus of mice
could prevent specific immune responses against exogenous antigens, they named these
cells ‘suppressor cells’.229 However, due to a lack of reliable molecular techniques at the
time, these suppressor T cells could not be further characterised and so their existence
was questioned.230 Suppressor cells were observed again in a series of experiments in
which high dose UVB exposure generated suppressor T lymphocytes in the spleen and
lymph nodes of mice.231–233 However, it was Sakaguchi et al in 1995 who were the first
to identify these cells by demonstrating that a population of CD4+ cells co-expressing
the IL-2 receptor α chain (CD25) had a suppressive function in mice.234 These cells,
renamed regulatory T cells (Tregs), constituted approximately 5-10% of peripheral CD4+
T cells and were found to be suppressive, but anergic.235,236 A similar population was
identified in humans in 2001,237–242 and over the years it has become clear that Tregs
are critical in human immunological homeostasis via their ability to control autoimmune
responses.243–247
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1.7.1 Development of Tregs
Multi-organ autoimmunity can be induced in mice through neonatal thymectomy, and
the adoptive transfer of CD4+CD25+ cells from normal mice can prevent autoimmune
disease.248–250 This, combined with the observation that the depletion of CD4+CD25+
cells in mice results in short term autoimmunity, led to the conclusion that Tregs develop
in the thymus.
In humans, it is believed that Hassall’s corpuscles, concentric epithelial cells found within
the medulla of the thymus, contribute to Treg development by expressing thymic stro-
mal lymphopoietin (TSLP). This activates dendritic cells which, in turn, induce the
differentiation of thymic CD4+ T cells into CD4+CD25+ regulatory cells.251,252
1.7.2 Phenotype of Tregs
The Treg population in mice has been well defined as being CD4+CD25+FoxP3+. Phe-
notyping human Tregs has proved to be difficult, as it has been found that these markers
are not specific to a regulatory population.253–258 The human Treg population has been
found to be heterogeneous in both phenotype and functional ability.
1.7.2.1 CD25
IL-2 has a range of effects on T cells leading to proliferation, differentiation, cytokine
production and even immune tolerance.259,260 Tregs do not secrete IL-2, but do express
the IL-2 receptor. The IL-2 receptor consists of three subunits, an α chain (CD25),
β chain (CD122) and the common cytokine receptor γ chain (CD132). Of the three
subunits, only CD25 is specific to the IL-2 receptor, whereas CD122 and CD132 form
parts of other cytokine receptors.261–263 Once bound, the IL-2-IL-2R complex is rapidly
internalised, the CD25 section is recycled and returned to the cell surface, whereas
IL-2, CD122 and CD132 are degraded in the lysosomal compartment.264 The CD25+
population in mice has been found to contribute to the maintenance of self tolerance via
the down regulation of immune responses to self and non-self antibodies in an antibody
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non-specific manner.234 However, CD25 is up-regulated on activated T cells, and in
adult humans a large population of CD4+CD25+ memory cells can be observed.265 Only
cells with the highest CD25 expression (CD25high) have been shown to have suppressive
abilities and can therefore, be considered regulatory.242 CD4+CD25high T cells are also
enriched for many other surface markers, although none have been found to be unique
to Tregs. Therefore, a combination of CD25 expression with other markers, linked to
Tregs and suppressive function, is used for the identification of Tregs.
1.7.2.2 FoxP3
FoxP3 (forkhead box P3) is a member of the forkhead/winged-helix family of transcrip-
tional regulators.266 The forkhead box is a DNA-binding motif which allows FoxP3 to
regulate expression of the genes controlling cell proliferation and differentiation.267
Mutations in FoxP3 are associated with ‘Scurfy’ in mice268–270 and immunodysregu-
lation, polyendocinopathy and enteropathy X-linked (IPEX) syndrome in humans.271
This mutation changes the amino-acid sequence in the DNA-binding domain of the pro-
tein,272–274 leading to dysfunction of Tregs and therefore, dysregulation of the immune
system and subsequent autoimmunity. This disorder presents in the first few months of
life and frequently results in death within two years. Mice that over express the FoxP3
gene have been shown to produce fewer mature T cells with reduced functional capac-
ities and are unable to mount an effective humoral response.275 This, combined with
the development of autoimmunity in FoxP3 deficiency, suggests that this transcriptional
regulator is essential for normal immune homeostasis.276
FoxP3 has been described as a master switch in Treg differentiation and function.267,277
FoxP3 can block the transcription factors NF-κB,278 NFAT,279 HAT/HDAC280 and
AML-1/Runx1281 which, through transcribing the cytokines IL-2 and IFN-γ, play im-
portant roles in the activation and differentiation of T cells.282,283 The presence of
FoxP3 not only blocks these transcription factors, but also overrides them to increase
the transcription of molecules associated with Tregs such as CD25.284
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FoxP3 is highly expressed in CD25+ Tregs and is currently considered to be the most spe-
cific marker, as its expression has been found to correlate with suppressive function.267
However, not all FoxP3+ cells possess suppressive abilities.258 FoxP3 expression can
be induced through TCR activation and low levels of expression have also been found
in non-suppressive CD4+CD25− cells.244,285 FoxP3 is localised to the nucleus and so
its identification requires fixing the cells followed by permeabilisation making functional
analysis impossible if this marker is used for isolating the cells.
1.7.2.3 CD127
The IL-7 receptor is a cell surface protein consisting of two subunits; an α chain (CD127)
and a γ chain (CD132) which is shared by other cytokine receptors (receptors for IL-2,
IL-4, IL-9, IL-15 and IL-21).261–263 CD127 plays a role in the proliferation and dif-
ferentiation of T cells and is expressed by many cells including mature T cells, B cell
progenitors, monocytes and thymocytes. Levels of CD127 expression have been found
to inversely correlate with FoxP3 and suppressive function.286,287 Therefore, CD127 has
been accepted as an alternative Treg marker. As CD127 is a cell surface marker, it pro-
vides an alternative to FoxP3 for identifying and isolating Tregs. However, it has been
demonstrated that Tregs up-regulate CD127 upon in vitro and in vivo activation.288
Furthermore, this marker can be down-regulated during the early stages of T cell acti-
vation and therefore, some non-suppressive FoxP3lowCD45+ T cells express low levels of
CD127.258,289
1.7.2.4 Other markers associated with Treg function
The markers mentioned above are commonly used to identify Tregs. There are several
other markers that have been linked to Tregs found in mice and humans. A brief
description of a few of these markers is included below.
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1.7.2.4.1 CD39
Extracellular ATP concentrations in healthy tissues are regulated by ATP/ADPases.290,291
Intracellular ATP concentrations are maintained at high levels of 3-5mM.292 If a cell is
lysed or the membrane damaged large quantities of ATP are leaked into the plasma. Ex-
tracellular ATP binds to the P2X7 and P2Y2 receptors promoting leucocyte recruitment
and release of proinflammatory cytokines such as IL-1β.293
CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1),
was originally considered to be a B cell activation marker, but has been shown to be
expressed by other cells such as dendritic cells and subsets of T cells.294 CD39 hydrol-
yses ATP and ADP to AMP,290,295 and the removal of extracellular ATP results in an
anti-inflammatory effect. The AMP produced by CD39 can be further metabolised by
CD73 to produce adenosine which, when bound to its A2A receptor, exhibits immuno-
suppressive effects on CD4+ and CD8+ T cells by increasing intracellular cyclic AMP
leading to the inhibition of IFN-γ and IL-2 production.296–298
CD39 has been found to be expressed in virtually all mouse CD25+ and FoxP3+ cells.299
The same group also report the majority of these Tregs co-expressed CD73, although
this was not found to correlate with FoxP3 expression. The Tregs of CD39−/− mice
have reduced in vivo suppressive abilities and in vivo are unable to prevent rejection
of an allograft.297 Through these studies, it is clear that CD39 and CD73 play an
important immunoregulatory role in mice. In adult humans, the role of CD39 is not so
well defined and it is found to be expressed on only a subset of Tregs.299 CD39+ Tregs
possess an activated memory phenotype and co-express CD45RO and CCR6.299 This
subpopulation has been shown to suppress production of the pro-inflammatory cytokine
IL-17 whilst CD39− cells produce IL-17.300
1.7.2.4.2 ICOS
Lymphocytes require two activation signals, the first is through interaction of the T
cell receptor (TCR) with major histocompatibility class antigens (MHC) on an antigen
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presenting cell (APC). The second activation signal is involves the interaction of a mem-
ber of the CD28 family with a B7 protein presented by the APC. This second signal
prevents the lymphocyte from undergoing apoptosis or becoming anergic.
Inducible costimulator (ICOS or CD278) is a member of the CD28 receptor family and
plays a role in T cell activation and survival.301 Although ICOS is expressed in the ma-
jority of murine Tregs,302 human Tregs can be divided into two subsets based on ICOS ex-
pression. Expression of ICOS is up-regulated upon antigen encounter and it is therefore,
expressed on most CD45RO+ cells,303 whereas ICOS− cells can be CD45RO+ or possess
a more na¨ıve CD45RO− phenotype.304 ICOS+ and ICOS− Treg subsets have been found
to suppress using different mechanisms.304 ICOS− Tregs express TGF-β (suppresses T
cell function) and are only able to suppress through cell-cell contact.304 The ICOS+
Treg subset also produce TGF-β, but at lower quantities than ICOS− cells.304 ICOS+
cells also suppress APC function through the production of IL-10,305 and they share
features with Tr1, Th1 and Th17 cells by expressing IL-17 and INF-γ.306
1.7.2.4.3 CTLA-4
Cytotoxic T lymphocyte antigen 4 (CTLA-4 or CD152) a cell surface marker, is expressed
by CD4+ and CD8+ T cells.307 The structure of CTLA-4 is closely related to CD28308
and so these receptors compete for B7 binding (CD80 and CD86) on the APC.309,310
Binding of CTLA-4 instead of CD28 to the B7 ligands results in an opposing signal;
although CD28 binding leads to the activation of T cells, CTLA inhibits IL-2 secretion
and cell proliferation resulting in an immunosuppressive effect.311 Although CTLA-4
functions at the cell surface, its expression is a dynamic process and it cycles between the
surface and intracellular vesicles, thereby regulating its immunosuppressive effects.312
Therefore, the detection of CTLA-4 is often achieved using intracellular staining which,
as for FoxP3, limits it usefulness for the isolation of functional cells.
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1.7.2.5 Expression of homing receptors by Tregs
Tregs are believed to suppress through multiple mechanisms, many of these would require
close contact with the target cells. Therefore, Tregs need to migrate from the circulatory
system into specific tissues.313
1.7.2.5.1 CCR4
Chemokines are a group of cytokines that can be divided into four subgroups based on the
arrangement of the N-terminal cysteine residues: C, CC, CXC and CX3C. Chemokines
play an important role in the homing and migration of leucocytes. T cells with differ-
ent functions express different sets of trafficking receptors in order to ensure that they
migrate to the appropriate tissue.314
C-C chemokine receptor type 4 (CCR4 or CD194) attracts T cells to non-lymphoid
tissues such as the skin and lung.315–317 Adult Tregs have been shown to express more
CCR4 compared with CD25− T cells,318–320 and FoxP3 transduced CD4+CD25− T cells
have been shown to upregulate CCR4 and acquire immunoregulatory abilities, suggesting
a relationship between CCR4 and suppressive function.277 The more mature memory
Tregs with a CD45RA− phenotype have been shown to express higher levels of CCR4
than the more na¨ıve CD45RA+ subset.319,321
1.7.2.5.2 CD62L
CD62L (L-selectin) is a lymphoid tissue T cell homing receptor which is required for
migration into the secondary lymphoid tissues.322 The T cells that express CD62L
have been found to possess the na¨ıve phenotype CD45RA+/RO−. After T cell recep-
tor engagement, CD62L+ is down-regulated and the cells adopt a memory phenotype
(CD45RA−/RO+).323
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CD62L deficient mice show a significant reduction of the number of lymphocytes lo-
calised to the lymph nodes, confirming the role L-selectin plays in the homing to lym-
phoid tissues.324 CD62L interacts with peripheral node addressin (PNAd) on the high
endothelial venules (HEV), and this initiates cell rolling.323,325 This activates lympho-
cyte function associated antigen 1 (LFA-1) via a G-protein-coupled receptor.326,327 The
activated LFA-1 binds to adhesion molecules (ICAM-1) on the HEV allowing the cell to
migrate into the lymph node (Figure 1.7).328
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Figure 1.7: Mechanisms of cell homing from the periphery into lymph nodes via
CD62L. Rolling of the cell is initiated when CD62L interacts with peripheral node
addressin (PNAd). Lymphocyte function associated antigen 1 (LFA-1) binds with
adhesion molecules (ICAM-1) to mediate firm adhesion to the epithelial surface and
allow diapedesis or migration of the cell through the epithelial cells. Figure created
using SmartDraw and adapted from Lewis et al.329
Both CD62L+ and CD62L− Treg subsets have been shown to be anergic and equally
suppressive in vitro upon polyclonal330,331 and allogeneic stimulation.322 Also both
subsets have been reported to be equally protective in a mouse model of colitis.332
However, only the CD62L+ Treg population is able to delay the onset of diabetes in
NOD/SCID (non-obese diabetic/severe combined immunodeficiency) mice333 and only
these cells can protect mice against GvHD.322 Since only the CD62L− donor T cells
induce GvHD,334,335 it has been suggested that this homing receptor is required to enter
the secondary lymphoid organs in order to localise the priming site of the alloreactive
CD4+ T cells.322
1.7.3 Types of Tregs
The Tregs described so far develop in the thymus336 and are known as naturally occurring
regulatory T cells (nTregs). Additional suppressor populations including induced T
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regulatory cells (iTreg) which develop in the peripheral blood215 and CD8+ suppressor
cells have been identified.337
1.7.3.1 Induced Tregs
Cells that develop from CD4+FoxP3− T cells in the periphery are known as adaptive
or induced Tregs (iTreg). These cells can be induced in vitro from CD4+CD25− T cells
in the presence of IL-2 and TGF-β.215–217 The production of iTregs has been found to
be completely independent of thymus derived nTregs, as mice devoid of nTregs are still
able to generate iTregs.338 Although nTregs and iTregs express CD25, FoxP3, GITR
and CTLA-4, the higher levels of Helios and Neurophilin-1 expression by nTregs allows
these cells to be identified using flow cytometry.338
The iTreg population contains Type 1 regulatory (Tr1) and T helper 3 (Th3) suppres-
sive cells. The in vitro induction of Tr1 cells was first described by Groux et al as a
consequence of stimulating na¨ıve CD4 T cells with high levels of IL-10.215 These cells
were found to mostly produce IL-10 and TGF-β, with which they are able to suppress
Th1 and Th2 cells.339 The suppressive role of Tr1 cells has found to be non-overlapping,
but complementary to nTregs.340 T helper 3 cells can be generated by the addition
of TGF-β to na¨ıve T cells.341 These cells exert suppressive effects over Th1 and Th2
cells via the production and secretion of TGF-β.342 The differences between nTregs and
iTregs are summarised in Table 1.1.
1.7.3.2 CD8 regulatory T cells
CD8+ suppressive cells display many similarities to their CD4+ counterparts; in that
they express CD25 and FoxP3 and consist of a heterogeneous population.356 These cells
have been found to suppress using similar mechanisms as CD4 Tregs and their presence
is believed to be complementary to these cells.357,358
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Table 1.1: Characteristics of nTregs and iTregs
Properities nTreg iTreg - Tr1 iTreg - Th3
Site of
maturation
Thymus336 Periphery215 Periphery215
Required for
activation
Costimulation343 IL-10215 TGF-β341
Markers FoxP3+267
Neurophilin-1+338
Helios+338
CD49d−344
FoxP3−345
Neurophilin-1−338
Helios−338
CD49b+346
FoxP3+347
Neurophilin-1−338
Helios−338
Mechanism Secretion of IL-10,348
TGF-β349 and IL-35350
Metabolic disruption351
Cytolysis352,353
Inhibition of DC354
Secretion of IL-10
and TGF-β339
Secretion of TGF-β342
Target cells APC and Teff355 Teff339 Teff342
1.7.4 Mechanism of suppression
Tregs remain anergic after TCR stimulation, even with the addition of co-stimulatory
signals by APC.359 Only in the presence of high doses of IL-2 in combination with TCR
stimulation will Tregs proliferate.360 TCR stimulation is required in order for Tregs
to become functional.343 This has been shown through the ability of fixed Tregs cells
to assert their suppressive effects if they had been activated before fixation.361 Once
activated, these cells suppress in an antigen non-specific manner331 and therefore, do not
have to be viable to mediate suppression.362 Tregs have been shown to suppress using
a variety of different mechanisms (shown in Figure 1.8) which can be grouped into four
different ‘modes of action’.355
1. Secretion by inhibitory cytokines
(a) IL-10
Interleukin-10 (also known as human cytokine synthesis inhibitory factor) has
been suggested to have an important role in controlling inflammation by sup-
pressing proinflammatory cytokines, chemokines and adhesion molecules.348
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IL-10 functions by suppressing the expression of proinflammatory cytokines
(such as IL-1 and TNF), chemokines that are involved in recruiting Teff and
by inhibiting the expression of costimulatory molecules and MHC class II
antigens in APCs.348
(b) TGF-β
Transforming growth factor β can be soluble or membrane bound. TGF-β has
been shown to inhibit the proliferation of T cells by inhibiting the production
of IL-2 and IFN-γ349,363 and also affects the differentiation of na¨ıve CD4+
cells.364 TGF-β null mice have increased expression of MHC class I and II
molecules and an increase in inflammation in multiple organs which leads to
death within three weeks of birth, suggesting that this cytokine plays a role
in controlling the expression of both MHC classes.365
(c) IL-35
A member of the IL-12 family, is expressed by resting and activated Tregs but
not Teff cells.350 IL-35 has been shown to suppress na¨ıve CD4+ T proliferation
in vitro and in addition, a loss of IL-35 expression leads to reduced suppression
in vivo.350
2. Suppression by metabolic disruption
(a) IL-2
IL-2 is essential for proliferation and differentiation of T cells.366 FoxP3+ cells
are unable to produce IL-2, suggesting that Tregs with their high expression of
CD25 can deplete the IL-2 from the local environment, thus depriving nearby
target cells from this cytokine.351 This theory has been further developed by
Pandiyan et al who suggest that apoptosis can be induced by Tregs through
deprivation of cytokines such as IL-2.367
(b) CD39
As described in §1.7.2.4.1, expression of CD39 can hydrolyse extracellular
ATP and ADP to AMP, thereby removing a proinflammatory signal.290,295
Extracellular AMP can be further metabolised by CD73 to produce adeno-
sine which binds to the A2A receptor and inhibits proinflammatory cytokine
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production.297,368,369 The binding of adenosine to the receptor not only sup-
presses the function of the target cells, but also through the inhibition of IL-6
and secretion of TGF-β, leads to the generation of induced Tregs.370
(c) cAMP
The generation of adenosine can also increase cyclic adenosine monophos-
phate (cAMP) levels. cAMP can be transferred to Teff cells through GAP
junctions.371 Raised levels of cAMP leads to inhibition of IL-2 and IFN-γ
and the subsequent proliferation of CD4+ T cells.372
3. Suppression by cytolysis
Tregs may also act as cytotoxic cells and exert their suppressive function by re-
leasing cytotoxic granules. Cytotoxic granules contain the pore-forming protein
perforin and granzymes (part of the serene protease) which directly kill effector
cells by initiating apoptosis.373 Activated nTreg cells have been shown to express
predominantly granzyme A,374 whereas iTregs generated from human CD4+ T
cells via CD3 and CD46 in the presence of IL-2 express granzyme B.375 Both
types of Tregs exhibit cytotoxic effects on CD4+ and CD8+ T cells, monocytes
and dendritic cells in a perforin-dependent but fasL-independent manner.375
4. Targeting the APC
(a) CTLA-4
Competes with CD28 and binds to CD80 and CD86 on DCs activating in-
dolamine 2,3-dioxygenase (IDO) which catalyses the degradation of trypto-
phan, depleting the stores needed for Teff cell proliferation, into kynurenine
which induces apoptosis in the Teff cells.376–378
(b) LAG3
Lymphocyte activation gene 3 (LAG3) is a CD4 homologue that binds MHC
class II molecules expressed by immature DCs. This engages a Immune-
receptor-Tyrosine-based-Activation-Motif (ITAM) which induces an inhibitory
signalling pathway and suppresses the maturation and immunostimulatory
capacity of the DC.354
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(c) Neurophilin-1
Promotes long interactions between Tregs and immature DCs, thereby block-
ing their maturation.379
2 8937.333333
1.5 16808
1 17901
0.5 17192.66667
0.25 12878
0.1 4356.333333
CD25
IL-2
 
Buy SmartDraw!- purchased copies print this 
document without a watermark .
Visit www.smartdraw.com or call 1-800-768-3729.
Figure 1.8: Mechanisms of immune suppression by Tregs through the release of in-
hibitory cytokines, disrupting metabolic activity, cytolysis and by targeting the APC.
Figure created using SmartDraw and adapted from Vignali et al.355
There is much debate on the mechanisms of Treg suppression with many contradictory
reports. However, as Tregs are able suppress a variety of immune cells in various tissue
sites, in all likeliness there is not one single mechanism through which Tregs function.
The mechanism of suppression is probably dependent on factors such as the site of the
immune reaction as well as the type and activation status of the target cell and the Treg
itself.
1.7.5 Use of Tregs in cell therapy
The importance of Tregs in both mice248,249,351 and humans237,238,242 has been well
documented. These cells have been shown to play an important role in controlling
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autoimmunity, tumour immunity, transplantation tolerance, allergy and microbial im-
munity.243,336,380 It is no surprise that these cells have been targeted for immunotherapy
in the treatment for many immune disorders, however, this has proved to be challeng-
ing. In order to activate their immunosuppressive functions, Tregs require stimulation
through their TCR. As there is no known method of stimulating Tregs without activat-
ing other T cells it is not possible to administer the activation signal directly into the
patient. Alternatively adoptive cell therapy techniques can be employed in which the
Tregs are isolated from a patient, activated ex vivo before reinfusion.381 This also allows
functional assessment of the cells prior to re-administration reducing the risk of adverse
reactions.
1.7.5.1 Tregs in autoimmunity
Autoimmunity compromises a large group of diseases characterised by a lack of self
tolerance and has been shown to affect ∼8% of the human population.382 Autoimmune
diseases can be caused by defective Tregs, for example in the case of IPEX syndrome
which is caused by mutations in the FoxP3 gene.383 Although HSCT is currently the only
curative option, a recent study reported that CD4+ T cells isolated from a patient could
be converted into functional Tregs after lentivirus-mediated FoxP3 gene transfer and
therefore, potentially provide an alternative approach for the treatment of this disease
in the future.384
Type 1 diabetes mellitus (T1D) results from the immune system destroying the insulin
producing β-cells in the pancreas.385 There is no consensus on the effect Tregs have
on T1D, some report that the frequency of these cells is altered,386 whilst others link a
reduction in suppressive ability with this autoimmune disease.387 Tregs have been used
in the treatment of T1D in NOD mice, with the adoptive transfer of Tregs slowing the
progression of diabetes and in some cases reversing the onset of this disease.333,388 There
is an ongoing clinical trial assessing the safety of infusing different doses of expanded
Tregs in patients T1D whilst also looking into the effects these cells have on insulin
β-cell function.389
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Systemic lupus erythemathosus (SLE) is a chronic autoimmune disease that can affect
almost any organ system. The majority of studies on Treg frequency within SLE pa-
tients report a decrease in this cell population,390–392 however, there are also reports
indicating an increase in Treg numbers.393,394 There are several possible reasons for
these discrepancies: Firstly, the disease activity in a patient varies between an active
state and phases of remission, these fluctuations can alter cytokine release and the dis-
tribution of immune cells. Secondly, some of these studies identify Tregs using FoxP3,
whereas others rely on the CD25high phenotype. The lack of a specific Treg marker is
particularly problematic in SLE sufferers as a non suppressive CD4+FoxP3+CD25low T
cell population has been identified which is not found in healthy humans.395,396 Ex vivo
expansion of Tregs isolated from SLE patients restored their functional capabilities and
suggests that these cells have potential for the treatment of SLE.397
1.7.5.2 Tregs in alloimmunity
Allorecognition occurs after transplantation when the host’s immune system reacts to
MHC complexes from the donor.398 Three pathways of allorecognition have been de-
scribed: direct, indirect and semi-direct. The direct pathway occurs when the host T
cell recognises the donor MHC molecules displayed on the transplanted cells. In the
indirect pathway, the donor MHC molecules are processed and presented by the host
APCs. The semi-direct pathway involves the transfer of intact MHC molecules from
the donor to the host’s APCs.399 The mechanism for this is not fully elucidated, but it
is believed to involve cell-cell contact400 or their release within exosomes which can be
internalised by APCs.401
1.7.5.2.1 Solid organ transplant
As with HSCT, if there is histoincompatibility between host and donor after a solid
organ transplant an immune response is elicited. Rejection of a graft can occur at dif-
ferent stages: hyperacute, acute and chronic rejection. Hyperacute rejection usually
occurs within the first few hours of the transplant. This type of rejection is humorally
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mediated and occurs if the patient has pre-existing antibodies specific to the donor anti-
gens. This type of rejection presents itself so quickly because vascularisation of the graft
is destroyed by the activation of the complement system leading to thrombosis in the
capillaries.398 Acute rejection is initiated by a T cell response and develops between one
week and six months of transplantation. This type of rejection is associated with the
direct allorecognition pathway and rapidly elicits an immune response as the antigen
is presented by APCs within the organ. All transplants will have some level of acute
rejection unless the donor is a perfect HLA match for the patient. This type of rejection
results in an increase in the risk of developing chronic rejection. Chronic rejection occurs
months or years after the transplant and is the major cause of organ failure. This type of
rejection can be humoral or cell-mediated and is associated with the indirect allorecog-
nition pathway. This requires more time to elicit an immune response, as it requires the
capturing and processing of the antigen. Chronic rejection is caused by inflammatory
vascular injury to the organ. This is characterised by accelerated atherosclerosis of the
blood vessels accompanied by collagen production by fibroblasts resulting in scarring
and atropy.
To prevent immunological rejection of the transplanted organ, patients often require
long-term immunosuppression which can leave them susceptible to microbial pathogens
and tumour formation. Infection and cancer are major contributors to mortalilty post-
transplant.402,403 Currently clinical trials are being performed in patients which have
previously undergone a liver transplant. These patients are being treated with several
courses of 1 ×106 Treg cells kg−1 whilst their immunosuppressive drug treatment is
withdrawn.404 Another current clinical trial involves kidney405 transplant patients in
which immunosuppressive drugs are administered with or without Tregs and both groups
monitored for three years.
1.7.5.2.2 HSCT
Allogeneic HSCT are routinely performed to treat blood disorders and cancers. The
most frequent complication of allogeneic HSCT is GvHD and occurs in 30-70% of pa-
tients.406 Pathophysiology of aGvHD has been described in three phases.407 The first
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phase (conditioning or afferent phase) begins with damage to the host’s tissue during the
conditioning regime. Damage occurs mainly in the liver and intestinal mucosa caused
by the release of inflammatory cytokines such as IL-1, TNF-α and IFN-γ, and the up-
regulation of the major histocompatibility complex (MHC) on APCs. In the second
phase (induction and expansion phase) the donor T cells are activated by the inflamma-
tory cytokines and APCs. These T cells proliferate and differentiate into effector cells.
In the third and final phase (effector phase), the activated T cells induce cytotoxicity,
Fas-FasL-mediated apoptosis and cytolysis mediated by granzyme B and perforin. This
results in damage to the host’s tissue and the characteristic features of aGvHD.
Lethally irradiated mice that received a Treg depleted HSCT have been shown to exhibit
increased severity of GvHD following a donor leukocyte infusion (DLI) compared to mice
that received a whole BM transplant.408 This, combined with several studies showing
that the adoptive transfer of Tregs ameliorates GvHD in mice undergoing HSCT409–411
whilst maintaining the GvL effect,412 suggests these cells have the potential to be used
therapeutically to prevent or reduce the severity of this disease.
There are conflicting reports on the frequency of Tregs in humans suffering from GvHD.
Magenau et al report a 40% reduction in patients with GvHD compared to those without,
and found the frequency of Tregs inversely correlated with the severity of GvHD.413 In
contrast, Clarke et al report elevated levels of Tregs in GvHD sufferers, but with reduced
CD62L expression compared to patients without GvHD.414
A CB derived Treg dose escalation study has been performed in patients undergoing a
double CB HSCT.415 Treg doses of 1 to 30×105 cells kg−1 were infused one day after
the transplant with no toxicity and a reduction in the incidence of grade II-IV aGVHD
compared to historical controls observed. There are other ongoing clinical trials assessing
the feasibility of using Tregs against GvHD, including a phase I trial in which ex vivo
expanded donor Tregs will be infused 2 days prior to allogeneic HSCT,416 and a phase
II trial in which donor Tregs and rapamycin will be administered to patients already
suffering from aGVHD.417
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1.7.6 Treg Banking
In some cases it may be convenient to isolate Tregs sometime prior to their use thera-
peutically. In these situations, it would be beneficial to cryopreserve these cells whilst
ensuring suppressive function remains intact.
1.7.6.1 Isolation of Tregs
Tregs for clinical use need banking procedures that comply with good manufacturing
practice (GMP). The isolation process should be performed in a closed and sterile system
using clinical grade CE marked reagents.
Tregs are a rare population (5-10% of CD4+ T cells) and large numbers of cells would
be required for therapeutic applications. Therefore, post-isolation expansion, involving
culturing cells with anti-CD3, anti-CD28 and high doses of IL-2, is often needed to reach
the cell doses required for clinical purposes.411 Although approaches used during expan-
sion tend to favour the proliferation of non suppressive T cells, Rapamycin can be added
during expansion in order to favour the proliferation of Tregs.418 Therefore, in order for
expansion to be successful, the starting population must be of high purity. The periph-
eral blood from adult humans can contain large numbers of activated CD25+ T cells
which do not possess immunosuppressive abilities.265 As Tregs are often isolated based
on CD25 expression, low purities with high numbers of contaminating CD25+CD127+
cells are often observed.419
The purity of these cells is also particularly important when treating patients with
autoimmune diseases, as it would be detrimental to put alloreactive cells into patients
already suffering from immunological imbalance.420 Purity may not be such a problem
if infusing during a HSCT, where Tregs can be used to prevent or reduce the severity of
GvHD; in this setting the infusion of non-regulatory T cells may aid in the GvL effect.421
GMP grade Treg isolation has previously been performed on leukapheresis samples re-
sulting in low CD4+CD25high cells purities of 40-60%.422 Expansion of these samples
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found the small number of contaminating B cells (1-3%) increased 10-fold after ex-
pansion. Impurities did not improve despite the addition of three consecutive CD25
enrichment procedures.423 In an attempt to improve purities of these samples, negative
selection or depletion of cytotoxic T cells and B cells (using CD8 and CD19 respectively)
have been performed prior to CD25 enrichment.419,424 Although this improved CD25+
purity to 80-95%, the percentage of CD25high remained low (30-60%) with high numbers
of contaminating CD127+ cells (20-30%). Peters et al improved Treg purity by depleting
CD127+ cells, however, as clinical grade CD127 microBeads are not available these cells
were depleted using fluorescent activated cell sorting (FACS).419
1.7.6.2 Cryopreservation of Tregs
In some cases it may be convenient to isolate Tregs some time prior to their use therapeu-
tically, in these situations it would be beneficial to cryopreserve these cells. However,
it is therefore, important to ensure that these cryopreserved cells will maintain their
immunosuppressive capabilities upon thawing.
It has been reported that cryopreserving adult PBMCs results in a significant reduction
in the frequency of Tregs cells after thawing (reduced from 5.58% of CD4+ cells to 3.57%,
p=0.0016).425 Peters et al cryopreserved Tregs isolated from leukapheresis products and
found them to have reduced post-thaw viabilities of 70-80%, with decreased suppressive
abilities. However, they observe these suppressive abilities could be restored following
expansion. Alternatively the cells maintained suppressive abilities if expanded prior to
cryopreservation.419
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1.8 Rationale and outline of this study
Approximately 20% of CB units arriving at the ANCTC meet the criteria to be banked
for HSCT use. However, samples that are unsuitable for this purpose (usually due to
low cell numbers or medical exclusions) can be used for other purposes such as research.
To avoid discarding these units, Anthony Nolan aims to create a Biobank within the
ANCTC, storing units either as whole blood, isolated CB mononuclear cells (CBMC)
or pure cell populations. This study aims to improve the protocols used within the
Biobank ensuring that they are efficient, reproducible and result in a cellular product
that maintains the highest possible level of viability and potency. This will be achieved
by breaking the banking processes down into sections: transportation of the sample
from maternity to ANCTC, the isolation of CBMC, cryopreservation of cells and finally
assessing the ability to bank a pure cell population. The outline of the study is shown
in Figure 1.9
CB collected
CB transported to bank
Isolate CBMC Freeze CBMC
Isolate Tregs Isolate TregsAdult Tregs
Freeze Tregs
Characterise subpopulation
Suppressive eﬀects
1
Figure 1.9: Outline of this study to improve CB cell isolation and cryopreservation
techniques in the creation of a Biobank at ANCTC
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The maternities collecting CB for the ANCTC are spread across the UK resulting in a
delay to processing and cryopreservation due to transportation of the samples. There is
currently no consensus for optimum fresh storage conditions for CB and it is vital that
the samples are of the highest possible quality on arrival. Therefore, the first area of
investigation is to assess the effects of temperature on the fresh storage of CB, in addition
to other sources of HPCs, and to ascertain the effects of delaying cryopreservation. This
part of the study will be of benefit to samples designated for the Biobank as well as
those cryopreserved for the HSCT bank, where any improvements in quality can lead to
improvements in transplantation outcomes.
Isolation of CBMCs is often required for research and is the first step towards pure cell
isolations. Cells are currently separated through the ficoll density gradient protocol,
a time consuming process with high user variability. The company Biosafe has devel-
oped an alternative approach to CBMC isolation. As with the ficoll density gradient
protocol this new method also exploits differences in cell density, but within a closed
system, and without needing to add density gradient media thereby reducing the risk
of contamination. Within this study, the cell fractions obtained using this new protocol
will be compared against ficoll-derived MNCs to determine if this method is a suitable
alternative.
The Biobank will require long term storage of cellular fractions; this will be achieved
through cryopreservation. Cryopreservation of cells can lead to a reduction in viability
and functional capabilities post-thaw, particularly due to toxicity from cryoprotectants
such as DMSO. Therefore, it is important to optimise the protocols in order to maintain
cell potency. To address this, the toxic effects of DMSO will be assessed at different
stages of cryopreservation before determining the optimal concentration of both DMSO
and dextran-40 within the cryoprotective solution. In addition, the effect of the speed
of addition of the cryoprotective solution will be addressed.
Finally, the Biobank will require the ability to store frozen samples of pure cell popula-
tions with the potential to be distributed as clinical grade products for therapy or for
research and developmental purposes. Tregs play an important role in the homeostasis
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of the immune system by suppressing the proliferation of other lymphocytes and there-
fore, have the potential to be used therapeutically in autoimmunity or transplantation.
These features, in addition to their tendency to protect tumours, also make these cells
an interesting target for researchers and are therefore, are an ideal candidate for the
Biobank. However, therapeutic application requires a large number of Tregs with high
purity and these cells are rare and potentially difficult to obtain from adult donors. To
begin with, the phenotype and suppressive ability of CB derived Tregs will be compared
to their adult counterparts. If CB is found to be a suitable source of these cells, isola-
tion and cryopreservation protocols (both research grade and GMP compliant) will be
developed whilst ensuring cell viability and potency is maintained.
CHAPTER 2
MATERIALS AND METHODS
2.1 Laboratory Consumables and Equipment
2.1.1 Reagents and a list of producers
Reagents were stored as per manufacturer’s instructions and used before the expiry date.
Culture Media Supplier
RPMI Lonza
Methocult GF H84434 Stem Cell Technologies
Methocult GF H84444 Stem Cell Technologies
Culture Media Supplements Supplier
DNase-1 Calbiochem
Human AB serum Lonza
IL-2 Prospec
Iscove’s modified Dulbecco’s medium (IMDM) Stem Cell Technologies
L-glutamine Lonza
Magnesium chloride (MgCl2) BDH, VWR International Ltd
Penicillin-streptomycin solution Sigma
Purified NA/LE mouse anti-human CD3 BD Pharmingen
Purified NA/LE mouse anti-human CD28 BD Pharmingen
Sodium citrate BDH, VWR International Ltd
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Chemical Reagents Supplier
3H-thymidine Perkin-Elmer
Acetic acid Fisher Scientific
Annexin V binding buffer BD Pharmingen
Carboxyfluorescein succinimidyl ester (CFSE) Invitrogen
CliniMACS buffer Miltenyi Biotec GmbH
Dextran-40 Origen Biomedical
Dimethyl sulphoxide (DMSO) solution Origen Biomedical
DMSO/dextran syringes Origen Biomedical
Ethanol Shield Medicare
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich
Ficoll-Paque Premium GE Healthcare
Fixation/Permeabilization concentrate eBioscience
Fixation/Permeabilization diluent eBioscience
Isopropanol Fisher Scientific
Liquid nitrogen Cryoservice
Microscint-O scintillation fluid Perkin-Elmer
Perfect count microspheres Cytognos
Permeabilization buffer eBioscience
Pharm Lyse BD Biosciences
Phosphate buffered saline (PBS) Lonza
Presept Johnson & Johnson
RoboSep buffer Stem Cell Technologies
Sodium azide (NaN3) BDH, VWR International Ltd
Trypan blue Sigma-Aldrich
Immunochemical Reagents Supplier
7AAD BD Pharmingen
Annexin V BD Pharmingen
Mouse anti-human CD3 Pacific blue Invitrogen
Mouse anti-human CD3 PE BD Pharmingen
Mouse anti-human CD3 PerCP Biolegend
Mouse anti-human CD4 APC Biolegend
Mouse anti-human CD4 Pacific orange Invitrogen
Mouse anti-human CD4 PerCP BD Bioscience
Mouse anti-human CD25 APC-Cy7 Biolegend
Mouse anti-human CD25 PE BD Biosciences
Mouse anti-human CD25 PE-CF594 BD Horizon
Mouse anti-human CD34 PE BD Pharmingen
Mouse anti-human CD39 PE BD Pharmingen
Mouse anti-human CD45 APC BD Pharmingen
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Immunochemical Reagents continued Supplier
Mouse anti-human CD45 APC-Cy7 Biolegend
Mouse anti-human CD45 FITC BD Pharmingen
Mouse anti-human CD49d PerCP-Cy5.5 Biolegend
Mouse anti-human CD62L APC-Cy7 Biolegend
Mouse anti-human CD69 Alexa Fluor 700 BD Pharmingen
Mouse anti-human CD127 FITC BD Pharmingen
Mouse anti-human CD127 PE-Cy7 eBioscience
Mouse anti-human CD133 PE Miltenyi Biotec GmbH
Mouse anti-human CD194 (CCR4) PerCP-Cy5.5 BD Pharmingen
Mouse anti-human CD278 (ICOS) PE-Cy7 eBioscience
Rat anti-human FoxP3 APC eBiosciences
Mouse IgG1,κ Alexa Fluor 700 isotype control BD Pharmingen
Mouse IgG1,κ APC isotype control BD Pharmingen
Mouse IgG1,κ APC-Cy7 isotype control Biolegend
Mouse IgG1,κ FITC isotype control BD Pharmingen
Mouse IgG1,κ PE isotype control BD Pharmingen
Mouse IgG1,κ PE-CF594 isotype control BD Horizon
Mouse IgG1,κ PE-Cy7 isotype control eBiosciences
Mouse IgG1,κ PerCP-Cy5.5 isotype control BD Pharmingen
Mouse IgG1,κ PerCP-Cy5.5 isotype control Biolegend
Mouse IgG2a Pacific Blue isotype control Invitrogen
Mouse IgG2a Pacific Orange isotype control Invitrogen
Mouse IgG2b,κ APC isotype control Biolegend
Mouse IgG2b,κ PE isotype control BD Pharmingen
Rat IgG2a,κ APC eBiosciences
Compensation beads BD Biosciences
CliniMACS CD4 reagent Miltenyi Biotec GmbH
CliniMACS CD25 reagent Miltenyi Biotec GmbH
CD133 MicroBead kit Miltenyi Biotec GmbH
EasySep CD25 positive selection kit Stem Cell Technologies
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2.1.2 Equipment
Disposable equipment and plasticware Supplier
0.2µm filters Fisher Scientific
40µm cell strainer BD Falcon
6-well flat bottomed plates Sarstedt
24-well plates Millipore
96-well U bottomed plates Nunc
96-well plate harvester filters Perkin-Elmer
5ml Polystyrene round bottom tube BD Falcon
14ml Polystyrene round bottom tube BD Falcon
150ml Transfer bag Miltenyi Biotec GmbH
AK-100 Biosafe
Blood transfusion filter Miltenyi Biotec GmbH
Centrifugation tubes (15ml, 50ml) Sarstedt
CliniMACS TS-600 tubing set Miltenyi Biotec GmbH
Cord blood collection bags containing 25ml CPD Grifols or Macopharma
Cryopreservation bags Biosafe
Cryovials StarLabs
Eppendorf tubes Sigma-Aldrich
Filter tips (10µl, 20µl, 200µl, 1ml) StarLabs
Leucosep tubes Greiner Bio One
MACS pre-separation filters Miltenyi Biotec GmbH
MACS separation columns LD columns Miltenyi Biotec GmbH
MACS separation columns LS columns Miltenyi Biotec GmbH
MACS separation columns MS columns Miltenyi Biotec GmbH
Needles BD Microlance
Needles blunt ended BD Microlance
Pasteur pipettes Fisher Scientific
SEPAX CS490 kits Biosafe
SEPAX CS530.4 eMNC kits Biosafe
SEPAX CS900 kits Biosafe
SepMate tubes Stem Cell Technologies
Seriological pipettes (5ml, 10ml, 25ml) Sarstedt
Transwell-96 permeable support with 0.4µm pore Sigma-Aldrich
Universal tubes Fisher
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Equipment Supplier
-80◦C Freezer Sanyo
Biofuge 13, microcentrifuge Heraeus Instruments
CliniMACS Miltenyi Biotec GmbH
CO2 incubator MCO-18AIC Panasonic
Controlled rate freezer (CRF) Planar
Coolmix Biosafe
Coulter AcT 5diff CP counter Beckman Coulter
Cryocart Chart
EasySep magnet Stem Cell Technologies
FACSCalibur flow cytometer BD
FACSCanto flow cytometer BD
Gallios flow cytometer Beckman Coulter
Haemocytometer Hawksley
Mars Flow hood Scanlaf
Microplate scintillation counter Packard
Microscope Olympus BH-2
Microscope, Inverted Olympus CKX41
MidiMACS separator Miltenyi Biotec GmbH
MiniMACS separator Miltenyi Biotec GmbH
MoFlow XDP cell sorter Beckman Coulter
Nalgene Mr Frosty Thermo Fischer Scientific
Nitrogen storage tanks Chart
Rotine 420R Centrifuge Hettich Zentrifugen
SEPAX Biosafe
Syringe pump WPI SP120P2
SYSMEX XE-2100 SYSMEX
TCD blade wafers Link Medical
Top count scintillation counter Packard
Total containment device (TCD) Link Medical
Transport boxes Sarsted
Tube sealer Sebra
Waterbath GD120 Grant
Software Supplier
CellQuest Pro BD Biosciences
FACSDiva BD Biosciences
FlowJo Tree Star
Gallios Beckman Coulter
InStat GraphPad Prism
SmartDraw SmartDraw, LLC
Summit Beckman Coulter
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2.1.3 Buffers
2.1.3.1 Buffers for tissue culture
White cell counting solution Trypan blue solution
0.6% (v/v) acetic acid 0.1% (v/v) Trypan blue
PBS PBS
Freezing solution Freezing media
50% (v/v) DMSO 1% (w/v) Dextran-40
5% (w/v) Dextran-40 10% (v/v) DMSO
PBS Human AB serum
Thawing solution MACS buffer
7.5% (w/v) Dextran-40 1mM EDTA
5% (v/v) Human AB serum 1% (v/v) Human AB serum
0.63% (w/v) Sodium citrate PBS
5 mmol L−1 MgCl2
1000 IU ml−1 DNase-1
Culture media Treg suppression assay media
2.5% (v/v) Human AB Serum 1 µg ml−1 CD3
500 mM L-glutamine 2 µg ml−1 CD28
1% (v/v) Penicillin-streptomycin solution 200 IU IL-2
RPMI Culture media
2.1.3.2 Buffers for flow cytometry analysis
FACS buffer FACS lysing solution
1% (v/v) human AB serum 1% (v/v) Pharm lyse
0.1% (w/v) NaN3 Distilled water
PBS
Annexin V binding buffer CFSE staining buffer
1% (v/v) Annexin V binding buffer 5% (v/v) Human AB serum
Distilled water PBS
Fixation/permeabilisation solution Permeabilisation wash buffer
25% (v/v) Fix/Permeabilization concentrate 1% (v/v) Permeabilization buffer
75% (v/v) Fix/Permeabilization diluent Distilled water
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2.2 Sample collection and transport to the Cell Therapy
Centre
2.2.1 Ethical approval
The use of bone marrow and mobilised peripheral blood samples was approved by the
Trent Ethics Committee and authorised by Nottingham University Hospital (REC ref-
erence number: 09/H0405/15). CB units collected for the ANCTC are consented for
research use if they are not suitable for HSCTs (REC reference number: 10/H0405/27).
All samples were obtained with written, informed consent and samples were stored in
accordance with the Human Tissue Act 2008.
2.2.2 Umbilical cord blood collection
CB was collected ex utero by trained midwives. The umbilical vein was punctured and
CB collected by gravity into collection bags containing 25ml citrate-phosphate-dextrose.
Throughout this procedure, the delivery of the baby and the timing of umbilical cord
clamping was not affected in anyway.
2.2.3 Bone marrow collection
BM samples were collected from donors (one autologous and nine allogeneic) from City
Hospital, Nottingham or University College Hospital, London. The anticoagulant used
was acid citrate dextrose (ACD-A), with added Heparin if the samples showed any signs
of clotting during the harvest. The cells were filtered to remove bone fragments and a
10ml sample from each harvest was used in this study.
2.2.4 PBSC collection
Mobilised peripheral blood samples were collected from patients at City Hospital, Not-
tingham. Donors underwent a stem cell mobilisation regime using granulocyte-colony
Chapter 2 Materials and Methods 59
stimulating factor (G-CSF) involving daily subcutaneous administration of Lenograstim
(the doses given are shown in Table 2.1). PBSC harvest commenced when peripheral
blood CD34+ count ≥10/µl. Harvest was performed using the Mononuclear Cell Col-
lection program on a Spectra Optia Apheresis system. ACD-A was used to prevent
coagulation of the sample. If the required cell dose was not met, the donor was given
a further 526mcg Lenograstin and the harvest was repeated the following day. Due to
ethical reasons, when samples were collected for this study, 1ml was taken from the
donor’s PBSC sample and diluted to 10ml with autologous plasma to ensure the patient
received their full dose.
Table 2.1: Daily doses of Lenograstim administered to mobilise stem cells from BM
to periphery
Patient weight Daily dose
(kg) (mcg day)
<55 526
55-80 789
81-110 1052
>110 1315
2.2.5 Transport
CB samples are transported in a cooled environment (4-15◦C) from the maternities to the
Cell Therapy Centre on a daily basis. Between collection and transportation, samples
were maintained at refrigerated temperatures (2-8◦C). After collection of BM and PBSC,
immediate transport was arranged to the Anthony Nolan Cell Therapy Centre using a
cooled environment (4-15◦C).
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2.3 Fresh storage, cryopreservation and thawing
2.3.1 Fresh storage
Unless otherwise stated, samples were maintained at refrigerated temperatures (4-8◦C)
without agitation.
2.3.2 Freezing whole blood or CBMC
2.3.2.1 Freezing methods - Controlled Rate Freezer (CRF)
Cryopreservation bags containing 20ml sample were chilled using a Coolmix device set at
4◦C and mixed for 10 minutes. A pre-chilled DMSO/dextran-40 syringe was attached to
the bag and using a syringe pump, 5ml of the solution was added over a 10 minute period
(unless stated otherwise, see §2.5.4) on the Coolmix to give a final DMSO and dextran-
40 concentration of 10% (v/v) and 1% (w/v) respectively (unless stated otherwise, see
§2.5.5).
The bags were frozen to -120◦C in a controlled rate freezer (CRF) (see Table 2.2 and
Figure 1.3 for the freezing program) and transferred via a Cryocart to the vapour phase
of liquid nitrogen storage tanks.
Table 2.2: Control Rate Freezer (CRF) freezing program used at ANCTC
Temperature change Target temperature
(◦C min−1) (◦C)
0.0 4.0
-1.0 -10.0
-20.0 -50.0
+15.0 -18.0
-1.0 -40.0
-2.0 -60.0
-3.0 -80.0
-10.0 -120.0
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2.3.2.2 Freezing methods - Nalgene Mr Frosty freezing container
Samples to be frozen in cryovials were cooled for 10 minutes at refrigerated temperature
before the addition of chilled freezing solution, resulting in a final concentration of 10%
(v/v) DMSO and 1% (w/v) dextran-40 (unless stated otherwise, see §2.5.1). The cells
were frozen overnight in a Nalgene Mr Frosty freezing container containing isopropanol
in a -80◦C freezer before being transferred to the vapour phase of liquid nitrogen tanks.
2.3.3 Thawing protocol
Samples were maintained for a minimum of 24 hours in liquid nitrogen tanks. The
sample to be thawed was removed from the liquid nitrogen tanks and rapidly thawed in
a 37◦C waterbath. The sample was then assessed for cell recoveries and viability.
2.3.3.1 Wash protocol
In some cases the samples were washed post-thaw in order to remove DMSO. After
thawing the sample in the water bath, an equal volume of chilled thawing solution was
added dropwise. The sample was further diluted by the addition of culture medium and
the cells sedimented at 450×g for 20 minutes at 4◦C. The supernatant was carefully
removed and the pellet treated for 2 minutes with 1-2 volumes of DNase (106 ml−1).
The sample was then washed and resuspended in culture media.
2.4 CBMC isolation
2.4.1 Ficoll-Paque Premium density gradient separation
Blood sample and Ficoll-Paque Premium were warmed to room temperature. 15-30ml
of blood was carefully layered on top of 15ml Ficoll-Paque Premium in 50ml centrifu-
gation tubes. The tubes were centrifuged at 400×g for 30 minutes at 20◦C with the
brakes switched off. After centrifugation, the plasma layer was removed followed by the
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mononuclear cell layer which was washed twice with PBS before being resuspended in
20ml autologous plasma.
2.4.1.1 Leucosep density gradient separation
Blood sample and Ficoll-Paque Premium were warmed to room temperature. 15ml
Ficoll-Paque Premium was added to the Leucosep tube. To pass the separation medium
through the porous barrier, before the addition of blood, the tubes were centrifuged at
1000×g for 30 seconds at 20◦C. After ensuring the separation media is below the porous
barrier, 15-30ml of blood sample was poured on top of the barrier and the Leucosep
tubes were centrifuged at 1000×g for 10 minutes at room temperature with the brakes
switched off. 20ml plasma was removed from the tubes before pouring off the remaining
sample into a 50ml centrifugation tube, the porous barrier avoids recontamination with
granulocytes and erythrocytes. The cells were washed twice with PBS and resuspend
with 20ml autologous plasma.
2.4.1.2 SepMate density gradient separation
Blood sample and Ficoll-Paque Premium were warmed to room temperature. 15ml
Ficoll-Paque Premium was added to the Sepmate tube by passing it through the hole in
the centre of the insert. 15-30ml of blood was pippetted down the side of the tube and
spun at 1200×g for 10 minutes with the brake on. The top layer poured off and cells
washed twice with PBS.
2.4.2 eMNC processing
CB units were processed using the eMNC program on a SEPAX machine. After removal
of 1ml of blood for initial analysis, the blood bag was attached to a CS530.4 SEPAX kit
using a Total Containment Device (TCD). The blood bag and CS530.4 kit was placed
on the SEPAX device and the eMNC program initiated. When complete, the kit was
taken from the SEPAX and the final product bag sealed and removed. 300µl of the final
sample was taken from the final product bag for post-process analysis and the remaining
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sample was either cryopreserved, as described in §2.3.2.1, or CD133 cells were isolated
as described in §2.8.1.1
2.5 DMSO toxicity assessment
2.5.1 DMSO toxicity in fresh samples
CBMC units were split in to five aliquots, cooled to 4◦C and an equal volume of chilled
freezing solution was added slowly to give final concentrations of: 0% (v/v) DMSO,
1% (w/v) dextran-40; 10% (v/v) DMSO, 0% (w/v) dextran-40; 10% (v/v) DMSO, 1%
(w/v) dextran-40; 20% (v/v) DMSO, 1% (w/v) dextran-40; 40% (v/v) DMSO, 1% (w/v)
dextran-40. Numbers of viable cells were assessed immediately (time point zero, t=0)
for each aliquot by flow cytometry (protocol described in §2.7.3.1 and 2.7.3.2) and the
functional ability of the HPCs was assessed using the colony forming unit (CFU) assay
(protocol described in §2.9). The remaining volume for each aliquot was split in two,
with half stored at room temperature (19-22◦C) and half at refrigerated temperature
(4-8◦C). After set time points (1, 2 and 24 hours) the quality of the cells was reassessed
for each concentration at each temperature.
2.5.2 DMSO toxicity when delaying cryopreservation
CBMCs from 11 samples were split into two fractions. DMSO and dextran-40 was added
to one fraction reaching a final concentration of 10% (v/v) and 1% (w/v) respectively. A
1ml aliquot (t=0) was immediately removed from this fraction and frozen according to
§2.3.2.2. The other fraction was maintained without DMSO and dextran-40 during this
stage (control sample). The remaining volumes were split again with half maintained at
room temperature and the other half refrigerated. At set time points after freezing the
t=0 sample (15 minutes, 30 minutes, 60 minutes, 120 minutes and 24 hours) an aliquot
was taken from each of the four groups and frozen (10% (v/v) DMSO 1% (w/v) dextran
added to the control cells before freezing). After a minimum of 24 hours in the vapour
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phase of the liquid nitrogen tank, the samples were thawed rapidly in a 37◦C waterbath
and the quality of the cells reassessed.
2.5.3 DMSO toxicity in thawed CB
CBMCs from 10 CB units were isolated, the cell potency assessed and the samples were
cryopreserved with a final concentration of 10% (v/v) DMSO 1% (w/v) dextran in a
controlled rate freezer. After a minimum of 24 hours in the nitrogen tank the samples
were thawed in a 37◦C water bath and split into three aliquots. The first was left un-
manipulated, designated ‘not washed’ and assessed for cell potency immediately, one
sample was washed to remove all DMSO using the protocol in §2.3.3.1 and designated
‘wash’. The final section was diluted 1:1 by the drop-wise addition of thaw media to
reduce the DMSO concentration by half, this fraction was designated ‘diluted’. All three
fractions were maintained at room temperature and cell viability was assessed at t=0
(immediately post-thaw after any manipulations), 30 minutes, 1 hour, 2 hours, 24 hours
and 48 hours after t=0.
2.5.4 DMSO addition speed
CBMCs were resuspended to 40ml in autologous plasma, split and placed in in cryop-
reservation bags which were chilled using a Coolmix device set at 4◦C and mixed for 10
minutes. A DMSO/dextran-40 syringe was attached to each bag and using a syringe
pump, 5ml of the solution was added to one sample at a rate of 0.5ml minute−1, and to
another sample at a rate of 10ml minute−1 on the Coolmix to give a final DMSO and
dextran-40 concentration of 10% (v/v) and 1% (w/v) respectively. The bags were then
frozen to -120◦C in a controlled rate freezer (see §2.3.2.1 for the freezing protocol) and
cell viability reassessed upon thawing.
2.5.5 Optimal concentration of DMSO
Cell potency of fresh CBMC samples was assessed. The samples were frozen using a
CRF with different DMSO final concentrations of 10%, 7.5%, 5%, 2.5% or 0% (v/v)
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(10 CB units were frozen with each concentration of DMSO). The samples were thawed
rapidly in a water bath at 37◦C and cell potency reassessed immediately without any
post-thaw manipulations.
2.6 Cell counts
2.6.1 Manual counts
Red cells were lysed prior to counting through 1 in 4 dilution of the blood sample in the
white cell counting solution. A haemocytometer was used to enumerate the cells.
To assess viability, an equal volume of the lysed red cell suspension was diluted with Try-
pan blue solution allowing identification of the dead cells which could then be excluded
from the cell count.
2.6.2 Automated counts
Leukocyte counts were performed using either a Beckman Coulter AcT 5diff CP Counter
or SYSMEX XE-2100. These instruments quantitate a range of parameters including
leucocytes (which can be further broken down into granulocytes, lymphocytes and mono-
cytes), erythrocytes and the haematocrit.
2.7 Flow cytometry
Flow cytometry was used to identify, enumerate and assess viability of different popula-
tions of cells expressing specific markers. This technique involves directing a laser beam
onto a stream of liquid containing cells in single file. Upon contact with a cell, the beam
of light is scattered onto a series of detectors. The forward scatter (FSC) detector is in
line with the original source of light and detects the light that is deflected by the cell
which is directly proportional to its size. The side scatter (SSC) detector is perpendic-
ular to the source of light, it receives the light deflected by the internal components of
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the cell (such as the nucleus), therefore, detecting the level of granularity and structural
complexity within the cell.
Antibodies with a fluorochrome attached can be bound to the cells surface markers
or internally. When a light beam of a particular wavelength hits the fluorochrome it
becomes excited causing a release of energy in the form of light at a wavelength specific to
that particular fluorochrome. This emitted light can then be detected by other detectors
through a series of filters and mirrors allowing the identification of a bound antibody to
a particular cell.
Different flow cytometers were used during this project, a list of instruments with their
laser and filter specifications are included in Table 2.3. Each flow cytometer was cali-
brated daily according to the manufacturer’s guidlines and the calibration beads specific
to that machine.
Table 2.3: Flow Cytometers used throughout project
Machine Company Lasers Filters Software
FACSCalibur BD
blue laser (488nm) 530/30, 585/42, 670LP CellQuest
red laser (635nm) 661/16 Pro
FACSCanto BD
blue laser (488nm) 530/30, 585/42, 670LP, 780/60
Diva
red laser (633nm) 660/20, 780/60
Beckman
blue laser (488nm) 525/40, 575/30, 620/30, 696/30, 755LP
Gallios
Gallios
Coulter
red laser (638nm) 660/20, 725/20, 755LP
Software
violet laser (410nm) 450/40, 550/40
MoFlo Beckman
blue laser (488nm) 530/40, 580/30, 613/30, 670/30, 740LP
Summit
XDP Coulter
red laser (635nm) 670/30, 720/45, 780/40
Software
violet laser (405nm) 450/65, 560/40
2.7.1 Compensation and use of isotype controls
The light emitted by the fluorochromes covers a range of wavelengths, and there can
be an overlap between different fluorochromes leading to some spill-over as the light
is picked up by other detectors. To remove this spectral overlap the signal can be
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subtracted from the unwanted detectors, a process known as compensation. Compen-
sation was achieved using compensation beads which were either stained with each of
the individual fluorochromes or their isotopes. This allowed identification of the posi-
tive and negative populations for each marker and the subtraction of peaks picked up
by undesired detectors. Compensation was performed manually on the FACSCalibur,
FACSCanto and MoFlo machines and using the automated protocol on the Gallios.
Isotype controls were used at identical concentrations and staining conditions as the
antibodies in order to confirm positive detection rather that non-specific binding. The
isotype of each primary antibody used is listed in Table 2.4.
Table 2.4: List of antibodies and concentrations used for flow cytometry analysis
Antibody Fluorochrome Company Clone Isotype
Concentration
(µg/µl)
CD3 Pacific Blue Invitrogen S4.1 Ms IgG2a 0.60
CD3 PE BD Pharmingen UCHT1 Ms IgG1,κ 1.00
CD3 PerCP Biolegend SK7 Ms IgG1,κ 0.25
CD4 APC Biolegend OKT4 Ms IgG2b,κ 0.25
CD4 Pacific Orange Invitrogen S3.5 Ms IgG2a 0.60
CD25 APC-Cy7 Biolegend BC96 Ms IgG1,κ 0.25
CD25 PE BD Bioscience 2A3 Ms IgG1,κ 0.03
CD25 PE-CF594 BD Horizon M-A251 Ms IgG1,κ 0.25
CD34 PE BD Pharmingen 581 Ms IgG1,κ 0.06
CD39 PE BD Pharmingen TU66 Ms IgG22b,κ 0.19
CD45 APC BD Pharmingen HI30 Ms IgG1,κ 0.06
CD45 APC-Cy7 Biolegend HI30 Ms IgG1,κ 0.50
CD45 FITC BD Pharmingen HI30 Ms IgG1,κ 0.04
CD62L APC-Cy7 Biolegend DREG-56 Ms IgG1,κ 0.30
CD69 Alexa Fluor 700 BD Pharmingen FN50 Ms IgG1,κ 1.00
CD127 FITC BD Pharmingen HIL-7R-M21 Ms IgG1,κ 0.38
CD127 PE-Cy7 eBiosciences eBioRDR5 Ms IgG1,κ 0.50
CD194 (CCR4) PerCP-Cy5.5 BD Pharmingen 1G1 Ms IgG1,κ 1.00
CD278 (ICOS) PE-Cy7 eBiosciences ISA-3 Ms IgG1,κ 0.13
FoxP3 APC eBiosciences PCH101 Rat IgG2a,κ 0.50
Annexin V FITC BD Pharmingen N/A N/A 0.05
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2.7.2 Titrations of antibodies
The antibodies were titrated in order to avoid wasting reagents whilst maintaining the
optimal separation between positive and negative populations. 1×106 cells were stained
with a range of concentrations of antibody. The population of interest for each antibody
dilution was observed by gating on the lymphocytes through their FSC and SSC proper-
ties. The positive and negative peaks were gated and the median fluorescence intensity
(MFI) and standard deviation (SD) were calculated for each peak. The stain index (SI)
calculated with the following formula:
SI =
(MFIpos−MFIneg)
SDneg
The dilution with the highest SI was taken as the optimal antibody concentration. A
list of antibodies used and their optimal concentration are shown in Table 2.4.
2.7.3 Haematopoietic progenitor cell analysis
2.7.3.1 ISHAGE CD34+ enumeration
CD45+ and CD34+ cell enumeration was assessed based on the International Society of
Haematotherapy and Graft Engineering (ISHAGE) guidelines.426,427 For this, 0.6×106
cells were stained with anti-CD45 fluorescein isothiocyanate (FITC) and CD34 phyco-
erythrin (PE) conjugated antibodies for 15 minutes at 4◦C. Erythrocytes were removed
by incubating the cells with FACS lysing solution for 15 minutes in the dark (at room
temperature). Viability was assessed by the exclusion of cells containing 7AAD. Perfect
count beads were used for enumeration, 2000 bead events were analysed for each sample.
The formula to calculate the absolute cell count is shown below:
absolute cell count = number of cells gatednumber of beads gated × number of beads per testsample test volume
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Flow cytometry was performed on either a BD FACSCalibur or FACSCanto and anal-
ysed using CellQuest Pro or FlowJo. The gating strategy for cell enumeration is shown
in Figure 2.1.
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Figure 2.1: Flow cytometry gating strategy: HPC enumeration. HPC cells were
identified using the following criteria: low CD45 expression, high CD34 expression and
a FSC and SSC similar to that of lymphocyte cells (low SSC and low/medium FSC).
Viability was assessed through the exclusion of cells stained with the 7AAD dye.
2.7.3.2 Apoptosis assessment
The 7AAD dye, used in the standard enumeration of HPCs, penetrates cells where
the membrane is no longer intact. Therefore, only cells undergoing late apoptosis or
necrosis are identified using this dye. In order to get a more accurate viability assessment
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Annexin V was used to identify early-stage apoptotic cells by staining surface exposed
phosphatidylserine.
Apoptosis was assessed using an adaption of the ISHAGE guidelines.428 For this,
0.6×106 cells were stained with anti-CD45 allophycocyanin (APC) and CD34 PE con-
jugated antibodies and the erythrocytes lysed with using FACS lysing solution. The
cells were washed and resuspended in Annexin V binding buffer and incubated with
7AAD and Annexin V. Flow cytometry was performed on a BD FACSCalibur or FAC-
SCanto and analysed using CellQuest Pro or FlowJo. The gating strategy for viable cell
assessment is shown in Figure 2.2.
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Figure 2.2: Flow cytometry gating strategy: HPC viability. HPC cells were identified
using a slightly modified version of the HPC enumeration strategy (see Figure 2.1)
before identifying the cells stained with 7AAD and/or Annexin V.
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Enumeration of AnnV− viable cells was calculated by running this method in parallel
with the standard enumeration protocol (§2.7.3.1) and applying the following formula:
viable cell count = absolute cell count × CD34+AnnV− gated
CD34+ cells gated
Where the absolute cell count was calculated during the standard enumeration protocol.
2.7.4 T regulatory cell analysis
2.7.4.1 Treg cell surface staining
0.5×106 cells were incubated with a previously prepared antibody cocktail (containing
the conjugated antibodies for the cell surface markers of interest) for 15 minutes at 4◦C.
Following this, the cells were treating with FACS lysing solution for 15 minutes at room
temperature. Samples were washed twice and resuspended in FACS buffer before flow
cytometry assessment.
2.7.4.2 FoxP3 staining
Staining for intracellular FoxP3 requires a different protocol in which the cells are fixed
and permeabilised to allow the dye to reach the nucleus. Intracellular staining was
performed as recommended by the manufacturer (eBioscience). Cells were stained for
surface antigens as described in §2.7.4.1. After washing off excess antibody, the cells were
vortexed in order to ensure that the pellet had completely dissociated. The cells were
then resuspended in 1ml fixation/permeabilisation solution and vortexed again. After 1
hour incubation at 4◦C, the cells were washed twice using permeabilisation wash buffer.
The cells were resuspended in 100µl permeabilisation wash buffer containing the FoxP3
APC antibody or isotype control. After incubating the cells for 1 hour at 4◦C, the cells
were washed twice using permeabilisation wash buffer and resuspended in FACS buffer
before flow cytometry assessment using a FACSCanto or Gallios machine. The gating
strategy for identifying Tregs is shown in Figure 2.3.
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Figure 2.3: Gating strategy identifying T regulatory cells through the expression of
CD3+CD4+CD25highCD127lowFoxP3+.
2.7.4.3 Treg viability assessment
Percentages of apoptotic and necrotic cells were assessed on Tregs using a protocol based
on the CD34 viability assessment described in §2.7.3.2. For this, 0.5×106 cells were
stained with CD45 APC-Cy7, CD4 APC, CD25 PE and CD127 PE-Cy7 for 15 minutes
at 4◦C. Following this the cells were washed and resuspended in Annexin V binding
buffer and incubated for 15 minutes with 7AAD and Annexin V at room temperature.
2.8 Cell isolation
2.8.1 Magnetic Activated Cell Sorting (MACS)
Magnetic activated cell sorting (MACS), developed by Miltenyi Biotec, involves labelling
cells with antibodies attached to magnetic MicroBeads. The cell suspension is passed
through a MACS column containing ferromagnetic spheres placed in a magnetic field.
The labelled cells remain within the column allowing unlabelled cells to flow through
and be collected (negative selection or depletion). After washing the labelled cells can
be eluted from the column and collected (positive selection).
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2.8.1.1 CD133+ isolation using Miltenyi Biotec protocol
CBMCs were resuspended in 300µl MACS buffer per 108 cells. 100µl FcR blocking
reagent followed by the same volume of CD133 Microbeads was added per 108 cells.
The cells were mixed well and incubated for 30 minutes at refrigerated temperatures.
After incubation, any unbound reagent was washed off in 20× their volume of MACS
buffer and centrifuged at 300×g for 10 minutes before being resuspended in 2ml MACS
buffer.
An LS column (capacity of up to 108 labelled cells or 2×109 total cells) was placed in
a MidiMACS magnet with a pre-separation filter on top of the column. The column
and filter was rinsed with 3ml MACS buffer. The cell suspension was added to the filter
1ml at a time allowing the first 1ml to enter the column before adding the next. The
buffer dripping through the column contains the negative fraction and was collected. The
column was washed 4× with 3ml MACS buffer. When the washing stage was completed,
the column was carefully removed from the magnet and the positive cells eluted with
2× 5ml MACS buffer using the plunger provided with the column. The positive fraction
was centrifuged at 300×g for 5 minutes and the pellet resuspended MACS buffer.
To increase the purity, the positive fraction was passed through a second column. When
using a MS column (capacity of 107 labelled cells or 2×108 total cells) the cells were
resuspended in 500µl MACS buffer. The MS column was placed in the MiniMACS
magnet and rinsed with 1.5ml MACS buffer. The cells were added to the column 500µl
at a time and the negative fraction washed through with 4× 500µl MACS buffer. The
positive fraction was eluted with 2× 1ml MACS buffer and the cells centrifuged at 300
×g for 5 minutes.
2.8.1.2 CD4+ enrichment using Miltenyi Biotec MidiMACS
CBMCs were resuspended in 300µl MACS buffer per 108 cells. 100µl CD4 Microbeads
was added per 108 cells. The cells were mixed well and incubated for 30 minutes at
refrigerated temperatures. After incubation, any unbound reagent was washed off in
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20× their volume of MACS buffer and centrifuged at 300×g for 10 minutes before being
resuspended in 2ml MACS buffer.
CD4+ cells were enriched by passing the sample through a single LS column as described
in §2.8.1.1.
2.8.1.3 CD25+ isolation using Miltenyi Biotec MidiMACS
CD25+ isolations were performed according to the protocol suggested by Figueroa et
al .429 Briefly, CBMCs were resuspended at 300×106 cells ml−1 in MACS buffer, 4%
(v/v) CD25 reagent was added and the cells incubated for 15 minutes at room temper-
ature. The cells were washed and passed through two columns as described in §2.8.1.1.
2.8.1.4 CD25+ isolation using Stem Cell Technology EasySep
CBMCs were resuspended at 1×108 cells ml−1 in RoboSep buffer in a 14ml polystyrene
round bottom tube. The EasySep CD25 Positive Selection Cocktail was added to the
cells at 50µl ml−1 cells, mixed and incubated for 15 minutes at room temperature.
EasySep Magnetic Nanoparticles were mixed using a pipette, added at 50µl ml−1 cells
and incubated at room temperature for 10 minutes. The volume of cells was made up
to 10ml with RoboSep buffer, mixed and the tube placed in the EasySep magnet for 5
minutes. To remove unwanted cells, the EasySep magnet and tube are inverted for 3
seconds pouring off the supernatant fraction. The tube was removed from the magnet
and the remaining cells resuspended in 10ml RoboSep buffer. The tube was placed back
in the magnet and the separation step repeated a further 3 times leaving the isolated
cells within the tube.
2.8.1.5 CliniMACS
4 to 6 CB samples were pooled into one collection bag and mixed well. The volume
of the blood was reduced to 100ml using the volume reduction program on a SEPAX
device in conjunction with a CS-490 kit. CBMCs were isolated from the sample using
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the Density Gradient protocol on the SEPAX with a CS-900 kit which had 90ml ficoll
injected into the output bag.
CBMC cells were resuspended at 300×106 cells ml−1 in MACS buffer and 4% (v/v)
CD25 reagent added. The cells were incubated at room temperature for 15 minutes
before washing in MACS buffer and resuspended in 75ml MACS buffer and transferred
to a 150ml bag. A CliniMACS TS-600 tubing set was prepared, a 1L CliniMACS buffer
bag containing 1% (v/v) AB serum was spiked onto the kit and a 150ml transfer bag was
attached onto the output line. Enrichment protocol 3.2 was initiated on the CliniMACS
and the sample bag attached when directed.
2.8.2 Fluorescent Activated Cell Sorting (FACS)
Fluorescent Activated Cell Sorting (FACS) is a specialised type of flow cytometry that
allows the separation of specific cell populations based on their binding to antibodies
attached to a fluorochrome. As with flow cytometry, cells are passed in single file through
a laser beam and a series of detectors receive the light emitted by the fluorochrome. The
flow of cells is then broken down into droplets containing a single cell which is directed
into different tubes using an electrical charge
The CD4+ population was enriched from CBMCs as in §2.8.1.2. The CD4+ cells were
resuspended at a concentration of 300×106 cells ml−1 in FACS buffer and incubated
with either 15% (v/v) CD25 PE or 5% (v/v) CD25 APC-Cy7 and 15% (v/v) CD39 PE
for 15 minutes at refrigerated temperatures. Excess antibody was washed off before the
cells were reuspended at 20×106 cells ml−1 and passed through a 40µm filter. Sorting
was performed on a Beckman Coulter MoFlo (laser and filter specifications shown in
Table 2.3) under a high purity setting with the drop envelope set to 1. Sorted cells were
gated on lymphocytes and CD25+ expression with doublets excluded, these cells were
collected in a tube containing chilled human AB serum.
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2.9 Haematopoietic progenitor functional assay
The Colony-Forming Unit (CFU) assay is an in vitro assay based upon the ability of
HPCs within a semi-solid media to proliferate and differentiate into colonies in response
to cytokines. The colonies formed are enumerated and characterised according to their
morphology. The CFU assay was performed using Methocult-4434. After flow cytometry
analysis, 450 CD34+ cells were seeded into 3ml Methocult and the sample volume made
up to 300µl with Iscove’s Modified Dulbecco’s Medium. Following thorough mixing,
1.1ml was plated in duplicate. After 14 days incubation at 37◦C in humidified air and
5% (v/v) CO2, CFU colonies were scored by examination under an inverted microscope.
2.10 Treg Functional assessment
The functional capacity of Tregs are assessed by their ability to suppress the prolifera-
tion of activated CD25− cells. Within this project, the level of CD25− proliferation is
measured either through the uptake of tritiated thymidine or by observing the number
of cell divisions using flow cytometry and carboxyfluorescein succinimidyl ester (CFSE).
2.10.1 CD25− cells for proliferation
Tregs have been shown to be equally suppressive of autologous and allogeneic CD25−
cells.430–432 Therefore, throughout this project, the CD25− cells used to assess Treg
suppression were from the same adult donor. A large batch of CD25− cells were produced
which were aliquotted, cryopreserved and a single vial was thawed as required. This
ensured similar levels of proliferation and Treg contamination with the CD25− fraction
in all experiments.
2.10.1.1 Depletion of CD25
Adult mononuclear cells (PBMCs) were isolated using the protocol described in §2.4.1.
CD25+ cells were depleted using the Miltenyi Biotec MidiMACS system, cells were
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resuspended at 100×106 cells ml−1 in MACS buffer, 10% (v/v) CD25 reagent was added
and the cells incubated for 15 minutes at room temperature. The cells were washed
and passed through two columns as described in §2.8.1.1. The CD25− fraction was
resuspended in AB serum at a concentration of 10×106 cells ml−1 and aliquotted into
cryovials (1ml or 10×106 cells per vial). The cells were cooled and DMSO and dextran-
40 were added slowly to reach final concentrations of 10% and 1% respectively. Vials
were frozen as described in §2.3.2.2 and thawed as described in §2.3.3. Post-thaw total
nucleated cell (TNC) recovery and CD45+ cell viability is shown in Figure 2.4.
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Figure 2.4: Total nucleated cell recovery (TNC) and viability (assessed by 7AAD
alone or 7AAD and AnnV) of thawed CD25− cells used in the assessment of the sup-
pression functions of Tregs (n=25). Data presented as a box and whisker plot showing
medians, quartiles and ranges.
2.10.1.2 Optimisation of proliferation
To initiate proliferation in the CD25− cells, anti-CD3 and anti-CD28 are added to the
culture media. These antibodies were titrated to ensure the optimum level of prolifer-
ation was achieved. When culturing 0.1×106 CD25− fresh cells per well the optimum
concentrations were found to be 1µg ml−1 for anti-CD3 monoclonal antibody (mAb)
and 2µg ml−1 for anti-CD28 mAb, shown in Figure 2.5A.
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Figure 2.5: Optimisation of the CD25− cell proliferation assay used in the assessment
of the suppression functions of Tregs. (A) anti-CD3 mAb and anti-CD28 mAb titration
and (B) CD25− cell titration when using 1µg ml−1 anti-CD3 mAb and 2µg ml−1 anti-
CD28 mAb (due to variability between experiments, data shown is representative of 3
repeats)
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To determine the optimal proliferation conditions in the thawed CD25− cells they were
split into two post-thaw, one half was washed (as described in §2.3.3.1), whereas the
other half was not washed prior to culturing. Although the washed cells had a higher
viability of 93.6% compared to the unwashed cells (85.6%), both fractions showed similar
levels of proliferation (CPM of 32,565 and 34,465 for washed and unwashed respectively).
Therefore, the wash step was found to be unnecessary for the thawed CD25− cells. To
ensure the optimal number of CD25− cells were used in the proliferation assay, a range
of cell concentrations were cultured with 1µg ml−1 anti-CD3 and 2µg ml−1 anti-CD28
mAbs. As shown in Figure 2.5B, 1×105 cell were found to be optimal for the proliferation
assessment.
2.10.2 Assessment using uptake of 3H-thymidine
A vial of CD25− PBMCs were thawed according to §2.3.3 and resuspended to 2×106
cells ml−1 in culture medium. 50µl of the CD25− cell suspension was added to each
required well of a 96-well plate (total of 0.1×106 cells per well). The isolated Tregs were
added at a range of CD25−:CD25+ ratios (1:1 to 1:20 CD25+:CD25−). Tregs were not
added to one set of CD25− cells in order to assess the level of proliferation in these
cells and therefore, the ability of Tregs to suppress when cultured together. Each well
was made up to 100µl with culture medium. To initiate proliferation in the CD25−
population, anti-CD3 mAb and anti-CD28 mAb were added to reach concentrations of
1µg ml−1 and 2µg ml−1 respectively in each well. Each combination was performed
in triplicate and all wells had a final volume of 200µl. As controls CD25− cells were
cultured alone without the anti-CD3 mAb and anti-CD28 mAb stimulation to assess
background levels of proliferation. Also Tregs were cultured alone with anti-CD3 mAb
and anti-CD28 mAb to ensure these cells remained anergic under these conditions.
Plates were incubated at 37◦C and 5% (v/v) CO2 for 4 days before the addition of 20µl
of 0.37MBq ml−1 3H-thymidine, plates were then incubated for a further 16-18 hours.
The cells were harvested onto Unifilter GF/C plates and the levels of 3H-thymidine
uptake assessed using a Packard Top Count Scintillation Counter.
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Results were expressed as mean counts per minute (CPM) and the percentage suppres-
sion by the Tregs calculated using the following formula:
percentage suppression = 1 − ( CPMCD25-CD25+ togetherCPMCD25- alone )× 100
2.10.3 Assessment using CFSE
Carboxyfluorescein succinimidyl ester (CFSE) is a fluorescent dye which is converted
from the more permeable, carboxyfluorescein diacetate succinimidyl ester within the
cytoplasm of the cell. As CFSE is less permeable it remains within the cell and during
proliferation is partitioned equally amongst daughter cells upon each division. CFSE
can be detected on a flow cytometer, with daughter cells showing peaks with increasingly
lower intensities of expression, the area of each peak represents the numbers of cell at that
stage of the cycle. Thawed CD25− PBMCs were stained with CFSE according to the
protocol suggested by Quah et al.433 Cells were resuspended in 1ml CFSE staining buffer
in a non-wetted tube. The tube was laid horizontally and 110µl CFSE staining buffer was
placed on the non-wetted portion at the top of the tube. 1.1µl CFSE (dissolved in DMSO
to a concentration 5mM as according to manufacturer’s instructions) was resuspended
in the 110µl CFSE staining buffer at the top of the tube. The tube was inverted and
vortexed immediately in order to ensure uniform distribution of CFSE amongst the cells.
Cells were maintained at room temperature for 5 minutes and washed three times with
10× volume of CFSE staining buffer. Cells were resuspended to 2×106 cells ml−1 in
culture medium and suppression assays were performed in triplicate in 96 well plates as
described in §2.10.2.
After four days the wells from each combination were combined, washed in FACS buffer
and the cells stained with APC-conjugated anti-CD4 mAb for 15 minutes at 4◦C. 7AAD
was added to cells prior to analysis using a FACSCanto.
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The percentage suppression by the Tregs was calculated using the following formula.
percentage suppression =
% CFSE proliferating cellsCD25-CD25+ together
% CFSE proliferating cellsCD25- alone
× 100
2.10.4 Transwell assay
96 well transwell plates with 0.4µm pore inserts were used to assess if Treg suppression
occurred through a cell-cell contact dependent manner. As in the standard suppression
assay (described in §2.10.2), 0.1×106 thawed CD25− cells were added per well, 0.05×106
Tregs were placed in either the upper chamber or lower well along with the CD25− cells
(CD25+:CD25− ratio of 1:2, combinations performed in triplicate). 1µg ml−1 anti-CD3
and 2µg ml−1 anti-CD28 were added and all wells were made up to 200µl. The plate
was incubated for 4 days before 3H-thymidine addition and plate harvesting performed
as described in §2.10.2.
2.11 Statistical analysis
Results are expressed as mean ± standard deviation. Due to low numbers of replicates
the data generated did not follow a normal (Gaussian) distribution, this was confirmed
using the Kolmogorov-Smirnov Test. Therefore, when comparing paired samples, the
Wilcoxon Matched Pairs Test (comparing two samples) and Friedman Test followed by
Dunn’s Multiple Comparison Test (comparing three samples) was used. For unpaired
samples, the Mann Whitney U Test and Kruskal-Wallis Test (followed by Dunn’s Mul-
tiple Comparison Test) were used for the comparison of two and three or more samples
respectively. In any given test p<0.05 was considered to be statistically significant.
Statistical analysis was performed using GraphPad InStat.
Graphs were created using Python and the PyX package. Statistically significant re-
sults are noted within graphs using the following symbols: *p<0.05, **p<0.01 and
***p<0.001.
CHAPTER 3
TRANSPORTING CORD BLOOD TO THE BANK
3.1 Introduction
Haematopoietic progenitor cell (HPC) transplants are routinely used to restore the
haematopoietic system after high dose chemotherapy.20,21 HPCs can be obtained from
three different sources: bone marrow (BM), mobilised peripheral blood (PBSC) and
umbilical cord blood (CB). Although HPC grafts can be infused after a short storage
period post-collection they are frequently cryopreserved, such as in autologous trans-
plantation and in the case of some allogeneic procedures, particularly when CB samples
are used. A delay between harvest of the cells and their cryopreservation is becom-
ing usual as processing laboratories can be some distance from the collection centres.
Jansen et al reported that the median transport time for HPC products collected in
Europe to the USA is 37 hours (range 19-50 hours).434 Worryingly, it has also been re-
ported that PBSC and BM products with an increased transport time can lead to slower
platelet engraftment,435–437 suggesting a potential impact of the conservation conditions
on the transplantation outcomes. Optimal fresh storage conditions have not as yet been
established and the current literature remains inconclusive; according to current litera-
ture CB, PBSC and BM all have optimal storage temperatures of either 4◦C or 25◦C
depending upon which group conducted the study and over what time period (Table
3.1).19,54,438–457
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Table 3.1: Literature review of HSC fresh storage
Group
HSC Effect of Effect of
Source storage temperature storage time
Rubinstein et al.54 CB CD34+ cell recovery highest
when maintained at ambient
temperatures prior to process-
ing
Not assessed
Campos et al.438 CB Significant decrease when
maintaining cells at 4◦C prior
to freezing
No significant losses pre- or
post-thaw observed for sam-
ples kept for 24 hours at room
temperature.
Moldenhauer et al.439 CB MNC and CD34+ recoveries
decrease when stored at 4◦C
compared to room tempera-
ture
After 24 hours CFUs de-
creased for both tempera-
tures. After 72 hours CFUs
decreased further for samples
at 4◦C but increased above
the 24 hour levels for samples
at room temperature
Broxmeyer et al.19 CB CFU recoveries maintained
when stored at 4◦C and 25◦C
but not 37◦C
Progenitor cells remain func-
tionally viable for 3 days at
4◦C and 25◦C
Shlebak et al.440 CB No difference in 4◦C or 25◦C,
assessed up to 9 hours
Processing should be done in
under 6 hours, definitely be-
fore 9 hours
Louis et al.441 CB 20◦C storage resulted in re-
duced MNC recovery and
CD45+ viability compared to
4◦C
72 hour storage at 20◦C led to
reduced MNC and CD34+ re-
covery. No significant loss at
4◦C after 72 hours
Hubel et al.442–444 CB Storage preferable at 4◦C
which resulted in higher MNC
counts
Can be stored for 24 hours be-
fore losses in pre- and post-
thaw MNC and CFU-GM
observed
Tsagias et al.445 CB Reduced MNC, CD34+ and
CFU when stored at 25◦C
compared to 4◦C
Recoveries reduced to ∼60%
and ∼80% for 25◦C and 4◦C
respectively after 24 hours
and ∼20% and ∼60% for 25◦C
and 4◦C respectively after 72
hours
Solomon et al.446 CB Higher TNC, viable CD34
and CFU recovery observed at
lower temperatures
Cells can be stored >80 hours
at 4◦C, 48 hours at 25◦C and
12 hours at 37◦C before signif-
icant losses were observed
Kurtz et al.447 CB Not assessed.
Maintained at 1-6◦C
No loss in CD34+ cells 3 days
after collection
Chapter 3 Transporting cord blood to the bank 84
Continued from Table 3.1
Group
HSC Effect of Effect of
Source storage temperature storage time
Mangalik et al.448 BM Not assessed. Maintained at
4◦C
Only minor CFU losses ob-
served when stored up to five
days
Michalova et al.449,450 BM Viability maintained for
longer at cooler temperatures
Cells remained viable for two
days at 37◦C and four days at
4◦C
Kohsaki et al.451 BM Not assessed. Maintained at
4◦C
BFU-E recovery was reduced
to 84% after 2 days, 44% after
4 days and 12% after 7 days
Lasky et al.452 BM CD34+ viability and CFU re-
covery declined rapidly when
stored at 37◦C. Higher recov-
eries when cells maintained at
4◦C compared to 22◦C
Poor CFU recovery after 7
days. Cell viabilities main-
tained for 3 days at 4◦C and
22◦C
Antonenas et al.453 BM No losses between 4◦C and
room temperature over 72
hours. 37◦C storage removed
all viable CD34+ cells
Numbers of cells recovered
reduced as time progressed
PBSC Significantly greater loss of
CD34+ cells when maintained
at room temperature. Stor-
age at 37◦C removed all viable
cells
Numbers of cells recovered
reduced as time progressed.
Higher losses in allogeneic
rather than autologous
samples
Ruiz-Argu¨elles et al.454 PBSC Not assessed. Maintained at
4◦C
MNC viability remained over
90% over 72 hours
Jansen et al.455 PBSC Cell viability decreased as
temperature increased with
significant losses in CFU-GM
observed at 17◦C and 22◦C
Cell viability decreased over
96 hours, significant CFU-GM
losses observed after 24 hours
and 72 hours for samples at
22◦C and 4◦C respectively.
Moroff et al.456 PBSC Not assessed. Maintained at
1-6◦C
Samples can be maintained
for 3 days without losses in
pre- or post-thaw cell counts
and viability
Petzer et al.457 PBSC Higher CFU recoveries were
obtained when storing at 4◦C
compared to room tempera-
ture
Cells may be stored overnight
(16-20 hours) at 4◦C without
significant losses in CFU
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Quality parameters used when assessing the potency of these stem cell products usually
consist of identifying the numbers of viable cells assessed using 7AAD and numbers
of colony forming units (CFUs). In this study post-thaw CFUs are focussed on as a
main graft potency surrogate, as this has been found to be the best current predictive
marker of engraftment with a minimum of 12.0 ×104 CFU-GM kg−1 required for rapid
neutrophil and platelet engraftment.458–460 No other studies have evaluated all three
sources of HPCs in the same laboratory with the same quality parameters. This is
becoming particularly important when more centralised facilities for cell processing are
being developed. This chapter investigates the effect of temperature on the fresh storage
of CB, BM and PBSC; to determine the maximum time these cells can be stored before
losing potency and to determine the effects that different storage conditions have on the
ability to freeze and thaw the cells.
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3.2 Results
Ten CB, eleven PBSC and ten BM samples were used in this study. A schematic
representation of the experimental protocol can be found in Figure 3.1. Within 4 hours
of collection, samples were split into 1ml aliquots. One was assessed immediately and
cryopreserved (designated t=0), whilst the others were split with three stored at room
temperature (19-22◦C [20◦C]) and the remaining three at refrigerated temperatures (4-
8◦C [4◦C]). At set time points (24, 48, and 72 hours from t=0), an aliquot was taken
from each storage condition and assessed. The remaining sample was cryopreserved and
reassessed upon thawing.
Collection of 10ml sample
(CB, BM or PBSC)
Split samples into
7x 1ml aliquots
3x 1ml aliquots. Fresh
storage at refrigerated
temperature (4-8◦C)
1ml aliquot baseline
assessment (t=0)
and cryopreservation
3x 1ml aliquots. Fresh
storage at room tem-
perature (19-22◦C)
Fresh analysis of aliquots
and cropreservation at
set time points (24, 48
and 72 hours after t=0)
Thawing of aliquots
and post thaw analysis
Figure 3.1: Schematic representation of the experimental protocol used to assess the
effects of fresh storage conditions on CB, BM and PBSC samples
The mean viable nucleated and CD34+ cell counts assessed by flow cytometry and
CFUs after collection (t=0) are shown in Table 3.2 and the mean viable cells counts
after cryopreservation at t=0 are shown in Table 3.3. At the time of collection the
cell concentration varied between samples and was 12.93 ± 7.02 x106µl−1 for CB, 20.88
± 6.25 x106µl−1 for PBSC and 29.70 ± 18.86 x106µl−1 for BM. The viability of the
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samples, assessed using 7AAD, gave viabilities of 95.67 ± 8.48%, 96.74 ± 3.78% and
94.63 ± 3.07% for CB, PBSC and BM samples respectively.
Table 3.2: Mean viable cell and CFU count per micro litre in fresh CB, PBSC and
BM samples assessed at t=0
CD45+7AAD− cell CD34+7AAD− cell CFU count
count (x103 µl−1) count (µl−1) (µl−1)
CB
Mean ± SD 12.21 ± 6.58 74.99 ± 115.50 14.16 ± 10.33
(Range) (5.83-25.85) (11.03-392.30) (4.58-41.33)
PBSC
Mean ± SD 21.10 ± 6.64 234.46 ± 325.55 41.35 ± 43.93
(Range) (9.48-32.60) (75.71-1205.60) (7.50-168.00)
BM
Mean ± SD 27.97 ± 17.26 484.29 ± 453.89 104.91 ± 102.53
(Range) (8.48-66.50) (93.87-1427.20) (16.50-297.75)
Table 3.3: Mean viable cell and CFU count per micro litre in post-thaw CB, PBSC
and BM samples after cryopreservation at t=0
CD45+7AAD− cell CD34+7AAD− cell CFU count
count (x103 µl−1) count (µl−1) (µl−1)
CB
Mean ± SD 10.55 ± 6.96 64.95 ± 119.58 7.98 ± 8.16
(Range) (3.38-23.63) (8.01-401.76) (1.56-30.00)
PBSC
Mean ± SD 18.62 ± 5.46 208.84 ± 278.36 15.92 ± 9.93
(Range) (6.99-28.32) (56.96-1026.19) (6.25-33.75)
BM
Mean ± SD 12.70 ± 10.77 252.98 ± 258.00 83.18 ± 98.89
(Range) (2.42-41.43) (41.99-900.00) (2.50-273.75)
3.2.1 The effect of storage temperature and time on CD45+7AAD−
cells
To elucidate the optimum storage condition for the three sources of HPCs, numbers of
viable CD45+ cells assessed by 7AAD were monitored and the effects of the two tem-
peratures compared, the results are shown in Figure 3.2. In CB the CD45+7AAD− cell
count shows a significant difference between the two storage temperatures after 72 hours
with recoveries of 86.78 ± 11.64% at 20◦C and 94.14 ± 9.57% at 4◦C (p=0.0004). This
significant decline at 72 hours was also observed in viable granulocytes (97.54 ± 16.29%
and 76.79 ± 23.71% for 4◦C and 20◦C respectively, p=0.02) and mononuclear cells (99.41
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± 8.86% and 90.68 ± 9.33% for 4◦C and 20◦C respectively, p=0.0008) identified by flow
cytometry through CD45 expression and side scatter. No statistical difference was ob-
served between the two fresh storage temperatures over the 72 hour time period in the
post-thaw analysis. The mean PBSC CD45+7AAD− cell count also showed a differ-
ence between the two storage temperatures after 72 hours (p=0.03). Post-thaw cells
stored at 20◦C for 24 hours prior to cryopreservation resulted in a higher recovery of
CD45+7AAD− (p=0.009), however, after 48 hours, cells stored at 4◦C exhibited higher
recovery over 20◦C and became significantly greater after 72 hours (p=0.02). Although
no significant difference was identified in BM CD45+7AAD− cells, a trend to higher
recoveries after storage at 4◦C was observed in fresh samples. With a recovery after 72
hours of 77.55 ± 15.62% at 20◦C and 97.24 ± 40.65% at 4◦C (p=0.24).
All three sample types maintained at 4◦C in fresh, and prior to cryopreservation re-
sulted in higher CD45+7AAD− recoveries post-thaw. As a result of this, the effects of
prolonged storage time were assessed in samples maintained at 4◦C. CB CD45+7AAD−
cell counts show a gradual decrease in the samples over the 72 hours time period, but
were not significant (p=0.08 for fresh and p=0.58 for thawed). However, the granulo-
cyte subpopulation declined by a significant amount after 72 hours (recovery of 76.79
± 23.71%, p=0.02). Mean PBSC CD45+7AAD− cell count decreased by a significant
amount after 48 hours of 4◦C storage (89.75 ± 13.32% recovery p=0.03). This loss was
observed earlier in thawed samples and resulted in a significant decrease after 24 hours,
with a recovery of 91.39 ± 10.53% (p=0.04). This decrease was observed in the gran-
ulocyte cell subpopulation (recovery of 74.76 ± 16.36%, p=0.01). BM CD45+7AAD−
recovery resulted in no significant difference after 72 hours of fresh storage. However,
when assessed post-thaw, a significant loss in CD45+7AAD− cells was detected after 72
hours with a recovery of 68.66 ± 26.85% (p=0.005). This decrease was also observed in
the mononuclear cell subpopulation with a recovery of 70.55 ± 29.93% (p=0.02).
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Figure 3.2: Mean CD45+7AAD− recovery in HPC products during prolonged fresh
storage at different temperatures and the effects of prolonged storage before cryopreser-
vation in (A) fresh CB cells, (B) post-thaw CB cells, (C) fresh PBSCs, (D) post-thaw
PBSCs, (E) fresh BM cells, and (F) post-thaw BM cells (n=10 for CB and BM and
n=11 for PBSC). Error bars correspond to the SEM. * p<0.05 between storage tem-
peratures. † p<0.05 in cells stored at refrigerated temperatures compared to t=0.
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3.2.2 The effect of storage temperature and time on CD34+7AAD−
cells
Temperature assessment of CD34+7AAD− in Figure 3.3, showed a trend towards higher
recoveries in fresh CB samples stored at 4◦C. However, a significant difference was
observed in the thawed samples after 48 hours storage prior to cryopreservation (74.95 ±
24.89% recovery after 20◦C storage against 90.14 ± 21.34% after 4◦C storage, p=0.046).
An increased loss of CD34+7AAD− cells was observed in PBSC samples after 72 hours in
cells stored at 20◦C over 4◦C, both in fresh and thawed samples (p=0.01 for fresh samples
and p=0.005 post-thaw). Although no significant difference was observed between BM
samples stored at 20◦C or 4◦C throughout the 72 hours, those at 4◦C exhibited a higher
mean recovery.
When assessing the effects of time on the HPC sources at 4◦C, CB showed a decrease
in the fresh CD34+7AAD− cell counts in the first 24 hours after collection (recovery
of 81.82 ± 19.24%, p=0.03). A significant reduction was also observed after 72 hours
in fresh samples as well as in the thawed samples (86.27 ± 16.39% p=0.03 for fresh
and 86.16 ± 18.29%, p=0.04 for thawed samples). A significant reduction in PBSC
CD34+7AAD− cells was observed after 48 hours in both fresh and thawed samples
(90.03 ± 14.84% fresh recovery p=0.05, 86.80 ± 14.13% thaw recovery p=0.005). This
significant difference continued to samples stored for 72 hours prior to cryopreservation
(p=0.002). In BM a significant loss was observed after 48 hours fresh storage at 4◦C
(recovery of 85.58 ± 17.02%, p=0.03) and later in the thawed samples after 72 hours
(recovery of 70.20 ± 24.46%, p=0.003).
Chapter 3 Transporting cord blood to the bank 91
† †
0
25
50
75
100
P
er
ce
n
ta
ge
re
co
ve
ry
0 24 48 72
A
∗ †
0
25
50
75
100
0 24 48 72
B
∗†
0
25
50
75
100
P
er
ce
n
ta
g
e
re
co
ve
ry
0 24 48 72
C
† †∗
0
25
50
75
100
0 24 48 72
D
†
0
25
50
75
100
P
er
ce
n
ta
g
e
re
co
v
er
y
0 24 48 72
Time (hours)
20C
4C
E
†
0
25
50
75
100
0 24 48 72
Time (hours)
F
Figure 3.3: Mean CD34+7AAD− recovery in HPC products during prolonged fresh
storage at different temperatures and the effects of prolonged storage before cryopreser-
vation in (A) fresh CB cells, (B) post-thaw CB cells, (C) fresh PBSCs, (D) post-thaw
PBSCs, (E) fresh BM cells, and (F) post-thaw BM cells (n=10 for CB and BM and
n=11 for PBSC). Error bars correspond to the SEM. * p<0.05 between storage tem-
peratures. † p<0.05 in cells stored at refrigerated temperatures compared to t=0.
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3.2.3 The effect of storage temperature and time on CD34+AnnV−7AAD−
cells
The use of 7AAD to assess cell viability is common in CB banks, however, this stain only
detects necrotic and late apoptotic cells. Consequently Annexin V was used to identify
early apoptotic cells giving an improved viability assessment, which has been found in a
previous study to correlate with CFU.428 The assessment of fresh storage temperature
on CD34+AnnV−7AAD− cells is shown in Figure 3.4.
In the CB samples, a trend to higher mean recoveries was observed when cells were stored
at 4◦C. As with the CD34+7AAD− enumeration, these differences were not found to be
significant. Lower CD34+AnnV−7AAD− counts were observed in PBSC samples stored
at 20◦C after 72 hours in both the pre- and post-thaw assessment (p=0.0151 and p=0.047
pre- and post-thaw respectively). As in the CB analysis, no significant difference was
observed between the two storage temperatures over 72 hours for BM samples (76.59 ±
41.67% and 81.45± 36.56% recovery after 72 hours for 4◦C and 20◦C respectively).
Storing CB at 4◦C for up to 72 hours prior to cryopreservation did not result in a signifi-
cantly reduced CD34+AnnV−7AAD− cell recovery (87.16 ± 7.03% and 89.97 ± 18.32%
for fresh and post-thaw analysis respectively). Higher numbers of CD34+AnnV−7AAD−
cells were lost in the PBSC samples with a mean recovery of 73.42 ± 11.67%, p=0.0395
after 48 hours, which was further reduced to 63.72 ± 18.01%, p=0.0097 after 72 hours.
Delaying cryopreservation of BM for up to 72 hours at 4◦C did not result in significantly
reduced CD34+AnnV−7AAD− recovery in the pre- and post-thaw assessment (76.59 ±
41.67% and 76.00 ± 48.65% for fresh and post-thaw analysis respectively).
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Figure 3.4: Mean CD34+AnnV− 7AAD− recovery in HPC products during prolonged
fresh storage at different temperatures and the effects of prolonged storage before cry-
opreservation in (A) fresh CB cells, (B) post-thaw CB cells, (C) fresh PBSCs, (D)
post-thaw PBSCs, (E) fresh BM cells, and (F) post-thaw BM cells (n=10 for CB and
BM and n=11 for PBSC). Error bars correspond to the SEM. * p<0.05 between storage
temperatures. † p<0.05 in cells stored at refrigerated temperatures compared to t=0.
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3.2.4 The effect of storage temperature and time on CFU assessment
CFU is currently considered to be the best predictor of engraftment and therefore, its
assessment is the best way of assessing the potency of HPC samples.458–460 CFU analy-
sis was performed on all aliquots, and photographs of CFU dishes from a CB sample are
shown in Figure 3.5. Comparing the two storage temperatures on the CFU recovery of
fresh HPC products a trend of higher recoveries when stored at 4◦C was observed, data
shown in Figure 3.6. However, in the post-thaw samples, the difference was shown to be
significant. In CB a significant difference was observed after 72 hours (recovery of 38.50
± 31.65% and 54.12 ± 34.2% for 20◦C and 4◦C respectively p=0.02), 48 hours for PBSC
(45.56 ± 20.23% for 20◦C against 67.34 ± 26.19% for 4◦C p=0.01) and 24 hours for BM
samples (40.51± 11.52% for 20◦C against 63.60± 28.03% for 4◦C p=0.02). This suggests
that 4◦C is the optimum temperature to maintain all three HPC samples after collection.
Figure 3.5: Photographs of CFU dishes from a CB sample taken during the assessment
of the effects of fresh storage conditions when delaying cryopreservation. CFU dishes
from a fresh (top row) and thawed (bottom row) CB sample at t=0 (left column) or
72 hours after storage at 20◦C (middle column) or 4◦C (right column). Dishes shown
are representative of 10 CB samples. Photographs taken and stitched together using a
StemVision (Stem Cell Technologies).
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Figure 3.6: Mean CFU recovery in HPC products during prolonged fresh storage at
different temperatures and the effects of prolonged storage before cryopreservation in
(A) fresh CB cells, (B) post-thaw CB cells, (C) fresh PBSCs, (D) post-thaw PBSCs,
(E) fresh BM cells, and (F) post-thaw BM cells (n=10 for CB and BM and n=11 for
PBSC). Error bars correspond to the SEM. * p<0.05 between storage temperatures. †
p<0.05 in cells stored at refrigerated temperatures compared to t=0.
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For samples stored at 4◦C, time had a continuous influence on the potency of the HPCs
both in the fresh and post-thaw data. A statistically significant reduction in CFUs from
those at t=0 in CB samples stored at 4◦C was observed after 48 hours in both fresh (61.82
± 24.36% recovery, p=0.0008) and thawed samples (60.40 ± 26.42% recovery, p=0.001).
Although a decline was noted, no significant loss of CFU was observed in fresh PBSC
samples stored at 4◦C. However, cryopreservation after 48 hours fresh storage resulted in
a thaw CFU recovery of 67.34 ± 26.19% compared to those frozen at t=0 (p=0.006). BM
samples resulted in a significant reduction in CFUs after 48 hours 4◦C storage (67.25 ±
31.25% recovery compared to fresh t=0 p=0.009). In contrast a significant reduction was
observed after 24 hours in the post-thaw samples (63.60 ± 28.03% recovery compared to
thaw t=0 p=0.003). Table 3.4 summarises the main results regarding banking showing
the CFU percentage losses after delaying cryopreservation.
Table 3.4: Mean post-thaw CFU loss in CB, PBSC and BM after prolonged storage at
refrigerated temperatures prior to cryopreservation. Percentages indicate mean recovery
± s.d. and p values indicate differences in cells stored at refrigerated temperatures for
up to 72 hours prior to cryopreservation compared to those frozen at t=0
24 hours 48 hours 72 hours
CB 19.59 ± 30.24% 39.62 ± 26.42% 45.88 ± 34.22%
p value 0.071 0.001 0.002
PBSC 21.88 ± 40.15% 32.66 ± 26.19% 39.46 ± 17.86%
p value 0.141 0.006 0.0002
BM 36.40 ± 28.03% 52.21 ± 11.68% 75.74 ± 8.73%
p value 0.003 9.1x10−7 5.1x10−9
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3.3 Discussion
These studies are the first to identify the effects of time and different storage temper-
atures prior to cryopreservation on the viability and CFU capacity of cells of all three
sources of HPCs. Higher recoveries were obtained, in all cell types assessed, for sam-
ples maintained at refrigerated temperatures prior to cryopreservation. The difference
between the two storage temperatures was significant in CD45+ cells after 72 hours for
PBSC samples; in CD34+ cells after 48 hours for CB and 72 hours for PBSC; and in
CFUs after 24 hours for BM, 48 hours for PBSC and 72 hours for CB. The assessment
of time showed continuous reductions in the numbers of viable cells and CFUs pre- and
post-thaw, however, there were slight differences between the sources of HPCs. CB post-
thaw viable CD45+ cell recoveries showed a gradual, but not significant decline over the
72 hours, however, PBSC and BM samples gave a significant difference compared to
samples frozen at t=0 after delays of 24 hours (p=0.04) and 72 hours (p=0.005) respec-
tively. The effect of an increased delay prior to cryopreservation on viable CD34+ cell
recovery in PBSC samples resulted in a significant difference after 48 hours (p=0.005),
a significant loss occurred later in CB and BM samples at 72 hours (p=0.04 and 0.003
respectively). CFU recovery declined significantly after a 24 hour delay prior to cry-
opreservation in BM samples and after a 48 hour delay in CB (p=0.001) and PBSC
samples (p=0.003). However, although losses in CFUs were not significant in CB and
PBSC samples until 48 hours, 19.59% of CFUs were lost in CB and 21.88% lost in PBSC
samples after a delay of 24 hours. CB units are routinely frozen and banked prior to
transplantation; this data suggests that units should be maintained at refrigerated tem-
peratures and cryopreserved as soon after collection as possible (preferably within the
first 24 hours, but no later than 48 hours) in order to retain the highest possible potency
of the cells. This range is in support of the current recommendations of FACT Netcord
standards461 and in agreement with other studies.441–445,462,463 The PBSC results con-
firm earlier reports that the viability of the cells within samples are maintained best
when stored at refrigerated temperatures.455–457,464,465 The fresh BM results are consis-
tent with those obtained by other groups.451–453 However, upon thawing, BM samples
resulted in low viable cell and CFU recoveries, suggesting it is better to maintain BM
Chapter 3 Transporting cord blood to the bank 98
samples in a fresh state for up to 72 hours than to cryopreserve. In this study cells were
stored in 1ml aliquots in cryovials to compare different conditions on the same sample.
However, in this experimental set up, the cryopreservation protocol is not consistent
with that used in clinical processing in which larger volumes are cryopreserved with
the use of controlled rate freezers. Although comparing these two methods of cryop-
reservation in CB samples resulted in 7.27% fewer CFUs recovered when freezing small
volumes (data shown in §5.2.2), we still consider the pattern of recoveries to be repre-
sentative. In conclusion, this study highlights the importance of minimising the delay
between collection of a sample and cryopreservation or infusion into a patient. Thawed
cell products resulted in significantly decreased CFU recoveries when cryopreservation
had been delayed for 24 hours in BM samples and 48 hours for both CB and PBSC
samples. As the CFU dose given to a patient is the best current predictive marker of
engraftment,458–460 this study shows that delays in cryopreservation can increase risk
for an unsuccessful transplant.
Based on these observations, CB samples are transported to the ANCTC in a cooled
environment using a validated transport box that maintains a temperature range of
4◦C to 15◦C. If this temperature range is not met during transportation, samples are
processed as normal but with additional viability tests post-thaw to ensure the cells
maintained an acceptable level of potency. The ANCTC now also aims to process and
cryopreserve all CB units designated for HSCT banking within 24 hours of collection.
However, this is not always possible due to the high costs of courier runs between the
maternity and ANCTC which cannot occur more than once per day. Therefore, to avoid
the CFU losses observed after 48 hours ANCTC has set a maximum time for cryop-
reservation to 36 hours after collection. Any CB samples that cannot be cryopreserved
within this timeframe are downgraded to research use only but can still be stored within
the Biobank.
CHAPTER 4
ISOLATION OF CBMC
4.1 Introduction
The collected volume of cord blood (CB) is highly variable; since August 2012 the average
volume received at the Anthony Nolan Cell Therapy Centre (ANCTC) is 97.36ml (range
14.32ml to 297.30ml, n=7195). For the efficient storage of a large number of different
units in cryotanks, each one has its volume reduced to 21ml, regardless of the cell density,
and is stored at 25ml (after the removal of a final sample for analysis and addition of 5ml
cryoprotectant solution). The CB units designated for potential haematopoietic stem
cell transplantation (HSCT) use undergo volume reduction by SEPAX (produced by
Biosafe).466 The samples that are unsuitable for HSCT and designated for the Biobank
will also require volume reduction in order to fit within the cryotanks.
A complete description of the SEPAX machine is beyond the scope of this work. Briefly,
this is a fully automated closed system which removes a proportion of the erythrocytes
and plasma, reducing the sample to the required volume for storage. The input blood
bag is attached to a single use, sterile tubing set consisting of separation chamber and
output bags for the different fractions connected by a series of tubes and valves (Figure
4.1). The separation chamber is a large syringe which when placed inside the SEPAX
device rotates along its vertical axis applying centrifugal forces on the blood sample. This
99
Chapter 4 Isolation of CBMC 100
Figure 4.1: Biosafe’s SEPAX device and CS540 processing kit. Images from
http://www.biosafe.ch
separates the sample into three fractions according to cell density; plasma collects down
the centre of the tube and denser erythrocytes are pushed to the outer wall leaving the
buffy coat to collect in the middle (Figure 4.2). After centrifugation, the blood is pushed
out of the separation chamber, plasma first followed by the buffy coat and finally the
erythrocytes. As the fractions are pushed into the tubing, they pass through an optical
sensor which detects the cellular content through differences in light absorbance, and
directs the various fractions to their designated collection bag through a series of valves.
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2.Centrifugation1. Chamber fills 3. Plasma extraction 3. RBC extraction4. Buffy coat extraction
Figure 4.2: The process of cell separation through centrifugation by Biosafe’s SEPAX
device and tubing sets. Images adapted from http://www.biosafe.ch
The isolation of mononuclear cells (MNC) is often required for their use in research and
cell therapy. A common procedure for obtaining mononuclear cells (MNC) is the Ficoll
Density Gradient Method (Ficoll).467–469 This involves the careful layering of blood on
top of Ficoll, a polysaccharide with a specific density, followed by centrifuging the blood
and Ficoll at a low speed. Upon contact with the Ficoll, the erythrocytes aggregate and
form a rouleaux∗ increasing their density. During centrifugation the denser red blood
cells (RBC) and granulocytes (Gr) sediment allowing easy removal of the MNCs. There
are several shortcomings with this procedure; the lack of processing reproducibility,
high user variability, the open nature of the system and the time consuming layering of
the blood on top of the Ficoll. If the layer between Ficoll and blood is not clear and
distinct prior to centrifugation, the MNC layer not form after centrifugation and cells
will be lost. Therefore, care must be taken when layering the blood on top of the Ficoll,
and when removing the MNC layer post-centrifugation, in order not to mix the layers.
This can take some time and requires a certain level of skill leading to low processing
reproducibility and high user variability. This process requires the addition of Ficoll and
is performed in 50ml tubes increasing the risk of contamination.
Biosafe has developed a protocol, named eMNC, using a SEPAX machine that would
be a potential alternative to the Ficoll method. Volume reduction processes involving
the SEPAX use sealed, sterile tubing sets consisting of a chamber for centrifugation
and various output bags for the different fractions all connected by a series of tubes
and valves. This tubing set ensures the samples maintain their sterility. The eMNC
∗Due to their flat discoid shape erythrocytes can stack together forming long chains which resemble
a stack of coins. These structures are called rouleaux and can be induced by resuspending the cells in
macromolecules such as dextran and Ficoll.470
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process aims to separate the MNC fraction through centrifugation alone without the
need for a density gradient media, such as Ficoll. As the sample is pushed back out
of the centrifugation chamber, it passes through an optical sensor which identifies the
cellular content, and a series of valves direct each fraction to a designated collection bag.
Removing the need to add Ficoll further minimises the risk of contamination. Although
the new protocol takes roughly the same time as the Ficoll method, another potential
advantage is that it is completely automated, removing user variability and allowing a
technician to be free to perform other duties.
As part of a collaboration with Biosafe, the aim of this study is to assess if this new
protocol can be used as an alternative to the Ficoll method. To achieve this the eMNC
products must have a final volume of 21ml with similar or improved MNC recovery,
granulocyte and erythrocyte depletion compared to the Ficoll method. A maximum
final haematocrit† limit of <5% has been set as a target for erythrocyte depletion.
†the percentage volume that the erythrocytes occupy within the blood sample
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4.2 Results
4.2.1 eMNC
CBMCs (cord blood mononuclear cells) were isolated using either the new eMNC pro-
gram on a SEPAX machine or with the Ficoll method. Data were reported back to
Biosafe who made alterations to the eMNC program and sent updated versions back for
testing.
Three versions of the eMNC protocol released by Biosafe were assessed and compared
to 116 CB units processed with Ficoll (versions 1 and 4 were not released for testing).
The CB samples processed using the eMNC protocol had a mean initial volume of
75.72ml (range 55.13 to 100.59ml). The eMNC program was successfully able to reduce
these volumes to a mean of 21.18ml (range of 14.79 to 22.47%). The first version of
eMNC tested (version 2) showed a greater total nucleated cell (TNC) recovery of 46.07
± 26.09% compared to 33.70 ± 10.98% in the units processed using Ficoll. This higher
TNC recovery was due to not as a result of an increase in MNC recovery (46.14 ± 18.73%
for eMNC against 46.26 ± 18.28% for Ficoll), but due to the higher granulocyte recovery
(32.06 ± 28.47% for eMNC against 11.88 ± 10.57% for Ficoll, p=0.00748). Version 2
also shows a higher erythrocyte (RBC) recovery for the eMNC product (6.60 ± 3.97%
for eMNC against 0.46 ± 0.72% for Ficoll, p<0.0001). The visual appearance of the
eMNC product also confirms higher levels of erythrocyte contamination when compared
to a product processed with Ficoll. The median post-process haematocrit level (HCT)
of the eMNC product is 8.44 ± 0.05% compared to 0.30 ± 0.86% for the Ficoll products
(p<0.0001). Version 3 (the second to be assessed) had alterations to the program in
an attempt to improve the granulocyte and erythrocyte depletion. The products from
this version had improved MNC recovery of 58.69%, but similarly poor granulocyte and
erythrocyte recoveries of 32.15 ± 23.97% and 7.73 ± 4.94% respectively. Changes made
to the final version released for testing (version 5) included an update in the tubing set
kit test prior to the process, the erythrocytes were redirected to a separate bag rather
than remaining in the separation chamber at the end of the run and also improvements
were made to the ‘tube cleaning’ with the aim to reduce erythrocyte contaminants. This
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version showed improved granulocyte depletion (recovery of 21.02 ± 10.34%), but a high
erythrocyte recovery of 8.96 ± 2.44% with a HCT of 11.88 ± 0.03% which is still much
higher then the 5% limit initially set. Viability assessment of both Ficoll and the three
eMNC versions tested all resulted in high levels of CD45+7AAD− (>99%).
∗∗∗∗∗
∗∗∗∗∗∗∗∗∗
∗∗∗∗∗∗∗∗∗
0
20
40
60
80
P
er
ce
n
ta
g
e
R
ec
ov
er
y
T
N
C
M
N
C
N
eu
t
C
D
34
+
R
B
C
H
C
T
Version 2 Version 3 Version 5 Manual Ficoll
∗∗∗∗∗
∗∗∗∗∗∗∗∗∗
∗∗∗∗∗∗∗∗∗
0
20
40
60
80
P
er
ce
n
ta
ge
R
ec
ov
er
y
T
N
C
M
N
C
N
eu
t
C
D
34
+
R
B
C
H
C
T
Version 2 Version 3 Version 5 Manual Ficoll
Figure 4.3: Isolation of CBMCs: eMNC versus manual ficoll - cell products. Com-
paring the three versions of the eMNC program against manual Ficoll in the isolation
of mononuclear cells from CB (n=14 for version 2, n=16 for version 3, n=5 for version
5 and n=116 for Ficoll). Error bars correspond to the SEM.
*p<0.05, **p<0.01 and ***p<0.001 compared to the Ficoll method
4.2.1.1 Cryopreserving eMNC products
The ability to cryopreserve the eMNC products was assessed and the cell recoveries
and viability compared to post-thaw Ficoll products (Figure 4.4). Lower TNC, CD34+
cell and CFU recoveries were observed post-thaw in the eMNC products compared to
samples processed using Ficoll. The eMNC units also had lower viabilities (assessed
using 7AAD and AnnV), however, these differences were not found to be significant.
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Figure 4.4: Isolation of CBMCs: eMNC versus manual ficoll - post-thaw cell recoveries
and viability. Comparing post-thaw cell recovery and viability of eMNC version 5 (n=4)
and Ficoll (n=4) processed products. Error bars correspond to the SEM.
4.2.1.2 Cell isolation from eMNC products
MNC enrichment procedures are commonly performed prior to isolating pure cell popula-
tions. Therefore, the ability to isolate CD133+ cells from eMNC products was compared
to isolations from cells processed using the Ficoll method. Seven CD133+ cell isolations
were performed, three of which were on units processed by eMNC and the other four
were on units processed using Ficoll. As shown in Figure 4.5, the isolations from the
eMNC products resulted in CD133+ fractions with lower purity compared to Ficoll sam-
ples (77.97 ± 8.03% and 88.98 ± 7.60% for eMNC and Ficoll respectively, p=0.0106).
Isolations using eMNC products also resulted in lower levels of CD133+ cell recovery
(36.6 ± 10.00% and 44.84 ± 12.28% for eMNC and Ficoll respectively). Similar CD133+
viability and CFU recoveries were observed for both MNC isolation methods.
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Figure 4.5: Isolation of CBMCs: eMNC versus manual ficoll - CD133+ cell isolation.
(A) Dot plot showing CD133+ cells in whole blood and post-isolation. Data shown rare
epresentative of 4 samples. (B) Comparing the products from CD133+ isolations from
CBMCs isolated using Ficoll (n=4) or the eMNC version 5 program (n=3). Error bars
correspond to the SEM. * denotes a p<0.05, ** denotes a p<0.01 and *** denotes a
p<0.001
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4.2.2 Optimising Ficoll density gradient protocol
The eMNC separation protocol was found not to be a suitable alternative to Ficoll due
to high levels of contaminating erythrocytes and granulocytes in the cell product. There-
fore, to improve Biobanking processes, the Ficoll method currently used at ANCTC (as
described in §2.4.1) was further optimised for CB samples.
4.2.2.1 Diluting blood before layering
Prior to isolating MNCs using Ficoll, blood is often diluted 1:1 or 1:2 with PBS. This
reduces the density of the blood making layering over Ficoll easier. Dilution also reduces
the cell concentration preventing MNCs from becoming trapped as the erythrocytes
aggregate and fall to the bottom of the tube. The need to dilute CB prior to MNC
enrichment was assessed. By removing the dilution step fewer tubes would be required,
speeding up the process and reducing the cost of reagents and consumables. To assess
the feasibility of using whole blood CB samples were split into two fractions, one of
which was diluted 1:1 with PBS, the other fraction left undiluted. Ficoll separation was
performed on both fractions and the cell products compared (results shown in Figure
4.6). Dilution of CB prior to MNC isolation resulted in an increase in TNC recovery
compared to undiluted samples. However, no difference in the MNC (lymphocyte and
monocyte populations) recovery was observed. The increase in TNC recovery was found
to be due to lower levels of granulocyte depletion (granulocyte recovery of 30.59 ± 16.42
and 18.44 ± 19.46 for diluted and undiluted samples respectively p=0.0195). Both
methods resulted in high levels of erythrocyte depletion with low final haematocrit levels
of <1%.
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Figure 4.6: Assessing the effects of diluting blood prior to CBMC isolation using the
Ficoll Density Gradient Protocol (n=10). Error bars correspond to the SEM. * denotes
a p<0.05, ** denotes a p<0.01 and *** denotes a p<0.001
4.2.2.2 Specialised tubes developed for Ficoll processing
Specialised tubes have been developed to improve the Ficoll density gradient method.
Greiner Bio-One have developed the Leucosep tube and Stem Cell Technologies devel-
oped the Sepmate tube. These tubes are similar to the ‘standard’ 50ml Falcon tubes
except the addition of a barrier separating Ficoll from the blood. This reduces the time
required for the Ficoll process (shown in Figure 4.7)
The Leucosep tubes contain a porous barrier which allows Ficoll to pass through into the
lower chamber during a short centrifugation step. Ficoll passes into the lower chamber
of a Sepmate tube through a small opening in the barrier. Blood can be poured directly
on top of the barrier without the risk of mixing with the Ficoll. During centrifugation
the barriers allow erythrocytes to pass through and remain in the lower chamber. As the
erythrocytes cannot remix with the MNCs in the top chamber, the brakes can be applied,
reducing the time for centrifugation. The cells remaining in the top chamber containing
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the MNCs are poured off and washed. The cell products isolated using Leucosep and
Sepmate tubes were compared to standard tubes without the barrier (Figure 4.8).
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Figure 4.7: Ficoll Density Gradient Protocol using different tubes: (A) Standard Fal-
con tubes, (B) Leucosep tubes or (C) Sepmate tubes. Diagram created using Smart-
Draw.
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Figure 4.8: Ficoll Density Gradient Protocol using different tubes: Mean cell recover-
ies after mononuclear cell isolation using either Leucosep, SepMate or standard Falcon
tubes (n=5). Error bars correspond to the SEM. * denotes a p<0.05, ** denotes a
p<0.01 and *** denotes a p<0.001
High levels of erythrocyte depletion was achieved using all three types of tubes with
a final haematocrit level of <1%. The TNC recovery was highest for Leucosep tubes
due to slightly increased lymphocyte and monocyte cell recovery, but also the high
granulocyte recovery of 63.49 ± 35.8% compared to 25.24 ± 10.07% for the Sepmate
tubes (p=0.0061) and 26.97 ± 13.5% for standard tubes (p=0.0029). The Sepmate tube
resulted in similar levels of granulocyte depletion compared to standard tubes, however,
the recovery of MNCs was slightly reduced. Therefore, the standard tubes proved to be
the most efficient when isolating MNCs using Ficoll.
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4.3 Discussion
The eMNC protocol was successfully able to reduce the volume of a CB unit to 21ml
allowing easier storage within the nitrogen cryotanks. The units processed by eMNC
resulted in a cell product with higher MNC recoveries and CD34 recoveries that are
comparable to units processed by Ficoll. The viabilities of the cells (assessed by 7AAD)
were comparable to units processed by Ficoll. However, the eMNC protocol consistently
resulted in a cell product with a lower depletion of granulocyte and erythrocytes and
with a final haematocrit above the 5% target. Post-thaw analysis of units processed
by eMNC and Ficoll resulted in slightly lower cell recoveries, viability and lower CFUs.
This is potentially due to the higher levels of contaminating granulocytes (discussed
further in Chapter 5).
The HPC isolations performed on both eMNC and Ficoll products resulted in a CD133
fraction with lower cell recovery, purity (p=0.0106) and viability possibly due to the
erythrocyte contaminants which increase the difficulty of the handling of the cells. For
example when washing the cells the high levels of erythrocytes result in an unstable/loose
pellet after centrifugation. The Ficoll method uses the differences in the cell’s density to
separate the MNC layer. During centrifugation, the denser aggregated red blood cells
and granulocytes will pass through the Ficoll towards the bottom of the tube, resulting
in the MNC and plasma layers remaining above the Ficoll. As the Ficoll separates
the erythrocytes and granulocytes from the MNCs, the required layer can be removed
avoiding contamination from any unwanted cells. The eMNC process does not have the
advantage of this separating layer and therefore, it may remain more difficult to avoid
contamination from unwanted cells.
The introduction of the eMNC protocol has many advantages including the lack of user
variability, it is a ‘walk away’ process leaving technicians free to perform other duties.
There is also a reduced risk of contamination as the sample remains within a closed
sterile tubing set without the need to add a separation media such as Ficoll. However,
no contamination was observed in either the eMNC or Ficoll samples suggesting that
although the risk is higher when using the Ficoll procedure, as long as correct techniques
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are applied the risk is minimal. When considering the eMNC as an alternative to the
Ficoll method, the low levels of granulocyte and erythrocyte depletion mean this is not
currently feasible and further improvements would need to be made.
As the eMNC was not found to be a suitable replacement, the ability to further optimise
the Ficoll protocol used at the ANCTC was assessed. Blood is often diluted prior to
being layered over Ficoll, this should minimise the risk of trapping MNCs within the
erythrocyte aggregates preventing a loss in MNC recovery.469 However, dilution of blood
samples increases the number of tubes needed to perform the procedure resulting in
increased expense and processing time. There is also the risk of a reduced MNC recovery
if the cells of interest are spread over several tubes. Therefore, the Ficoll procedure was
performed on diluted and undiluted CB samples and the products compared. Similar
erythrocyte depletion was observed with both products resulting in low haematocrit
levels of <1%. However, higher TNC recovery was observed in samples diluted prior to
isolation which was found to be due to lower levels of granulocyte depletion (p=0.0195).
These data suggests that diluting CB prior to layering over Ficoll is not only unnecessary,
but also results in poorer granulocyte depletion.
Several specialised tubes for Ficoll processing have been developed. These involve the
use of permeable barriers which prevent the blood from mixing with the Ficoll during
the layering stage and also allow rapid removal of the MNC layer after centrifugation.
Two such tubes (Leucosep and Sepmate) were tested and compared to the standard
Falcon tube without a barrier. These tubes reduced the time for MNC enrichment from
∼45 minutes to ∼15 minutes. All tubes tested resulted in high levels of erythrocyte
depletion. However, the cells isolated using the Leucosep tubes had higher levels of
granulocyte contamination (p=0.0029 and p=0.0061 compared to the standard Falcon
and Sepmate tubes respectively). This suggests that the granulocytes were not able
to pass through the permeable barrier of the Leucosep tube during centrifugation. Us-
ing the Sepmate tubes resulted in a MNC fraction with similar levels of granulocyte
depletion, but a slightly reduced lymphocyte and monocyte recovery compared to the
standard Falcon tubes. Therefore, the cheaper, standard Falcon tubes remain optimal
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for Ficoll processing, as they resulted in cell products with high MNC recovery and
granulocyte depletion.
Based on these observations, the Ficoll processing performed at the ANCTC Biobank will
be carried out on undiluted, whole CB using the standard Falcon tubes. This will ensure
high levels of erythrocyte and granulocyte depletion are achieved whilst minimising the
cost and time required for this cell separation protocol.
CHAPTER 5
OPTIMISING THE CRYOPRESERVATION OF CORD BLOOD
MONONUCLEAR CELLS
5.1 Introduction
A CB Biobank would involve cryopreservation and potentially long term storage of
samples until their use is required. Therefore, the next stage of the Biobank development
would be to improve on the methods used in cryopreservation and thawing of the CB
cells.
There is a risk of damage to the cells during freezing and thawing stages of cryopreser-
vation and suboptimal conditions can result in reduced cell viability. The cause of the
damage to the cells is due to changes in osmotic pressure as ice forms in the extracellular
space, resulting in a reduction of water between cells leading to an increasing concentra-
tion of the solutes.82,86 This leads to shrinkage of the cells as water exits to compensate
for the rising solute concentration.87 If the cells are maintained at low temperatures for
too long before freezing the cells can shrink to the point of irreversibly damaging their
membranes.88 Whilst frozen there should be no further risk to the cells provided they
are cooled low enough to block cell metabolism.80,81 During thawing of the cells the
ice crystals melt reducing the concentration of solutes in the extracellular space, there
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is then an influx of water into the cell, counterbalancing the osmotic gradient, result-
ing in the cells swelling potentially to the point of bursting. Therefore, it is crucial to
optimise cryopreservation protocols in order to maintain the highest possible number of
functional HPCs.
Dimethyl sulphoxide (DMSO) is a commonly used cryoprotectant which protects the
cells from the changes in osmotic pressure by slowing the formation of ice crystals in the
extracellular compartment, and by preventing the formation of ice crystals within the cell
which can disrupt the membrane.101 Currently the cryoprotectant freezing mix, added to
the cells prior to freezing, contains DMSO and dextran-40, which functions as an osmotic
stabiliser. The cryoprotectants are added to the samples resulting in a final concentration
of 10% (v/v) DMSO and 1% (w/v) dextran-40.55,86,471 However, there is evidence to
suggest that DMSO may be toxic to cells if added in high concentrations or for prolonged
periods.122 Reports have been published suggesting that lower concentrations of DMSO
result in higher viable cell recoveries post thaw.140,141,148,153,472 Different concentrations
of DMSO will be compared in the cryopreservation of CBMCs to identify the optimum
freezing media. Furthermore, the toxic effects of DMSO will also be assessed by storing
cells in different concentrations at different temperatures over 24 hours. This will ensure
viable cells are not lost in the time between DMSO addition and the starting of the
CRF.
This part of the study aims to optimise the cryopreservation conditions for CBMCs.
This will be achieved through assessing the quality of the cells through viable cell and
CFU recoveries throughout the cryopreservation processes. Also, by assessing the toxic
effects of DMSO and dextran-40 on cells, identifying the optimal concentration of these
chemicals, as well as investigating the effect of DMSO addition speed and its removal
post-thaw.
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5.2 Results
5.2.1 Freezing whole CB v. CBMC
Different cells may require different cryopreservation protocols. Compared to mononu-
clear cells, granulocytes are more susceptible to thermal shock during freezing and thaw-
ing, and poor cryopreservation of these cells may have a detrimental effect on the rest
of the sample due to the release of nucleoproteins and lysosomal enzymes which can
lead to cell clumping.473,474 Therefore, the post-thaw cellular recoveries were compared
when cryopreserving whole CB versus granulocyte-depleted CBMCs using either the
controlled rate freezer (CRF) or a Nalgene Mr Frosty.
Both freezing methods resulted in higher viable cell recoveries in the granulocyte depleted
CBMC samples. When using the CRF (Figure 5.1A), significantly higher percentages
of total nucleated cells (TNC) were observed in CBMC samples (71.74 ± 9.36% when
freezing whole CB, 85.84 ± 10.35% when freezing CBMC, p=0.0077), CD45+7AAD−
(63.90 ± 8.27% for CB, 85.94 ± 12.47% for CBMC, p=0.0009), viable mononuclear
cells (MNC 7AAD−) (75.80 ± 9.78% for CB, 89.83 ± 15.02% for CBMC, p=0.0434),
CD34+7AAD− (58.09 ± 19.92% for CB, 88.02 ± 19.99% for CBMC, p=0.0062) and
CD34+AnnV− (34.69 ± 12.58% for CB, 60.45 ± 19.15% for CBMC, p=0.0085). A
higher CFU recovery was also observed when freezing CBMC, although the difference
was not significant (57.89 ± 28.40% for CB and 76.49 ± 22.40% for CBMC).
Whilst using the Mr Frosty to freeze whole CB and CBMC samples (Figure 5.1B) sig-
nificant differences were observed for TNC (71.66 ± 5.64% using the CRF, 84.25 ±
9.19% for CBMC, p=0.0021), CD45+7AAD− (59.49 ± 9.78% for CB, 77.39 ± 11.01%
for CBMC, p=0.0031) and CD34+7AAD− (50.50 ± 14.34% for CB, 72.14 ± 12.77% for
CBMC, p=0.0031). Although higher recoveries of MNC, CD34+AnnV− and CFUs were
observed for CBMCs, the differences were not significant ( MNC 7AAD− recoveries of
72.90 ± 11.65% for CB, 81.85 ± 13.27% for CBMC CD34+AnnV− recoveries of 23.39 ±
13.71% for CB, 37.73 ± 16.94% for CBMC and CFU recoveries of 50.62 ± 18.88% for
CB, 53.04 ± 4.29% for CBMC).
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Figure 5.1: A comparison of post-thaw recoveries when freezing whole CB v. CBMC
(A) in a CRF or (B) Nalgene Mr Frosty. (n=8 for CB and n=10 for CBMC) Error bars
correspond to the SEM. *p<0.05, **p<0.01 and ***p<0.001
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5.2.2 Freezing methods - CRF v. Mr Frosty
Two different methods of freezing cells were employed during this project. Larger sam-
ples of 20ml were cryopreserved in cryobags in a controlled rate freezer (CRF) with a
set cooling program (Figure 1.3). Smaller samples (up to 2ml) were frozen in cryovials
using a Nalgene Mr Frosty in an -80◦C freezer, which cools at 1◦C minute−1 before
being transferred to liquid nitrogen tanks. Both freezing protocols were compared when
cryopreserving whole CB (Figure 5.2A) and CBMC samples (Figure 5.2B).
When freezing whole CB higher recoveries were observed when using the CRF, although
the differences between the two methods were not significant (TNC recovery of 71.74 ±
9.36% when using the CRF and 71.66 ± 5.64% when using the Mr Frosty, CD45+7AAD−
recovery of 63.90 ± 8.27% using the CRF and 59.49 ± 9.78% using the Mr Frosty,
CD34+7AAD− recovery of 58.09 ± 19.92% using the CRF and 50.50 ± 14.34% using
the Mr Frosty, CD34+AnnV− recovery of 34.69 ± 12.58% using the CRF and 24.39 ±
13.71% using the Mr Frosty and CFU recovery of 57.89 ± 28.40% using the CRF and
50.62 ± 18.88% using the Mr Frosty).
As with freezing whole CB, higher recoveries were observed in CBMC samples when
using the CRF for TNC (85.84 ± 10.35% using the CRF, 84.25 ± 9.19% using the Mr
Frosty, not significant), CD45+7AAD− (85.94 ± 12.47% using the CRF, 77.39 ± 11.01%
using the Mr Frosty p=0.002), CD34+7AAD− (88.02 ± 19.99% using the CRF, 72.14 ±
12.77% using the Mr Frosty p=0.0039), CD34+AnnV− (60.45 ± 19.15% using the CRF,
37.73 ± 16.94% using the Mr Frosty p=0.0039) and CFU (76.49 ± 22.40% using the
CRF, 53.04 ± 4.29% using the Mr Frosty p=NS).
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Figure 5.2: A comparison of post-thaw recoveries from the two freezing protocols
(CRF or Mr Frosty) when freezing (A) whole CB and (B) CBMCs. (n=8 for CB and
n=10 for CBMC) Error bars correspond to the SEM. *p<0.05 and **p<0.01
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5.2.3 Resuspension media - plasma concentration
Throughout this project the mononuclear cell samples have been resuspended in 100%
(v/v) autologous plasma post-isolation. Cryopreserving CBMCs in autologous plasma
was assessed and compared to cells resuspended in a lower concentration of 20% (v/v)
plasma and RPMI. Reducing the final concentration of plasma to 20% (v/v) before freez-
ing (Figure 5.3) resulted in similar post-thaw cell recoveries compared to 100% (v/v)
plasma. Therefore, for the rest of this project 100% (v/v) plasma was used when resus-
pending CBMCs prior to cryopreservation.
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Figure 5.3: The effect on cell recovery when resuspending CBMCs in different con-
centrations of plasma prior to cryopreservation (n=7 for 20% (v/v) and n=10 for 100%
(v/v)) Error bars correspond to the SEM.
5.2.4 Optimal dextran-40 concentration
Dextran-40 is often added to the sample along with the cryoprotectant to reach a final
concentration of 1% (w/v). The effect of the presence of dextran-40 in the cryopreser-
vation solution was assessed. First the toxic effect of dextran-40 on CB was assessed
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by maintaining fresh CBMCs in 1% (w/v) dextran-40 for 24 hours. This was shown to
have little effect on cell count, viability and on CFU recovery (Figure 5.4A).
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Figure 5.4: The effect of dextran-40 on CBMCs. (A) Mean cell and CFU recoveries
when fresh CBMC samples were stored with or without 1% (w/v) dextran-40 for 24
hours (n=10). (B) Mean post-thaw cell and CFU recoveries when CBMC samples were
cryopreserved with a range of dextran-40 concentrations (from 0% to 3% (w/v)) (n=10).
Error bars correspond to the SEM. *p<0.05, **p<0.01 and ***p<0.001 compared to
samples in 1% (w/v) dextran-40
The optimal dextran-40 concentration was assessed when cryopreserving CBMCs. The
concentration of dextran-40 was shown to be critical (Figure 5.4B). Compared to 1%
(w/v) dextran-40, 0% resulted in similar nucleated cell recoveries, but lower recoveries
when assessing viable cells and a significantly lower CFU recovery (p=0.0391). Cryopre-
serving cells with 2% (w/v) dextran-40 resulted in lower recoveries of TNC (p=0.0078),
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CD45+7AAD− (p=0.0078), CD34+7AAD− (p=0.0078), CD34+AnnV− (p=0.0156) and
CFU (not significant) compared to using 1% (w/v). Increasing the concentration further
to 3% (w/v) also resulted in significantly lower viable and functional cell recoveries (TNC
p=0.0078, CD45+7AAD− p=0.0078, CD34+7AAD− p=0.0078, CD34+AnnV− p=0.0078
and CFU p=0.0078). Therefore, for the rest of this project, the DMSO freezing solution
added to cells prior to freezing contained dextran-40 to reach a final concentration of
1% (w/v).
5.2.5 Toxic effects of DMSO
The effects of DMSO on CB cells through the different stages of cryopreservation was
assessed. First, the effect of different concentrations in fresh CB over 24 hours at either
refrigerated or room temperature (protocol summary shown in Figure 5.5A). Then, the
effects of delaying cryopreservation after DMSO addition (Figure 5.5B), followed by the
effect of DMSO post-thaw looking into the benefits of washing to completely remove
DMSO or dilution to reduce its post-thaw concentration (Figure 5.5C). The effects of
adding DMSO at different speeds to the cells post-thaw and finally assessing the optimal
DMSO concentration for cryopreserving CB samples.
CBMC split
into 4x aliquots
Diﬀerent concen-
trations of DMSO
(0-40% (v/v)) added
to each aliquot
Split aliquots and
store at refrigerated
or room temperature
Aliquot from each
condition was as-
sessed at set time
points (t=0, 1,
2 and 24 hours)
CBMC quality assessed
10% (v/v)
DMSO added
Split samples and
store at refrigerated
or room temperature
At time points t=0,
15 mins, 30 mins,
1 hour, 2 hours
and 24 hours an
aliquot was frozen
Samples were thawed, reassessed and com-
pared to assessment before DMSO addition
Controls (DMSO not
added at this stage)
Split samples and
store at refrigerated
or room temperature
At the same
time points 10%
(v/v) DMSO was
added to the con-
trols and frozen
CBMC samples frozen
with 10% (v/v) DMSO
Samples thawed and
split into 3x aliquots
Un-
manipulated
Diluted Washed
Samples were assessed
at set time points post
thaw (t=0, 30 mins,
1, 2, 24 and 48 hours)
D
B C
A B C
Figure 5.5: Flow chart of the protocols used to assess DMSO toxicity at different
stages of cryopreservation
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5.2.5.1 In fresh CB
The effects of different concentrations of DMSO on fresh CBMC samples maintained
at refrigerated temperatures is shown in Figure 5.6. Increasing the concentration of
DMSO resulted in lower numbers of viable cells and CFUs recovered showing a dose
related toxic effect. This is particularly apparent in the CFUs and Annexin V analysis
of the CD34+ cells; concentrations of 40% (v/v) DMSO resulted in an immediate loss
of CD34+AnnV− cells with a recovery of 1.75 ± 2.23% (p=0.0002) and a CFU recovery
of 3.75 ± 8.00% (p=0.0313) compared to samples without DMSO at time point zero.
Recoveries declined further over 24 hours to 0.64 ± 1.17% (p=0.0039) and 1.70 ± 1.29%
(p=0.002) for Annexin V and CFU analysis respectively.
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Figure 5.6: Mean (A) CD45+7AAD−, (B) CD34+7AAD−, (C) CD34+AnnV− and
(D) CFU recovery in CBMC samples after fresh storage at 4◦C, for up to 24 hours, with
a range of DMSO concentrations from %0 to 40% (v/v) (n=10). Error bars correspond
to the SEM. *p<0.05, **p<0.01 and ***p<0.001 compared to 0% DMSO at the same
time point
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The addition of 20% (v/v) DMSO resulted in a recovery of 43.03 ± 16.35% (p=0.002)
of CD34+AnnV− cells at time point zero and a CFU recovery of 57.68 ± 23.94%
(p=0.0313). After 24 hours of storage recoveries were reduced to 13.14± 6.71% (p=0.0039)
for Annexin V analysis and 23.76 ± 26.37% (p=0.0313) for CFU analysis.
Samples stored with 10% (v/v) DMSO (the concentration commonly used during cry-
opreservation) resulted in no significant difference, compared to samples with 0% (v/v)
DMSO, when assessed immediately after addition with average viable cell recoveries of
98.53 ± 10.18% for CD45+7AAD− cells, 95.18 ± 13.57% for CD34+7AAD− cells, 93.52
± 19.00% for CD34+Annexin V− cells and 93.86 ± 21.37% for the CFUs. The mean
viable cell and CFU recoveries were assessed after 1, 2 and 24 hours of storage with 10%
(v/v) DMSO (data shown in Table 5.1). With 10% (v/v) DMSO fresh CBMC samples
showed no significant reduction in recovery for up to 2 hours compared to the assessment
at time point zero and also when compared to the samples stored without DMSO for
the same length of time. When reassessed at 24 hours after addition, samples with 10%
(v/v) DMSO had significantly reduced recoveries compared to samples stored without
DMSO for 24 hours (Figure 5.6) and compared to assessment immediately after DMSO
addition (Table 5.1).
Table 5.1: Mean viable cell and CFU recovery after fresh storage of CBMCs with 10%
(v/v) DMSO at refrigerated temperatures (n=10). Percentages indicate mean recovery
± s.d. and p values indicate differences at the same DMSO concentration compared to
t=0 NS indicates a non significant result
Storage CD45+ CD34+ CD34+
CFU
time 7AAD− 7AAD− Annexin V−
1 hour 96.55 ± 4.91% 92.12 ± 11.96% 88.52 ± 16.78% 91.97 ± 12.22%
p value NS NS NS NS
2 hours 99.72 ± 12.03% 95.5 ± 11.42% 82.96 ± 14.31% 83.92 ± 15.33%
p value NS NS NS NS
24 hours 82.06 ± 10.94% 84.91 ± 10.75% 38.02 ± 14.86% 61.28 ± 17.05%
p value 0.0039 0.0098 0.0078 0.0313
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The effects of two different temperatures (refrigerated (4◦C) and room (20◦C) tempera-
ture) on the samples stored for 24 hours with 10% (v/v) DMSO was assessed. As shown
in Figure 5.7, there was no significant differences between the temperatures in the mean
recovery of viable cells and CFUs.
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Figure 5.7: Mean viable cell and CFU recovery in fresh CBMC samples stored with
10% (v/v) DMSO for 24 hours at either refrigerated (4◦C) or room (20◦C) temperatures
(n=10). Error bars correspond to the SEM.
5.2.5.2 Delaying cryopreservation of CB
The effects on CBMCs of delaying freezing after addition of 10% (v/v) DMSO were
assessed (Figure 5.8). As shown in Figure 5.5B, CBMC samples were split into two
fractions; DMSO was added to one half whilst the other was left without DMSO (control
fraction). At set time points (0 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours and 24
hours after DMSO addition) an aliquot was taken from each fraction and frozen (DMSO
was added to the control just before freezing).
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Figure 5.8: Mean (A) CD45+7AAD−, (B) CD34+7AAD−, (C) CD34+AnnV− and
(D) CFU recovery when delaying cryopreservation of CBMCs for up to 24 hours after
addition of 10% (v/v) DMSO (n=10). Error bars correspond to the SEM. †p<0.05
between samples with DMSO and control at the same time point and *p<0.05 compared
to t=0
As with the assessment of DMSO toxicity in fresh CBMC samples, significant losses
in post-thaw viable cell recoveries were not observed until samples had been stored
with 10% (v/v) DMSO for 24 hours prior to freezing compared to those frozen imme-
diately (CD45+7AAD− 69.43 ± 10.62% p=0.0098 and CD34+7AAD− 67.71 ± 15.54%
p=0.0195. A noticeable decline in CFU recovery was observed when delaying freezing
for 15 minutes, however the loss was not significantly lower until after a delay of 1 hour
(50.44 ± 21.02% p=0.0098).
No significant difference was found in post-thaw cell recovery between the samples stored
with DMSO for up to 2 hours prior to cryopreservation compared to the controls (stored
for the same time period, but without DMSO). However, samples that had been stored
in 10% (v/v) DMSO for 24 hours before being cryopreserved resulted in lower recoveries
compared to the control samples; CD45+7AAD− (69.43 ± 10.62% with DMSO, 75.12 ±
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12.57% control p=0.0098), CD34+7AAD− (67.71 ± 15.54% with DMSO, 81.04 ± 18.56%
control p=0.0195), CD34+AnnV− (38.06 ± 16.68% with DMSO, 33.99 ± 19.67% control
p=0.0098), and CFU (21.44 ± 17.08% with DMSO, 42.68 ± 31.96% control p=0.002).
The effect of storing samples with or without 10% (v/v) DMSO at different temperatures
(room or refrigerated) prior to cryopreservation was assessed (Figure 5.9). Post-thaw
analysis showed significantly lower recoveries for samples containing DMSO stored at
room temperature, but only after delaying cryopreservation for 24 hours (CD45+7AAD−
p=0.0098 and CD34+AnnV− p=0.001).
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Figure 5.9: Mean post-thaw viable cell and CFU recovery in fresh CBMC samples
stored with 10% (v/v) DMSO for 24 hours at either refrigerated (4◦C) or room (20◦C)
temperatures prior to freezing (n=10). Error bars correspond to the SEM. * denotes a
p<0.05
5.2.5.3 Effect of DMSO post-thaw
In the assessment of the toxic effects of DMSO post thaw, CBMCs were cryopreserved
with 10% (v/v) DMSO, thawed and split into three samples; un-manipulated (DMSO
concentration maintained at 10%), diluted (gradual addition of thawing solution to re-
duce DMSO concentration to 5%) and washed (dilution followed by centrifugation to
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remove DMSO before resuspending the cells in culture media). Cell potency was com-
pared over a period of 48 hours post-thaw. The t=0 assessment (assessed immediately
after any post thaw manipulations) resulted in lower cell counts in the washed samples
due to some of the cells being lost during the procedure (mean CD45+ cell counts of
13.26 ± 4.36×106 ml−1 for un-manipulated cells, 14.08 ± 7.58×106 ml−1 for diluted and
11.44 ± 3.42×106 ml−1 for washed samples). However, in order to assess the effects
of DMSO on post-thaw samples, the cell recoveries were normalised against t=0 for
each subsequent time point (Figure 5.10). After the wash losses had been taken into
account, the washed samples retained higher recoveries over the 48 hours compared to
diluted samples and both retained higher recoveries compared to the un-manipulated
samples. Significant differences were observed between the three post-thaw procedures
in CFUs after 2 hours (p=0.0130) and in the viable cells after 24 hours (p=0.0476 for
CD45+7AAD−, p=0.0476 for CD34+7AAD− and p=0.0307 for CD34+AnnV−).
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Figure 5.10: Mean (A) CD45+7AAD−, (B) CD34+7AAD−, (C) CD34+AnnV−
and (D) CFU recovery in post-thaw CBMC samples that had either been left un-
manipulated, diluted 1:1 or washed to remove all DMSO (n=10). Error bars correspond
to the SEM. *p<0.05, **p<0.01 and ***p<0.001 between different protocols
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The numbers of viable cells and CFUs identified decreased over time for all the post-thaw
protocols, with significant losses compared to recoveries at time point 0 after 2 hours for
un-manipulated samples, 24 hours for diluted samples and 48 hours for washed samples.
To assess at what time point within 2 hours of thawing that the un-manipulated cells
lost significant numbers of viable cells and CFUs this experiment was repeated with
recoveries assessed 30 minutes, 1 hour and 2 hours after thawing. Figure 5.11 shows the
significant losses occurred after 1 hour of thawing (CD45+7AAD− recovery of 91.08 ±
8.28% p=0.0059, CD34+AnnV− recovery of 81.38 ± 21.98% p=0.0371 and CFU recovery
of 69.71 ± 32.31% p=0.0313). The time points at which significant loses were observed
in the different parameters is summarised in Table 5.2.
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Figure 5.11: Mean viable cell and CFU recovery in post thaw CBMC samples that
have been left un-manipulated for up to 2 hours (n=10). Error bars correspond to the
SEM. *p<0.05 and **p<0.01 compared to recoveries 0 hours post-thaw
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Table 5.2: Mean viable cell and CFU recoveries when significant losses were observed
post-thaw in samples which have either been left un-manipulated, diluted 1:1 or washed
to remove DMSO
Post thaw CD45+ CD34+ CD34+
CFU
protocol 7AAD− 7AAD− Annexin V−
Un-
Time point 1 hour 2 hours 1 hour 1 hour
manipulated
% recovery 91.08 ± 14.18 95.81 ± 11.63 81.38 ± 19.90 69.71 ± 32.31
p value 0.0059 0.002 0.0371 0.0313
Time point 24 hours 24 hours 24 hours 24 hours
Diluted % recovery 96.88 ± 16.95 72.85 ± 14.86 48.72 ± 20.59 62.77 ± 21.25
p value 0.002 0.0078 0.0039 0.0313
Time point 48 hours 48 hours 48 hours 48 hours
Washed % recovery 91.64 ± 7.20 95.50 ± 12.33 66.85 ± 32.79 66.99 ± 24.80
p value 0.002 NS 0.001 0.0451
5.2.5.4 Optimal DMSO concentration
In spite of the low levels of toxicity found when using 10% (v/v) DMSO to cryopreserve
CB samples, the effects of reducing the concentration further when freezing was assessed.
Different CBMC samples were cryopreserved with a range of DMSO concentrations
(0-10%) and their post-thaw cell viability and CFU recoveries compared. The mean
leukocyte count (WBC) of post-thaw CBMCs gave similar counts for all concentrations
of DMSO (Figure 5.12), however this is a total cell count without any indication of
viability. 7AAD exclusion shows a decline in viable CD45+ and CD34+ cell recovery as
the concentration of DMSO is reduced with those frozen with 5% (v/v) DMSO and less
giving a significantly lower recovery compared to those frozen with 10% (p=0.0226 for
both CD45+7AAD− and CD34+7AAD− when 5% DMSO was used).
However, the use of Annexin V to exclude apoptotic cells from the viable CD34+ count
resulted in the measurement of higher recoveries (although not significantly higher than
10%) when a concentration of 7.5% (v/v) DMSO was used (76.42 ± 38.30% with 7.5%
(v/v) DMSO and 65.10 ± 20.65% with 10% (v/v) DMSO). This increase in HPC potency
after cryopreservation with 7.5% (v/v) DMSO was confirmed by the CFU assay (78.10
± 37.60% with 7.5% (v/v) DMSO and 60.38 ± 32.13% with 10% (v/v) DMSO) with
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significantly low recoveries when 2.5% (34.20 ± 18.94% p=0.0047) and 0% (30.07 ±
28.69% p=0.0011) was used.
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Figure 5.12: Mean post-thaw cell and CFU recoveries when CBMC samples were
cryopreserved with a range of DMSO concentrations (from 0% to 10%) (n=10). Error
bars correspond to the SEM. *p<0.05, **p<0.01 and ***p<0.001 compared to recoveries
when 10% (v/v) DMSO was used
5.2.6 Cryoprotective solution addition speed
DMSO is commonly added to the cells in a slow drop-by-drop fashion or by syringe
pump at a rate of 0.5ml minute−1. The effect of adding the DMSO at a faster rate of
10ml minute−1 was assessed and the post-thaw viable cell and CFU recoveries compared
to the current protocol. Mononuclear cells were mixed, split into two freezing bags, pre-
cooled to 4◦C on a Biosafe Coolmix before the DMSO was added at the different rates.
The two bags were frozen using a CRF and transferred to the gas phase of a liquid
Chapter 5 Optimising the cryopreservation of cord blood mononuclear cells 132
nitrogen tank for a minimum of 24 hours. The bags were thawed at the same time and
the recovery of viable and functional cells assessed. Figure 5.13 shows no significant
differences between the two DMSO addition rates in the recoveries of viable CD45+ and
CD34+ when assessed using 7AAD and Annexin V and also similar recoveries of CFUs
post-thaw.
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Figure 5.13: Mean post-thaw viable cell and CFU recovery when 10% (v/v) DMSO
is added at 0.5ml minute−1 (slow) or 10ml minute−1 (fast) prior to freezing (n=10).
Error bars correspond to the SEM.
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5.3 Discussion
This Chapter looks into optimising the cryopreservation procedures for CB samples by
identifying the different stages of the process that can have a negative impact on the
cells.
Different cells within CB have different levels of tolerance to the osmotic stress during
the freeze and thaw stages of cryopreservation. Polymorphonuclear cells such as granulo-
cytes are known to require different cryopreservation conditions.133,474,475 Consequently
the ability to cryopreserve whole CB versus granulocyte depleted CBMC samples was
assessed. TNC and CD45+ recoveries were found to be significantly lower in the whole
CB samples, but also the viable MNC and CD34+ recoveries were reduced when com-
pared to CBMC samples. This could be due to the release of lysosomal enzymes and
nucleoproteins as the granulocytes lyse which is known to have a negative impact on
other cells and cause clumping.131,132,134 However, no post-thaw cell clumping or gel
formation was observed in the whole CB samples.
Two freezing methods have been used throughout this project, freezing larger samples of
20ml using a controlled rate freezer (CRF) and smaller samples of 1ml using a Nalgene
Mr Frosty freezing container. When comparing these two methods, higher recoveries
were obtained when using the CRF, this was particularly apparent when cryopreserving
CBMC cells where significant differences were detected when during the viable CD45 and
CD34 cell assessment. At the freezing point of the samples, when the water crystallises,
heat is released which can have deleterious effects of the viability of the cells. Using
a CRF the temperature changes can be pre-programmed in order to compensate for
the latent heat released. However, this is not possible in a Mr Frosty, which cools at a
constant rate of 1◦C minute−1, although as the samples in the Mr Frosty are a much
smaller volume the quantity and duration of the liberated heat is reduced.
It was originally believed that the higher the concentration of a cryoprotectant, the
higher its cryoprotective ability.148 However, this study has demonstrated a concentra-
tion dependant toxicity of DMSO to cells within fresh CB. High concentrations of 40%
(v/v) DMSO removed almost all viable and functional HPCs with a CFU recovery of 3.75
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± 8.00% when assessed immediately after the addition of the cryoprotectant. Baxter and
Lathe suggest DMSO may impair glycolysis by binding to fructose diphosphatase deacti-
vating it.128 Fahy suggested another more general hypothesis involving the denaturation
of all proteins by the interaction of DMSO with their hydrophobic residues.127 How-
ever, at concentrations as high as 40% the loss of viable cells could in part be due to the
heat released upon DMSO addition, despite attempts to maintain samples at 4◦C. The
addition of 10% (v/v) DMSO (the concentration commonly used in cryopreservation)
to fresh CBMCs did not result in significant viable CD45+ or CD34+ cell losses, when
assessed using 7AAD of Annexin V, for up to 2 hours at either refrigerated or room tem-
perature. After 24 hours incubation of fresh CB with 10% (v/v) DMSO significant losses
were observed in CD45+7AAD− (p=0.0039), CD34+7AAD− (p=0.0039), CD34+AnnV−
(p=0.0039) and the CFU assay (p=0.002) compared to samples stored without DMSO
for the same time period. It was also not until assessment at this time point that the
samples with 10% (v/v) DMSO also showed significant losses compared to the assessment
immediately after DMSO addition (CD45+7AAD− p=0.0039, CD34+7AAD− p=0.0098,
CD34+AnnV− p=0.0078 and the CFU assay p=0.0313). Therefore, our study builds on
the work of Rowley et al123 who observed that HPCs can tolerate 10% (v/v) DMSO for
up to an hour, but refute that of Douay et al who found a 24% CFU recovery after 30
minutes of exposure to 10% (v/v) DMSO at 4◦C reducing to 10% after 3 hours.122
The effects of DMSO exposure may be different in cryopreserved samples as the concen-
trations of solutes, such as DMSO, increases upon the formation of ice.476 Therefore,
the effect of delaying cryopreservation after the addition of DMSO was assessed. Com-
pared to samples frozen immediately after DMSO addition, significant losses in viable
cell recovery were observed after 24 hours in analysis of CD45 and CD34 (p=0.0098 and
0.0195 respectively), but earlier for CFU recovered after a 1 hour delay (p=0.0098). Sam-
ples in which cryopreservation was delayed for 2 hours after 10% (v/v) DMSO addition
showed no significant losses in viable cells or CFUs compared to control samples stored
for the same time period but with DMSO added just before freezing. However, as with
the fresh samples, lower viable CD45+7AAD− (p=0.0098), CD34+7AAD− (p=0.0195),
CD34+AnnV− (p=0.0098) cell and CFU (p=0.002) recoveries were observed compared
to control samples when cryopreservation was delayed for 24 hours. Therefore, the HPCs
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were found to be tolerant of the increase in DMSO concentration during the freezing
process perhaps due to the cooler temperatures. This tolerance to concentrations of 10%
can also be demonstrated by the ability of cryopreserved HPCs to consistently engraft
in patients.
It has been recommended that cells are maintained at chilled temperatures after DMSO
addition in order to minimise the toxic effects of DMSO.55,122 However, no significant
difference was observed in fresh CBMC samples stored with 10% (v/v) DMSO at refrig-
erated or room temperature for up to 24 hours, thereby supporting the work of Rowley
et al who report no toxic effects of DMSO to bone marrow cells at 37◦C.123 However,
losses were noted in samples maintained in 10% (v/v) DMSO at room temperature for 24
hours prior to freezing compared to those at refrigerated temperatures (CD45+7AAD−
p=0.0098 and CD34+AnnV− p=0.001).
CB is commonly washed post-thaw in order to remove DMSO and avoid its toxic effects
to cells and the adverse effects noted in patients upon infusion.55,105–107,161 A hyperos-
molar solution is added to the cells in order to decrease the risk of osmotic shock after
the intracellular ice melts; this is followed by a washing centrifugation step removing
DMSO. However, a washing step can lead to cell losses, in this study an average of 13.7%
of CD45+ cells were lost compared to the un-manipulated samples. It is crucial to avoid
this loss, as there is already a low cell dose associated with CB. After the initial losses
had been taken into account, the washed samples retained higher recoveries of viable
and functional HPCs over the 48 hours compared to the diluted and un-manipulated
samples. A significant reduction in CFU was observed 1 hour after thawing in the un-
manipulated samples (69.71 ± 32.31%, p=0.00313), after 24 hours the diluted samples
(62.77 ± 21.25%, p=0.0313), and after 48 hours in the washed samples (69.99 ± 24.80%,
p=0.0451). Therefore, the most suitable post-thaw procedure to obtain highest levels of
viable cells depends upon the length of time expected before infusion can be achieved;
within 1 hour the samples do not require any manipulation, within 2 hours it is better to
reduce the DMSO concentration through dilution, if more than 2 hours then all DMSO
should be removed through washing.
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The CB bank guidelines for cryopreservation are based upon the protocols used in freez-
ing BM or PBSC samples in which 10% (v/v) DMSO is used as the cryoprotectant.477,478
Although this study has shown that this concentration of DMSO has limited toxic effects
on cells within CB for up to 2 hours before freezing it is still linked to complications in
patients after transplantation. As the toxic effects post infusion has been linked to the
dose, the symptoms should decrease as concentration and volume of DMSO decreases.
Therefore, the effect of reducing the concentration of DMSO during cryopreservation
of CB was assessed. Although there are studies suggesting 5% (v/v) DMSO is a vi-
able option141,148 significant losses were found in CD45+7AAD− and CD34+7AAD−
cells at this concentration compared to samples frozen with 10%. Cryopreservation in
7.5% (v/v) DMSO was found to result in higher CFUs recovered compared to samples
frozen in 10%. However, this higher recovery was not found to be significant suggesting
cryopreserving CB within a range of 7.5-10% (v/v) DMSO would be acceptable.
Dextran-40 is a polysaccharide comprising of multiple glucose units with a molecular
weight of 40 kDa. Due to its high molecular weight, dextran-40 is a non-penetrating
cryoprotectant and can aid cells during both the freezing and thawing stages by main-
taining the osmotic balance. In 1995 Rubinstein et al published an article stating that
they had observed in preliminary experiments an improvement in post-thaw viability of
CB leucocytes by 3-10% when 1% (w/v) dextran-40 was used in combination with 10%
(v/v) DMSO.55 Although this data was never published, many CB banks have added 1%
(w/v) dextran-40 to their cryoprotective solution. However, the introduction of dextran-
40 to the cryoprotective solution has coincided with an increase of severe CB infusion
reactions.176 Therefore, this study is the first to show the effect on both cell viability
and potency when cryopreserving CB with a range concentrations of dextran-40 in com-
bination with 10% (v/v) DMSO. The presence of dextran-40 was shown to be crucial
as removing it resulted in lower post thaw recoveries of CD45+7AAD−, CD34+7AAD−,
CD34+AnnV− and CFUs (p=0.0391) compared to freezing with 1%. Increasing the con-
centration to 2% significantly reduced the recoveries of TNC (p=0.0078), CD45+7AAD−
(p=0.0078), CD34+7AAD− (p=0.0078) and CD34+AnnV− (p=0.0156). 2% (w/v) dex-
tran also reduced the CFU recovery but the reduction was not significant until the
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concentration was increased to 3% (p=0.0078). This confirmed that the optimal con-
centration of dextran-40 when cryopreserving CBMCs is 1%.
Current CB banking protocols suggest the cryopreservation solution containing DMSO
be chilled to 4◦C and added at a slow rate to prevent sudden changes in osmotic gra-
dient.55 However, a comparison of two different addition speeds (slow rate of 0.5ml
minute−1 and faster rate of 10ml minute−1) resulted in no significant difference in post-
thaw viable cell and CFU recoveries. This furthers the work of Radke et al who found
that prompt addition of DMSO did not alter the percentage of apoptotic cells in fresh
samples,139 however, unlike in this study, they did not confirm the effect post-thaw.
This observation could lead to positive changes in cryopreservation protocols, as a faster
rate of cryoprotectant addition would allow samples to be transferred to a CRF sooner,
thereby, reducing DMSO exposure time.
In conclusion, a dose-dependant toxicity of DMSO to cells within CB was observed.
When freezing CBMC samples, short term exposure of up to 1 hour to 10% (v/v) DMSO
prior to freezing results in no significant losses in viable or functional HPCs, however
significant losses are observed when increasing the exposure time or concentration. The
optimum concentration of DMSO and dextran-40 in the cryoprotectant solution when
cryopreserve CB was found to be 7.5-10% (v/v) and 1% (w/v) respectively. In order to
avoid toxic effects of DMSO post-thaw, the procedures taken should depend upon the
time until infusion; within 1 hour leave samples un-manipulated (to avoid any losses
through washing), up to 2 hours it is better to dilute to reduce the DMSO concentra-
tion by half, if more than 2 hours then the samples should be washed to remove all
cryoprotectant.
CHAPTER 6
BANKING A PURE CELL POPULATION
6.1 Introduction
Chapters 3 to 5 describe the optimisation of the processes involved in transportation
of CB to the bank, isolation of CBMC and their subsequent cryopreservation whilst
ensuring the maximum numbers of viable and functional cells are maintained. This will
form the start of the Biobank. The next stage will be to allow the Biobank to store
and distribute frozen samples of pure populations of a particular cell type. This will
involve developing isolation techniques for a specific cell, ensuring production of a pure
population that can be cryopreserved and thawed whilst maintaining its potency. In
this project one particular cell type found within CB has been chosen for investigation,
that of regulatory T cells (Tregs).
Tregs play an important role in the regulation of the immune system by suppressing
the proliferation of other lymphocytes.234,237–241,243–247 Due to this suppressive quality
Tregs are a potential source of treatment for many immune disorders.430,431,479 How-
ever, therapeutic application in humans requires large numbers of Tregs with high pu-
rity.415,480 Unfortunately these cells are rare (5-10% of peripheral CD4+ T cells) and
potentially difficult to obtain as a functional product with high levels of purity.419
138
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One obstacle in isolating Tregs is the absence of specific markers; the Treg population
in adults has been found to be heterogeneous both phenotypically and functionally.
Generally, Tregs are considered to be CD4+CD25highFoxP3+CD127low. However, these
markers are not unique to these cells.253–258 CD25, the α chain of the IL-2 receptor,
is up-regulated on activated T cells resulting in a large population of CD25+ cells with
the adult CD4+ population that do not have suppressive capabilities,265 therefore, only
cells with the highest expression of this marker are considered regulatory.242 FoxP3 is
currently considered to be the most specific marker, it is highly expressed in CD25+ Tregs
and has been linked to suppressive ability.267 However, low levels of this intracellular
marker have been observed in non-regulatory CD4+CD25− cells.244,285 The expression
of FoxP3 in regulatory cells has been found to inversely correlate with expression of
CD127, the α chain of the IL-7 receptor.286,287 However, it has been observed that
upon activation Tregs can up-regulate expression of this marker288 and CD127 has been
found to be down-regulated in some non suppressive cells.258,289
Although FoxP3 is currently the most accepted marker for Treg identification, its detec-
tion involves fixing and permeabilising cells and it is therefore, unsuitable for isolating
viable cells. The lack of a unique cell-surface Treg marker makes it difficult to iso-
late a pure population. Most strategies involving adult blood consist of multiple steps
starting with depletion of B cells and cytotoxic T cells prior to isolating the CD25
population.419,422–424 Although these strategies have resulted in high CD25+ purities
(80-95%), these contain a large proportion of non-regulatory CD25+CD127+ cells (20-
30%).419 In contrast to adult Tregs, CB contains fewer activated cells and the CD25+
cells forms a well defined population consisting of regulatory cells, facilitating isolations
and often only one CD25 enrichment step is required, as described by Figueroa et al.429
The first stage in improving Treg isolation is to further characterise these cells, com-
paring CB cells to those from adult sources. Once Tregs can be identified, preferably
by a single specific marker or by a combination of cell surface markers, the processes
involved in isolation and cryopreservation can be optimised ensuring these cells retain
their functional potency post-thaw and therefore, are suitable for banking.
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6.2 Results
This Chapter aims to improve CB Treg banking procedures. First, by further charac-
terising the phenotype and functional differences between Tregs from CB against adult
blood. This is followed by assessing different isolation techniques for research grade
Tregs, the ability to cryopreserve these cells, and finally GMP grade isolations.
6.2.1 Comparing CB v. adult Tregs
This section aims to compare differences between Tregs from cord blood (CB), adult
peripheral blood (PB) and peripheral blood from the pregnant mothers (MB). This will
be assessed first through their expression of different markers followed by differences in
their functional abilities.
6.2.1.1 Characterisation of CB v. adult Tregs
Analysis of CB lymphocytes show a mean expression of CD25 in 7.27 ± 2.13% of the
CD4+ cells (Figure 6.1A), whereas higher numbers were observed in the adult blood
samples (28.90 ± 15.00% and 59.30 ± 11.20% for PB and MB respectively). The CB
CD25+ cells can be observed as one distinct population, however, within the adult
samples two subpopulations were observed (Figure 6.1B); a small population with high
intensity of CD25 (CD25high, 3.42 ± 2.07% and 4.15 ± 1.21% of CD4+ cells in PB and
MB respectively) and a larger population with intermediate levels of CD25 expression
(CD25int, 37.50 ± 9.01% and 52.60 ± 10.70% of CD4+ cells in PB and MB respectively).
FoxP3 is considered to be a reliable marker for identifying Tregs,238 as it has been shown
to correlate with their suppressive function.336,481,482 Intracellular staining techniques
were employed to analyse FoxP3 in the CD25+ populations (Figure 6.1C). In the CB
samples, 76.71 ± 14.86% of CD25+ cells expressed FoxP3. Comparing the two CD25+
subgroups in the adult samples, a higher percentage of cells expressed FoxP3 in the
CD25high population (81.91 ± 9.05% against 3.82 ± 2.04%, p=0.0078 and 78.24 ±
15.04% against 2.73 ± 1.29%, p=0.0039 for PB and MB respectively) with a higher
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intensity than that of the CB CD25+ cells (MFI=1466 for adult CD25high and 1027 for
CB CD25+). Whereas the CD25int subpopulation showed similar FoxP3 intensities as
the CD25− cells.
CD127 expression has been found to inversely correlate with FoxP3 and therefore, sup-
pressive function.286,287 The levels of CD127 expression in CB, PB and MB are shown
in Figure 6.1D. A mean of 78.65 ± 15.03% of CB CD25+ cells were found to express low
levels of CD127. As with the FoxP3 analysis of the adult cells, CD127low was observed
in the CD25high rather than the CD25int population (89.15 ± 3.15% against 4.08 ±
1.39%, p=0.0078 and 84.33 ± 7.20% against 2.55 ± 1.03%, p=0.0039 for PB and MB
respectively). The higher levels of FoxP3 and reduced CD127 expression in the CD25high
group suggest that this subpopulation of adult CD25+ T cells have suppressive abilities
and therefore, are considered to be Tregs.
The percentage of Tregs (identified with the following phenotype CD25+FoxP3+CD127low)
in CD4+ T cells was assessed (Figure 6.2) and found to be higher in MB than PB (3.41
± 1.26% and 2.33 ± 1.16% for MB and PB respectively), but highest in CB samples
(5.67 ± 2.07%). However, these differences were not found to be statistically significant.
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Figure 6.2: Mean percentage of Tregs (CD25highFoxP3+CD127low) in CD4+ lym-
phocytes from MB (n=9), PB (n=7) and CB (n=12) samples. Error bars correspond
to the SEM.
Chapter 6 Banking a pure cell population 143
To further characterise the phenotype of CD3+CD4+CD25+FoxP3+CD127low T cells
from PB, MB and CB whole blood samples, cells were stained with additional Treg-
associated markers and their levels of expression assessed and compared (Figure 6.3).
Levels of the homing receptors CCR4 (homes to the skin and lung) and CD62L (homes
to secondary lymphoid tissues) were assessed in the three sources of Tregs. CCR4
expression was found to be significantly lower in CB Tregs (40.51 ± 11.21%) compared
to those from MB (68.24 ± 6.97%, p<0.0002) and PB (74.98 ± 9.88%, p=0.0002).
Although MB CD25high cells had lower levels of expression of CCR4 than those from
PB, the differences were not found to be statistically significant. Levels of CD62L
expression in Tregs was lowest at 77.48 ± 16.03% in the PB samples, 82.90 ± 3.76% in
MB and highest levels were observed in CB (87.79 ± 4.85%).
CD39, an ectoenzyme, has immunoregulatory properties through the hydrolysis of proin-
flammatory extracellular ATP to AMP290,295 which can be further converted by CD73
to the immunosuppressive adenosine.297 CD39 expression was found to be highest at
59.13 ± 8.64% in PB samples, reduced to 47.18 ± 17.03% in MB and significantly lower
in CB (20.19 ± 11.99%, p=0.0015 and p=0.0008 compared to PB and MB respectively).
Differences between MB and PB CD39 expression were not found to be statistically sig-
nificant. Flow cytometry analysis of the CD4+CD25+/high populations reveal that the
CD39 subset is mostly expressed in the FoxP3+ cells with only 4.31 ± 1.25%, 1.61±2.27
and 1.11 ± 2.19% CD39 expression in FoxP3− cells for PB, MB and CB respectively
(Figure 6.4). Intensity of FoxP3 expression was found to be significantly higher in CD39+
compared to the CD39− subpopulation (MFI=1455 ± 645 for CD39+ and 914 ± 366
for CD39−, p<0.0001).
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Figure 6.3: Further characterisation of Tregs within CB, MB and PB. (A) Histograms
showing levels of expression of CCR4, CD39, CD62L, CD69 and ICOS in PB and
MB CD25high and CB CD25+ compared to the isotype (grey line). Data shown are
representative of 4 PB, 9 MB and 11 CB samples. (B) Mean percentage expression of
these cell surface markers in CD4+CD25+CD127lowFoxP3+ in CB (n=11), PB (n=4)
and MB (n=9) samples. Error bars correspond to the SEM. *p<0.05, **p<0.01 and
***p<0.001 between CB, MB and PB samples
Chapter 6 Banking a pure cell population 145
CBVPB_10COLOUR.jo Layout-3
4/1/14 20:29 Page 1 of 1 (FlowJo v9.3)
0 102 103 104 105
<FL6-A>: FOXP3 APC
0
102
103
104
105
<F
L2
-A
>:
 C
D
39
 P
E
4.17 64.9
23.87.14
0 102 103 104 105
<FL6-A>: FOXP3 APC
0
102
103
104
105
0.112 48.9
50.50.224
0 102 103 104 105
<FL6-A>: FOXP3 APC
0
102
103
104
105
0.128 20.7
76.82.42
PB CBMB
Figure 6.4: Levels of CD39 and FoxP3 expression in CD4+CD25high adult cells (PB
and MB) and CD4+CD25+ CB cells. Data shown are representative of 4 PB, 9 MB
and 11 CB samples.
Inducible costimulator (ICOS), a member of the CD28 receptor family, plays a role
in T cell activation and survival.301 ICOS is upregulated upon antigen encounter and
identifies memory-like Tregs.304 Similar levels of ICOS expression were observed in the
different sources of Tregs (9.72 ± 5.19% for CB, 9.59 ± 13.30% for MB and 13.30 ± 0.65
for PB%) with equal levels of CD69 (early activation marker) expression (∼3%).
6.2.1.2 Functional ability of CB v. adult Tregs
The suppressive abilities of Tregs derived from CB were compared to those from PB sam-
ples. CD25+ Tregs were isolated using a MACS system with a mean CD25+CD127low
purity within CD4+ cells of 95.1 ± 4.68% and 95.4 ± 1.41% for CB and PB respectively.
These cells were co-cultured at different ratios with CD25− cells, stimulated with solu-
ble anti-CD3 (1µg ml−1), and anti-CD28 (2µg ml−1) to initiate proliferation. Changes
in proliferation of the CD25− cells was assessed by uptake of tritiated thymidine (Fig-
ure 6.5) or through changes in CFSE intensity (Figure 6.6). In order to compare the
suppressive abilities of Tregs from CB and PB samples, the CD25− cells used in all
experiments were from the same batch of PB cells (described in §2.10.1).
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Figure 6.5: Comparing suppression of proliferating CD25− cells by CB and PB Tregs:
Assessed through the uptake of tritiated thymidine. (A) Thymidine uptake of CD25−
cells when co-cultured with (i) PB or (ii) CB Treg under the indicated conditions. Data
shown are representative of 4 PB and 14 CB samples. (B) Mean percentage suppression
of proliferating CD25− cells by different ratios of CB (n=14) and PB (n=4) Tregs.
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Figure 6.6: Comparing suppression of proliferating CD25− cells by CB and PB Tregs:
Assessed using CFSE and flow cytometry. CFSE stained CD25− cells stimulated with
or without the presence of Tregs (Treg:Teff ratio of 1:2). Data shown are representative
of CB (n=5) and PB (n=3) samples
Consistently high levels of [3H] thymidine uptake were observed for the stimulated
CD25− cells (Figure 6.5A), with negligible levels for unstimulated cells. The CD25+
cells from both PB and CB did not proliferate when stimulated and were therefore,
shown to be in an anergic state. The CD25+ cells, from both PB and CB, suppressed
the proliferation of the CD25− cells in a dose dependant fashion. PB Tregs were found
to have higher levels of suppressive function for all CD25+:CD25− ratios compared to
CB Tregs (Figure 6.5B), however, the differences between the two Treg sources were not
found to be statistically significant.
It has been suggested that after activation through the TCR, Tregs require cell-cell
contact in order to suppress effector cell proliferation.351 Therefore, the suppressive
abilities of CB and PB Tregs through cell-cell contact or soluble factors was assessed
using transwell plates (Figure 6.7). It was observed that both CB and PB Tregs were
able to suppress proliferating CD25− cells when mixed or separated by the transwell
membrane.
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Figure 6.7: Comparing suppression of proliferating CD25− cells by CB and PB Tregs:
Using a transwell system to assess cell-cell contact dependence or independence. Mean
suppression of Teff by CB (n=5) or PB (n=3) Tregs (Treg:Teff ratio of 1:2) when
cultured together or separated by a transwell membrane with pore size of 0.4µm. Error
bars correspond to the SEM.
6.2.2 Isolation of Tregs
The practical use of Tregs required their isolation from whole blood samples. Unfortu-
nately these cells are rare and potentially difficult to obtain as a pure and functional
product.419 Although FoxP3 is not unique to Tregs it is considered to be the most
specific marker in their identification.238 However, this is an intracellular marker and
requires fixing and permeabilisation of the cells, therefore, the use of FoxP3 for isola-
tions is unfeasible. CD25 is commonly used when isolating Tregs, however, CD25 is
up-regulated as T cells become activated,265 therefore, using this marker alone in the
isolation of adult Tregs can result in low purities. To combat this, CD127, which has
been shown to inversely correlate with FoxP3 expression,286,287 is often used in com-
bination with CD25+ to improve the purity of Treg isolations. As shown in section
6.2.1.1, there are fewer activated CD25 cells in CB and a high proportion of the CD25+
population express FoxP3 and low levels of CD127. Therefore, this marker alone can be
employed to isolate pure populations of Tregs from CB.429
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In order to create a Biobank Bank of pure cell populations, different methods of isolating
Tregs from CB samples were tested using expression of CD25 to separate cells. These
methods can be grouped into two different techniques:
1. Magnetic Activated Cell Sorting (MACS)
Involves attaching an antibody, labelled with a magnetic bead, to the cells and
separating labelled cells using a magnetic field. Within this study two different
MACS techniques from two companies were employed:
(a) Miltenyi Biotec MidiMACS system (MBio)
Miltenyi Biotec developed the MACS technique which involves passing the
labelled cells through a column, containing ferromagnetic spheres, within a
magnetic field. The labelled cells remain within the column allowing the
unlabelled cells to pass through. Any remaining unlabelled cells can then be
washed and the labelled cells eluted from the column by the removal of the
magnetic field.
(b) Stem Cell Technologies EasySep system (SCT)
The method developed by SCT uses a similar concept to MBio, but instead
of passing cells through a column, the sample remains in a tube placed within
a magnetic field and the unlabelled cells are poured off.
2. Fluorescence Activated Cell Sorting (FACS)
A specialised type of flow cytometry, separates specific cell populations based on
their binding to antibodies attached to a fluorochrome. A rare target population
within a large sample can extend sorting times. To avoid this, the CD4+ cells
were first enriched using MACS followed by CD25+ isolation using the Beckman
Coulter MoFlo cell sorter.
These three different isolation procedures were used to separate Tregs from other CB
cells based on their expression of CD25+. Total nucleated cell (TNC) recovery (assessed
as the percentage recovery of nucleated cells from the pre-isolation nucleated cell count)
from the starting cell count was lowest when using the cell sorter (0.08 ± 0.04% (range
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0.06 to 0.11%)) and MBio (0.09 ± 0.04% (range 0.05 to 0.14%)) protocols compared to
SCT (0.35 ± 0.13% (range 0.23 to 0.52%) p=0.00787 compared to both flow cytometric
cell sorting and MBio). The CD25+ cell yield (assessed as the percentage of CD25+ cells
recovered from the pre-isolation CD25+ cell count) was also highest in the SCT samples
(33.59 ± 16.91%), compared to 8.37 ± 5.10% (p=0.0087) for samples isolated using the
MBio protocol and 4.87 ± 0.57% for flow cytometric cell sorting).
The purity of the Tregs, their viability and their suppressive ability were also compared
between the three methods (Figure 6.8). Flow cytometric cell sorting resulted in the
highest purity of CD4+ cells in the CD45+ population of 90.95 ± 4.60% compared
to 82.07 ± 5.03% when using the MBio method (p=N.S.), and lowest when using the
SCT method (66.96 ± 11.85%, p<0.01 compared to sorted cells and p=0.03 compared
to MBio). Flow cytometry analysis of the isolated products (Figure 6.9) shows the
presence of contaminating monocytes (observed in the SSC v. FSC plots) and B cells
(identified as CD3−CD4− lymphocytes) in the SCT isolations. However, the identity
of these contaminating cells was not confirmed by further staining (for example CD14
or CD19 staining to identify monocytes and B cells respectively). CD25 purity within
the CD45+ population was again highest in the flow cytometric cell sorted samples with
a mean of 89.90 ± 5.94% compared to 81.73 ± 4.94% for MBio (p=N.S.) and 66.54 ±
11.70% for SCT isolations (p<0.01 compared to sorted cells and p=0.03 compared to
MBio). Cell sorting also resulted in a higher (although not significantly so) proportion of
FoxP3+ within the CD4+CD25+ population. However, these isolated cells had a slightly
lower CD25+ purity within the CD4+ cells and lower CD127low purity within the CD25+
population compared to the MACS protocols. Similar levels of CD39+ expression was
observed between the cells isolated from all three protocols.
Isolating Tregs using the MACS methods resulted in similar viabilities (86.91 ± 3.10%
and 89.52 ± 3.50% for the MBio and SCT protocols respectively) compared to a reduced
viability of 75.25 ± 4.46% when using the flow cytometric cell sorter (p=N.S.).
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Figure 6.8: Comparison of Treg purity and suppressive abilities when using different
isolation protocols. (A) Assessment of post-isolation purity through mean percentage
expression of Treg markers (B) suppressive effects of isolated cells from each separation
method (MBio n=14, SCT n=7 and flow cytometric cell sorting n=3). Error bars
correspond to the SEM. *p<0.05, **p<0.01 and ***p<0.001 between isolation protocols
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Figure 6.9: Comparison of Treg purity when using different isolation protocols: Flow
cytometry dot plots showing purity of Tregs pre- and post- CD25 isolation (data are
representative of MBio n=14, SCT n=7 and flow cytometric cell sorting n=3 samples).
The suppressive abilities of the cells isolated using the different methods are shown in
Figure 6.8B. When using a higher proportion of Tregs to CD25− cells in the suppression
assay, a greater difference is observed between the methods. At a Treg:Teff ratio of
1:1 the mean percentage suppression by the flow cytometric cell sorted samples was
highest at 99.37 ± 0.32% followed by 80.5 ± 13.16% for the MBio samples and 49.03 ±
28.92% for the SCT cells (p=0.0028). At a ratio of 1:5 and below, the MBio samples
had greater suppressive abilities (although not significantly higher) compared to the two
other methods. A high correlation was observed between the purity of Tregs isolated
using the various methods and their suppressive capabilities (r2=0.59; p=0.0003, shown
in Figure 6.10).
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Figure 6.10: Correlation between percentage Treg purity (percentage
CD4+CD25+CD127low within the CD45+ fraction) with percentage suppression
(at a Treg:CD25− ratio of 1:2) (n=12). Red dotted lines correspond to the 95% CI,
analysis performed using Spearman’s nonparametric correlation.
6.2.2.1 Characterisation of the positive and negative fractions post-isolation
Isolation of CD25+ cells using Miltenyi Biotec’s MidiMACS system (MBio) removed
almost all CD25+ cells from the negative fraction with an average contamination of 0.21
± 0.02% CD4+ cells, p=0.0278 (Figure 6.11A). The positive fraction also contained the
majority of FoxP3+ and CD127low cells (p=0.0278).
The distribution of cells expressing the markers tested in section 6.2.1.1 was assessed in
the positive and negative fractions of MBio isolations, shown in Figure 6.11B. It can be
observed that almost all the CCR4+ and CD39+ cells are found in the CD25+ fraction
(56.67 ± 6.45% and 1.35 ± 0.57% CCR4 expression in the positive and negative frac-
tions respectively, p=0.0278 and 20.80 ± 9.05% against 1.74 ± 2.01% CD39 expression,
p=0.027). Higher level of ICOS expression were also found in the positive fraction (7.85
± 1.37% in CD25+ versus 1.72 ± 1.67% in CD25− and CD69 was also increased (6.89 ±
2.65% versus 0.97 ± 0.37%). High levels of CD62L were observed in all fractions (83.11
± 8.28% CD62L expression in whole CB, 87.62 ± 12.91% in CD25+ fraction and 84.78
± 8.14% in the CD25− fraction).
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Figure 6.11: Characterisation of post-isolation positive and negative fractions: (A)
Levels of CD25 expression in whole CB, the positive and negative fraction post-
isolation, representative of 14 samples (B) Mean percentage cells expressing CCR4,
CD39, CD62L, CD69 and ICOS in CD4+ cells from whole CB, CD25 positive and
negative fractions (n=14).
6.2.2.2 Isolation of CD25+CD39+/− subpopulations
The Tregs from PB samples were found to contain higher levels of CD39 expression
(shown in Figure 6.3). To assess if this marker is important for Treg suppressive function,
and perhaps contributing to the higher suppression observed by the adult cells, CB
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cells were enriched for CD4+ (using MBio) prior to isolating the CD25+CD39+ and
CD25+CD39− subpopulations through cell sorting.
Figure 6.12A shows the purity of these isolations, with the CD39 positive fraction ex-
pressing CD25+CD39+ in 75.63 ± 5.99% of its cells and a mean contamination of CD39−
cells in 14.88 ± 9.66% of the population (p=0.0039).
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Figure 6.12: Comparison of the suppressive abilities of CD25+CD39+ and
CD25+CD39− subpopulations (A) CD25+CD39+ and CD25+CD39− subpopulations
were isolated from enriched CD4+ cells, data are representative of three samples. (B)
suppressive effects of isolated subgroups (n=3). Error bars correspond to the SEM.
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High levels of CD39 depletion were observed in the CD25+CD39− population (88.43
± 4.01%) with low levels of CD39+ contaminating CD39+ in 2.44 ± 4.16% of cells
(p=0.0022). However, despite pre-enriching the CD4 population prior to sorting, the
isolation procedure took an extended amount of time and the isolated cells were found
to have low viabilities of 59.33 ± 29.21% and 50.77 ± 37.68% for CD25+CD39+ and
CD25+CD39− populations respectively.
The CD25+CD39+ population was found to have higher levels of suppression of prolifer-
ating CD25− cells than the CD25+CD39− population (Figure 6.12 B) with a significant
difference observed at a ratio of 1:2 (p=0.0341).
6.2.3 Cryopreservation and thawing of Tregs
There are two options for the cryopreservation and storage of Tregs:
1. Cryopreservation of isolated pure populations of Tregs
2. Isolation of Tregs from cryopreserved CBMCs
6.2.3.1 Cryopreservation of isolated pure Treg population
Tregs were isolated, using the MBio protocol, with an average purity of 87.03 ± 8.11%
CD25+ cells within the CD45+ population, and frozen at a concentration of 2.0×106 cells
ml−1 in AB serum and 10% (v/v) DMSO 1% (w/v) dextran. Post-thaw yields of 82.84
± 10.39% for TNC and 76.33 ± 12.40% for CD25+ cells were observed. Thawing these
cells exhibited a reduced viability of 76.46 ± 15.00% (AnnV−7AAD−) and an increase
of 14.84% in the percentage of apoptotic cells (AnnV+7AAD−). The thawed cells were
found to maintain their levels of expression of CD4 (83.32 ± 8.23% of CD45+ cells),
CD25 (98.28 ± 0.70% of CD4+ and 81.74 ± 8.07% of CD45+ cells), CD127 (98.90±
0.42% of CD25+ cells), Figure 6.13A)
The suppressive abilities of the thawed Tregs, shown in Figure 6.8B, were found to be
reduced compared to the pre-freeze analysis. At a CD25+:CD25− ratio of 1:2 the
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suppression induced by thawed cells was 58.70 ± 23.91% compared to 82.07 ± 10.72%
pre-freeze (p=0.0313).
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Figure 6.13: Comparison of Treg purity and suppressive abilities pre- and post-thaw.
(A) Mean percentage expression of Treg markers in pre- and post-thaw isolated CD25+
cells (B) suppressive effects of pre-freeze and post-thaw isolated cells at a CD25+:CD25−
of 1:2 (n=6). Error bars correspond to the SEM. *p<0.05 between isolation protocols
Chapter 6 Banking a pure cell population 158
6.2.3.2 Isolation of Tregs from cryopreserved CBMC
The ability to isolate Tregs from thawed CBMC samples was assessed; first by deter-
mining the effects of freezing Tregs within the CBMC fraction, followed by the potential
to isolate these cells post-thaw.
6.2.3.2.1 Effects of freezing WB/CBMC on Treg frequency
The effects of cryopreservation on the frequency of the Treg population within either
whole blood (WB) or CB mononuclear cell fractions (CBMC) samples was assessed by
comparing pre-freeze and post-thaw cell counts measured using flow cytometry.
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Figure 6.14: Frequency of Tregs in CD4+ T cells from fresh and thawed WB (n=9)
and CBMC (n=8) samples. Error bars correspond to the SEM.
Compared to the fresh analysis, the mean proportion of Tregs (CD25+CD127low) in
CD4+ T cells was reduced in the post-thaw samples for both WB and in CBMC (Figure
6.14). For WB the proportion was reduced from 4.66 ± 1.40% in freshly isolated samples
to 3.94 ± 1.30% in the post-thaw analysis and CBMC samples from 3.40 ± 1.28% in fresh
to 3.01 ± 0.94% post-thaw, however, these reductions were not found to be statistically
significant.
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Using Spearman’s Test, a strong correlation was observed between percentages of Tregs
found in fresh and thawed WB (r2=0.9666, p=0.0002) and CBMC (r2 =0.7931, p=0.0046)
samples (Figure 6.15). This suggests that the thaw method used results in a consistent
cell product.
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Figure 6.15: Correlation between percentage of Tregs (CD25+FoxP3+CD127low) from
CD4+ T cells in fresh and frozen (A) WB (n=9) and (B) CBMC (n=8) samples. Red
dotted lines correspond to the 95% CI, analysis performed using Spearman’s nonpara-
metric correlation.
Viability assessment of the Tregs in pre- and post-cryopreserved samples was performed
using Annexin V to identify apoptotic cells and 7AAD to exclude cells with disrupted
membranes. A reduction of 9.87% in the mean percentage of viable cells and an increase
in apoptosis of 9.40% was observed after thawing in the WB samples (Table 6.1), whereas
in the CBMC samples similar levels of viable and apoptotic cells were observed between
fresh and thawed cells.
Table 6.1: Mean percentage of viable and apoptotic Tregs in fresh and thawed WB
(n=9) or CBMC (n=8) samples
Sample Fresh % Viable % Apoptotic
fraction or thaw Tregs Tregs
WB
Fresh 93.4 ± 2.10% 6.52 ± 1.99%
Thaw 83.53 ± 7.72% 15.92 ± 7.41%
CBMC
Fresh 85.17 ± 3.21% 14.13 ± 2.54%
Thaw 88.69 ± 2.90% 11.27 ± 2.54%
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6.2.3.2.2 Isolation of Tregs from cryopreserved CBMC
Another Treg banking option involves the storage of cryopreserved CBMC followed by
CD25 isolation after thawing. CBMC samples were cryopreserved in 10% (v/v) DMSO
1% (w/v) dextran using a controlled rate freezer (CRF) and stored for a minimum of
24 hours. The samples were thawed and washed to remove DMSO and maintain the
osmotic balance. CD25+ cells were then isolated using either the MBio or SCT method.
A recovery of 0.17 ± 0.05% TNC and 6.10 ± 2.48% CD25+ was observed when iso-
lating Tregs from thawed CBMC using the MBio protocol. Higher recoveries were ob-
tained using the SCT protocol (0.61 ± 0.08% TNC and 15.14 ± 4.15% CD25 recoveries,
p=0.0223). The isolated cells had similar viabilities of 93.45 ± 1.98% and 90.13 ±
13.02% for MBio and SCT respectively. Apoptosis was observed in 6.27 ± 2.01% of
MBio isolated cells and 6.75 ± 8.01% SCT cells. As with the fresh isolations, the MBio
method resulted in higher purities of CD25+ cells in the CD45+ population (92.14 ±
4.28% and 86.40 ± 5.63% for MBio and SCT respectively, Figure 6.16A). Both meth-
ods had high levels of FoxP3 and CD127low expression in the CD25+ cells. Due to the
increase in purity, the MBio isolated cells had significantly higher suppressive abilities
across a range of CD25+:CD25− ratios compared to cells isolated using the SCT protocol
(Figure 6.16B).
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Figure 6.16: Comparison of Treg purity and suppressive abilities when using different
isolation protocols on thawed CBMC samples. (A) Assessment of post-isolation purity
on the basis of mean percentage expression of Treg markers (B) suppressive effects of
isolated cells from each separation method (MBio n=5 and SCT n=3). Error bars
correspond to the SEM. *p<0.05 between isolation protocols.
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6.2.3.3 Treg banking: pure population or isolation from thawed CBMC?
The two different methods of banking Tregs have been assessed (cryopreservation of
isolated pure Treg populations and isolation of cells from cryopreserved CBMCs).
Comparing the thawed CD25+ populations, isolated using the MBio protocol, resulted
in similar TNC recoveries from the starting number in the fresh WB samples (0.04 ±
0.02% for frozen CBMC and 0.03 ± 0.01% for thawed CD25, shown in Figure 6.17A).
Higher CD25 yields from the initial fresh WB count were observed when isolating from
thawed CBMCs (1.61 ± 0.24% and 1.09 ± 0.09% for thawed CBMC and thawed CD25
respectively, p=0.0049). These two methods resulted in CD25+ cells with similar pu-
rities and levels of both FoxP3 and CD127low expression (Figure 6.17B). However, the
cells isolated from thawed CBMC had higher viabilities than the thawed pure cell pop-
ulations (93.14% against 76.46%) and lower levels of apoptotic cells (5.43% against
23.25%), shown in Figure 6.17C. The suppressive abilities of these cells were assessed at
Treg:CD25− ratio of 1:2 and the thawed CBMC isolations resulted in higher suppres-
sion than the thawed CD25+ cells (76.76% against 58.70%, p=0.0012 shown in Figure
6.17D).
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Figure 6.17: Comparison of cryopreserved CD25+ cells (n=6) against cells isolated
from thawed CBMC samples (n=5) (A) TNC and CD25+ recovery from initial fresh
whole blood samples, (B) purity of post-thaw isolated samples, (C) cell viabilities and
levels of apoptosis (D) suppressive effects of Tregs. Error bars correspond to the SEM.
**p<0.01 compared to 0% DMSO at the same time point
6.2.4 GMP grade isolations and banking
For their use in therapeutic applications, Tregs need to be isolated with high levels of
purity under GMP grade conditions. To achieve this, cells will be isolated using clinical
grade reagents (such as the CE marked CD25 microBeads) and performed under aseptic
techniques through the use of closed systems (CBMC separations using a SEPAX and
CD25 enrichment using a CliniMACS device).
Four to six cord blood units were pooled, resulting in a mean volume of 546.67ml. These
pooled units underwent a volume reduction protocol and gradient separation using ficoll
on a SEPAX machine to isolate CBMCs. The cells were stained for CD25 using clinical
grade microBeads and the labelled cells were isolated using the enrichment 3.2 protocol
on a CliniMACS.
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The initial pooled samples contained a mean TNC count of 52.05×108 cells with a mean
CD25+ cell count of 1.04×108. Volume reduction of these samples using a SEPAX
machine resulted in a mean TNC recovery of 95.35% (49.63×108 cells). The density
gradient cell separation protocol on the SEPAX reduced the TNC count to 19.39×108
(recovery of 37.24%) through the removal of granulocytes and reduced the CD25+ cell
count to 0.52×108 (recovery of 50.06%).
Isolating CD25+ cells from fresh CBMC using a CliniMACS resulted in a TNC yield
of 0.13 ± 0.07% and CD25 recovery of 5.08 ± 2.97%. These cells had high levels of
CD25 purity with a mean of 76.84 ± 8.63% in the CD45+ population (Figure 6.18A).
These cells expressed high levels of FoxP3 (82.88 ± 15.23%) and CD127low (90.00 ±
4.97%) with a mean viability of 94.82 ± 3.31% and 4.46 ± 3.09% apoptotic cells. The
isolated cells from pooled units suppressed in a dose-dependant manner (Figure 6.18B)
with levels similar to to the single MBio isolations in Figure 6.8B.
In some cases it may be convenient to isolate Tregs some time prior to their use ther-
apeutically, in these situations it would be beneficial to cryopreserve these cells whilst
ensuring suppressive function remains intact. Cryopreserving these GMP grade isolated
cells resulted in post-thaw recoveries of 67.81 ± 13.45% for TNC and 68.24 ± 22.68% for
CD25. Compared to the pre-freeze assessment, these thawed cells had lower viabilities of
73.70 ± 8.75% (p=0.06) and higher levels of apoptosis (21.72 ± 4.98% of cells were apop-
totic (p=0.0079). The thawed cells maintained their levels of purity (75.82 ± 13.83%
CD25 expression in the CD45+ cells), but had slightly reduced levels of suppression
(shown in Figure 6.18).
As with the smaller scale research grade Treg isolations (§6.2.3.2.2), the ability to isolate
functional cells from thawed CBMC samples was assessed using GMP grade protocols.
Cryopreserved CBMC samples were thawed, washed using a SEPAX and pooled (4-6
units per experiment) resulting in mean TNC and CD25+ cell counts of 16.76×108 and
0.68×108 cells respectively. The pooled samples were washed to remove DMSO (post-
wash mean TNC count of 13.21×108 with a recovery of 78.82%) and labelled with clinical
grade CD25 microBeads. Isolating CD25+ cells from thawed CBMC using a CliniMACS
resulted in a recovery of 0.29 ± 0.22% of the post-thaw TNC and 4.04 ± 0.96% of the
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Figure 6.18: GMP grade isolations on fresh samples (n=5), cryopreserved isolated
CD25+ cells (n=5) and cells isolated from thawed CBMC (n=4). (A) Assessment of
post-isolation purity through mean percentage expression of Treg markers (B) suppres-
sive effects of isolated cells from each banking method. Error bars correspond to the
SEM.
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initial CD25+ population. These isolated cells had viabilities of 95.83 ± 1.62% and
3.47 ± 1.61% were apoptotic. These cells had slightly elevated CD25 purity in the
CD45+ population compared to the fresh isolations (86.13 ± 6.48%) and similar levels
of FoxP3 and CD127 expression (shown in Figure 6.18A). The suppressive capabilities
of the cells isolated from thawed CBMC were similar to those from fresh isolations at
higher CD25+:CD25− ratios, but at ratios of 1:5 to 1:20 these cells were found to be
more suppressive, however, the differences were not found to be statistically significant
(shown in Figure 6.18B).
6.2.4.1 GMP Treg banking: pure population or isolation from thawed CBMC?
From the fresh WB samples a slightly lower TNC recovery was observed in the thawed
CD25+ cells (0.07 ± 0.04%) compared to the cells isolated from thawed CBMC (0.08
± 0.06%). A similar pattern was noted when assessing the CD25 yield (1.12 ± 0.68%
thawed CD25 recovery against 1.22 ± 0.36% thawed CBMC recovery). The CD25+ cells
isolated from thawed CBMC also had higher viabilities and lower levels of apoptosis
compared to the thawed CD25+ cells (p=0.0159 for both viable and apoptotic cells).
The same pattern of higher viabilities and functional abilities in the CD25+ cells isolated
from thawed CBMCs over the cryopreserved pure CD25+ cell population was observed
in the research grade MBio isolations shown in §6.2.3.3.
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6.3 Discussion
This Chapter aimed to improve isolation and cryopreservation techniques for a pure cell
population from CB allowing their long term storage within the Biobank. Tregs were
chosen as these cells are crucial for the homeostasis of the immune system through the
suppression of immune cells and have therapeutic applications during transplants and
in the treatment of autoimmunity.
Tregs from CB and PB sources are known to have different properties. Therefore,
the first aim of this Chapter was to assess the differences in phenotype and functional
activity between Tregs from these two sources to ensure the CB cells are a suitable
product for the Biobank. A difference in CD25 expression was observed between CB
and adult samples with a larger proportion of CD4+ cells expressing the CD25 marker
in the adult samples. Within these adult CD25+ populations two subsets were observed;
a larger CD25int and smaller CD25high (p=0.0001). However, only the CD25high cells
showed high levels of expression of the intracellular marker FoxP3 (p<0.001) and low
levels of the cell surface marker CD127 (p=0.002) compared to CD25int, suggesting
that these cells possess a regulatory phenotype. This correlates with Baecher-Allen
et al who demonstrated that the CD25high, but not CD25int, population was able to
suppress proliferating T cells in vitro.242 The CD25int population is believed to be
recently activated or memory T cells and have been found to express CD45RO and the
CD25− population are na¨ıve or resting T cells.238,483 As antigen stimulation is scarce
in CB, the CD25int or memory population is much smaller, therefore, a more distinct
CD25+ population with high expression can be observed. This population was found to
poses a regulatory phenotype through expression of low levels of CD127 and high levels
of FoxP3, although the intensity of this intracellular marker was reduced compared
to adult CD25high cells. It has been shown that na¨ıve CD45RA+ Tregs have a lower
FoxP3 intensity than memory CD45RO+ cells,484 therefore, the lower levels of intensity
observed in this study could be linked to the lower levels of CD45RO+ cells found in
CB.485
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Due to high intracellular ATP concentrations,292 if a cell is damaged large amounts
of ATP are released inducing a proinflammatory response.486,487 CD39 plays an im-
munoregulatory role through the removal of extracellular ATP, converting it to AMP
thereby preventing inflammation.290,295 CD39 is constitutively expressed in mouse
CD25+ cells but only in a subset of human adult Tregs.299 In this study the major-
ity of FoxP3+ cells expressed CD39, these CD39+ cells were also found to have a higher
intensity of FoxP3 expression than the CD39− Treg subpopulation (p<0.0001). How-
ever, lower levels of CD39 expression in the Tregs were observed in CB compared to
PB (p=0.0015) and MB (p=0.0008). Borsellino et al observed a much larger variation
of CD39+ expression in adult FoxP3+ cells (2-60%). They further characterised this
population and discovered they had an activated or memory-like phenotype through the
expression of the memory markers CD45RO, CCR6 and HLA-DR.299 The co-expression
of activated/memory markers with CD39 accounts for the reduced levels in CB where
cells tend to posses a more na¨ıve phenotype.485
As cells mature they can change their expression of specific homing receptors.321 This
study has shown the more na¨ıve CB Tregs express higher levels of the lymphoid tissue
homing receptor CD62L than the PB cells which tend to contain a larger memory popula-
tion. In other studies both the CD4+CD25+CD62L+ and CD4+CD25+CD62L− subpop-
ulations have been shown to be anergic, to suppress proliferating cells in vitro330,331,333
and can also prevent adoptive transfer of colitis in mouse models.332 However, only the
CD4+CD25+ CD62L+ population have been shown to protect mice from diabetes333
and lethal GvHD.322 Donor CD62L− T cells do not cause GvHD in mice,334,335 suggest-
ing this marker may be necessary to enter the site where the allo-reactive T cells cause
GVHD.322 Higher levels of expression of CCR4, which attracts cells to non lymphoid or
intestinal tissues,318 were observed in the PB samples compared to CB (p=0.0002). It
has been previously reported that expression of these two different trafficking receptors
are linked to CD45RA/RO expression.319 This confirms that the more na¨ıve CD45RA+
CB cells express higher levels of CD62L, whilst the adult cells with a larger population
expressing the memory phenotype of CD45RO+ express higher levels of CCR4. This
switch in trafficking receptor expression is believed to occur sometime between 18 months
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and 3 years of life.321 Therefore, the reduced CCR4 and increased CD62L expression in
CB Tregs demonstrates a more na¨ıve phenotype compared to their adult counterparts.
The presence of persistent paternal antigens poses a unique challenge to the mater-
nal immune system during pregnancy and the mechanism by which the maternal im-
mune system tolerates the foetus is not fully understood. One proposed mechanism is
through an increase production of Tregs by both the mother and foetus243 and low levels
of these cells during pregnancy have been linked to preeclampsia488,489 and recurrent
miscarriage.490–492 Conflicting observations in the frequency of Tregs in the periphery
during pregnancy and postpartum have been noted. It has been reported by differ-
ent groups that frequency of maternal peripheral Tregs increases dramatically in early
pregnancy493,494 and the up-regulation of these cells has been linked to the increasing
oestrogen concentrations in both mice495 and humans.496 These groups also report that
peripheral Treg frequency remains high throughout pregnancy but declines dramatically
during labour, although, frequency still remains higher than before the pregnancy.493,494
However, it has also been reported that the frequency of peripheral Tregs in maternal
blood does not increase, instead Tregs are found to be enriched at the maternal-foetal
interface,490,497,498 particularly at the decidua parietalis.499,500
In this study although a higher frequency of CD25+FoxP3+CD127low cells within the
CD4+ population were observed in MB samples compared to the non-pregnant PB group,
the difference was not found to be statistically significant. A higher frequency within
the periphery during pregnancy could leave both the mother and foetus vulnerable to
infection due to the non-specific nature of Treg suppression. Therefore, an increase
in Tregs at the maternal-foetal interface rather than in the periphery would promote
tolerance without the risk of infection.
The homing marker CCR4 attracts cells to non-lymphoid tissues, such as the skin and
lung.315–317 Within this study, CCR4 was also found to be highly expressed on MB
peripheral Tregs. The expression of this homing marker could aid migration of these
cells to the maternal-foetal interface through its ligand CCL17, which has been found to
be highly expressed in the decidua.501 The presence of this ligand has also been shown
to be important in the migration of CCR4+ Th2 cells to the decidua.501
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A comparison of the suppressive capabilities of Tregs isolated from CB or PB was per-
formed. Wing et al reported CB Tregs suppressed CD25− cells stimulated with myelin
oligodendrocyte glycoprotein (MOG), but not staphylococcal enterotoxin B (SEB), whereas
PB Tregs suppressed both.253 Whereas Fujimaki et al reported CB Tregs not only
showed no suppressive capability when stimulated with anti-CD3/anti-CD28 beads but
they proliferated themselves and were therefore, not in an anergic state.502 Differences
in alloreactivity of CD25− cells from CB and PB have been observed due to an increased
frequency of memory cells in PB compared to the more na¨ıve CB cells. This leads to a
lower threshold of activation and therefore faster and higher levels of proliferation.503,504
As third party Tregs have been shown to be equally suppressive as those from the same
donor,430–432 all suppression assays were performed using thawed CD25− cells from the
same PB sample. This allows comparison of Treg suppressive abilities from different
samples by ensuring similar levels of proliferation and Treg contamination with the
CD25− fraction. Tregs were isolated with similar CD25+CD127− purities of 95.1% and
95.4% from CB and PB respectively. Isolated Tregs, from both sources, were shown to
be anergic, as culturing them with anti-CD3 and anti-CD28 did not result in an increase
in proliferation as detected by tritiated thymidine uptake. Co-culturing Tregs with stim-
ulated CD25− cells resulted in lower levels of suppression from the CB Tregs across a
range of CD25+:CD25− ratios. A lower intensity of FoxP3 expression was observed
in the CB CD25+ cells compared to those from the adult CD25high population which
could account for their reduced suppressive capabilities. Adult CD25high cells were also
found to have higher levels of CD39 expression compared to CB cells. Cells expressing
this marker were found to have higher levels of intensity of FoxP3 than CD25+CD39−
cells (p<0.0001). It was also observed that the CD25+CD39+ population, isolated from
CB, showed higher suppressive abilities than those that were CD25+CD39− (p=0.0341).
Reduced levels of CD39+ Tregs have been observed in patients with multiple sclerosis
and patients with renal allograft rejection, whilst no differences in CD39− levels were
observed.300,505 This suggests that CD39 plays a regulatory role and may serve as a
more specific marker for Tregs. Therefore, the higher levels of CD39 noted in adult
Tregs could lead towards their higher suppressive abilities.
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There are many reports suggesting that Treg suppression is dependant on cell-cell con-
tact.351 However, Collison et al reported that cell contact was only critical in activating
the suppressive function of Tregs and that once activated they could suppress in a con-
tact independent manner.506 The manner of which Tregs suppress (whether contact
dependent or independent) was compared between adult and CB Tregs. Using transwell
plates, Tregs stimulated with soluble anti-CD3 and anti-CD28 were either cultured with
the target CD25− cells together in the lower chamber or separated by the transwell
membrane. Similar levels of suppression were observed, in both CB and PB samples,
between Tregs cultured with the target CD25− or separated by the transwell membrane.
This suggests that Tregs from both sources are able to suppress in a contact independent
manner. This result is controversial as the majority of studies suggest the function of
nTregs are contact dependent.351,359 However, there are a number of studies that report
Tregs suppress though the release of suppressive cytokines.507,508 The data obtained in
this study could be followed up by assessing if the suppression is due to the presence of
suppressive cytokines, such as IL-10 and TGF-β, through experiments that block these
cytokines.
Despite their reduced suppressive activity compared to PB cells, CB Tregs are still an at-
tractive product for the Biobank due to their higher frequency and more defined CD25+
population which would facilitate the isolation process. In this study the efficiency of
two different isolation techniques were assessed; MACS (of which two protocols were
tested) and cell sorting. Comparing the MACS protocols, higher TNC and CD25+ cell
recoveries were obtained through the SCT isolations (p=0.0079 and p=0.0087 for TNC
and CD25 respectively). Very few CD25+ cells were observed within the negative frac-
tion of MBio isolations, therefore, differences in cell yield may be due to the different
techniques of retaining the labelled cells. In the SCT protocol the cells are held within a
magnetic field surrounding a tube whilst the unlabelled cells are poured away, whereas in
the MBio method the cells are passed through a column where some may remain despite
repeated purging after washing the unlabelled cells off. The cells isolated using the SCT
protocol had lower CD4 (p=0.03) and CD25 (p=0.03) purities within the CD45 popu-
lation. SCT cells also had lower expression of FoxP3 and CD127low within the CD25+
population than the MBio cells. Contaminating cells were identified as monocytes and
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B cells. These reduced purities resulted in significantly lower suppressive abilities from
the SCT isolated cells (at Treg:CD25− ratios of 1:1 p=0.0109, 1:2 p=0.0025 and 1:5
p=0.0083).
MACS techniques enrich the positively labelled population regardless of expression lev-
els, therefore, an advantage of sorting cells is the ability to gate and isolate the pop-
ulations of interest. This is particularly useful when isolating Tregs as the CD25high
population can be targeted specifically. Compared to the MBio technique, the cell sort-
ing protocol resulted in slightly lower TNC and CD25+cell recoveries. However, the cell
sorted isolations had higher CD4 and CD25 purities within the CD45 population and
higher suppressive capabilities, however, these differences were not found to be signifi-
cant. One disadvantage of using cell sorting to separate rare populations is the amount
of time it can take to sort through a large sample, this leaves cells exposed to the FACS
sheath fluid for long periods of time reducing viability. In an attempt to reduce sorting
time, the cells were enriched for CD4 using MACS prior to CD25 isolation. This would
account for the higher CD4 purities compared to the single isolation step MBio protocol.
Within the CD4+ cells, the cell sorted isolations resulted in a slightly lower mean CD25+
purity compared to MBio. Despite attempts to reduce the sorting time, the sorted cells
had lower viabilities (mean of 75.25%) compared to MBio (86.91%).
Overall, the MBio protocol has been shown to be the most efficient. These isolated cells
had high Treg purities of 81.73% CD25+ within CD45+ cells (these purities were signif-
icantly higher than SCT) and expressed high levels of FoxP3 and low levels of CD127
(89.63% of CD25+ cells were FoxP3+ and 98.47% were CD127low). High Treg purities
were observed in one separation step from CB with no further purification needed, un-
like isolations from PB which can require CD8, CD19 and CD127 depletion depending
on the level of purity needed.419 For example, high levels of purity are essential when
expanding cells as the conditions used tend to favour proliferation of non suppressive
T cells.418 These cells had high levels of viability 86.91% and significantly higher levels
of suppression than SCT isolations. Although these assessments were lower than those
observed when using the flow cytometric cell sorting protocol, the differences were not
found to be significant between these two isolation methods. The flow cytometric cell
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sorted isolations required two stages; CD4 enrichment by MACS followed by CD25 iso-
lation. This results in a long process putting the cells under strain and resulted in lower
viabilities compared to MBio (which required only one isolation step). Therefore, the
MBio protocol was found to be the most efficient for Treg isolation.
Due to the high levels of purity, viability and suppressive capabilities of the MBio isolated
cells, this method was used prior to cryopreserving CD25+ cells. Cryopreserving the
isolated CD25+ cells resulted in a mean post-thaw TNC yield of 82.84%. These cells
maintained their expression levels of CD4, CD25, FoxP3, CD127 and CD39. The CD25+
cells had significantly lower suppressive abilities post-thaw compared to the fresh analysis
(p=0.0313). Peters et al reported that cryopreserved adult Tregs required expansion
post-thaw in order to regain functional capabilities.419 This post-thaw expansion was
found to be unnecessary by Mavin et al as thawed Tregs were able to suppress CD8+
cells in an MLR as efficiently as the pre-thaw assessment and were able to protect GvHD
target tissue.509 However, the reduced suppressive ability of the thawed CB Tregs in
this study is likely to be due to the reduction of the percentage of viable cells (76.46%)
and increase in apoptosis (23.25%).
Cryopreservation of WB or CBMC resulted in a reduction of Treg frequency of CD4+ T
cells from 4.66% to 3.94% and 3.40% to 3.01% in WB and CBMC respectively. This had
only been previously reported in PB studies by Elkord et al who found the frequency
of PB Tregs to be significantly reduced post-thaw.425 In this study although post-thaw
CB Treg frequency was reduced, it was not found to be significantly lower than the
pre-freeze levels. The significant reduction that Elkord et al reported could be in-part
due to their freezing protocols which involved resuspending PBMCs directly into FBS
containing 10% (v/v) DMSO rather than resuspending the cells before the slow addition
of pre-cooled DMSO. Viability assessment of these samples showed a reduction in the
percentage of viable cells in the post-thaw WB samples, whereas in the CBMC samples
similar levels of viable and apoptotic cells were observed between fresh and thawed cells.
A similar pattern was observed in Chapter 6 (§5.2.1) where numbers of viable CD45+ and
CD34+ cells were lower when cryopreserving WB rather than the granulocyte depleted
CBMCs.
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As the frequency of Tregs in cryopreserved CBMCs were conserved post-thaw, the ability
to isolate Tregs from these samples was assessed using the MBio and SCT protocols. As
with the fresh isolation, the SCT method resulted in higher yields of TNC and CD25
compared to MBio (p=0.0223). However, unlike the fresh isolations, the two methods
resulted in cell products with comparable purities. Despite the similarities in purity, the
suppressive abilities of the SCT isolation were significantly reduced compared to MBio
(at CD25+:CD25− of 1:1 p=0.014, 1:2 p=0.0104, 1:5 p=0.0137, 1:10 p=0.0285 and 1:20
p=0.0285).
Biobanking requires potentially long term storage of samples, this can be achieved
through cryopreservation. Within this study two banking options were assessed. The
first involved isolation of CD25 from fresh cells and their subsequent cryopreservation.
Upon thawing these cells maintained their expression of Treg markers CD25, FoxP3 and
low levels of CD127. However, losses in cell viability and suppressive potency (p=0.0313)
were observed. The alternative approach to Treg banking involves maintaining the cells
as part of the CBMC fraction during cryopreservation and isolating the cells of interest
post-thaw. Isolating Tregs from thawed CBMC resulted in lower TNC and CD25+ cell
recoveries from the starting fresh WB sample compared to fresh isolations (p=0.0238 and
p=0.0341 for TNC and CD25 respectively). However, calculating the TNC yield from
the CBMC fraction prior to isolation results in higher recoveries in the thawed isolations
(p=0.0238). Therefore, the differences in recovery from the fresh WB samples occur
during the cryopreservation of CBMC (p=0.0476). Compared to fresh isolations, higher
purities of CD4 (p=0.0043) and CD25 (p=0.0087) in the leucocytes were observed, this
in combination with higher viabilities led to higher levels of suppression of proliferat-
ing CD25− cells. Therefore, once the cell losses associated with the cryopreservation of
CBMCs were taken into account, the use of thawed CBMCs was found to be an efficient
isolation strategy to obtain a pure, functional Treg population. Between the two types of
thawed Tregs, the cells maintained as CBMCs during cryopreservation resulted in higher
CD25+ cell recovery (p=0.0049). These cells also had higher viabilities, less apoptotic
cells and therefore, higher levels of suppression (p=0.0012). Therefore, the most efficient
CB Treg banking procedure involves the storage of CBMCs followed by a CD25+ cell
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isolation post-thaw, unless a set cell dose is required in which case cryopreservation of
pre-isolated Tregs may provide a better predictor of post-thaw cell dose.
The TNC yield from GMP grade fresh CD25 isolations was found to be slightly higher
than the research grade MBio isolations (0.13% and 0.09% for CliniMACS and MBio
respectively). However, the percentage of CD25+ cells in the CD45+ population was
reduced (76.84% versus 81.73%). This led to a lower CD25+ recovery of 5.08% (compared
to 8.37% for MBio isolations). Despite the lower levels of CD25 purity, these cells had
high levels of FoxP3 expression (82.88% of CD25+ cells), high viability (94.8%) and were
found to be as equally suppressive as the MBio cells.
The two banking options, performed on the MBio isolations, were also assessed on the
GMP grade separations and a similar pattern was observed. Although cryopreserving the
isolated CD25+ population resulted in a reduction in viability (p=0.06) and slightly lower
suppression post-thaw, they did not require expansion as recommended for cryopreserved
adult Tregs by Peters et al.419 As observed in the MBio isolations, GMP isolation of
CD25+ cells from thawed CBMC resulted in higher viabilities (p=0.0159) and higher
suppressive abilities than the cryopreserved CD25+ population.
In summary, CB Tregs showed phenotypic and functional differences to their adult coun-
terparts. The CD25+ population within the CD4+ cells appear as a distinct population
in CB of which the majority co-express FoxP3 and low levels of CD127. The CD25+
population is much larger in adult CD4+ cells but mostly consists of activated non sup-
pressive T cells, only the CD25high cells had a regulatory phenotype (FoxP3+ CD127low).
CB Tregs were found to be less suppressive in vitro than adult cells, this is in part could
be due to the differences in intensity of FoxP3 and levels of CD39 expression observed.
Due to the lower levels of activated non suppressive CD25+ cells, CB Tregs can be iso-
lated from mononuclear cells in a single step, with no further purification as required
by adult Tregs. These cells can be banked, either as research or clinical grade prod-
ucts, as a pure isolated population. Alternatively, Tregs can be cryopreserved as part of
the CBMC fraction and isolated post-thaw. Post-thaw, using either banking procedure,
these cells retained high levels of CD25 and FoxP3 expression. However, cells isolated
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from thawed CBMC samples had higher viabilities and suppressive capabilities than
those cryopreserved as a pure population.
CHAPTER 7
DISCUSSION
Anthony Nolan Cell Therapy Centre (ANCTC) currently receives an average of 393 cord
blood (CB) units to the bank every month (calculated from the last 10 months: April
2013 to January 2014). Of these units, an average of only 22.54% were found to be
suitable for potential use in haematopoietic stem cell transplants (HSCT) and banked
for that purpose. The majority of samples are considered to be unsuitable due to the
quality thresholds put in place at ANCTC such as a minimum total nucleated cell (TNC)
count of 1.2×109 and a minimum CD34+ cell count of 3.2×106. The consent obtained
from the mother prior to collection allows for these samples to be used for other purposes
such as research. Therefore, instead of discarding these samples ANCTC aims to create
a Biobank storing CB either as whole blood, mononuclear cells (CBMC) or pure cell
fractions allowing the distribution of these samples to researchers around the globe.
This study aimed to aid ANCTC in creating this Biobank through the optimisation of
the procedures required for the isolation and storage of CB fractions. For the purpose of
this study, the procedures were broken down into four sections; transportation of fresh
CB from the collection site to the bank, CBMC isolation, cryopreservation of CBMC
and the isolation and banking of pure cell populations. Throughout each section the
quality of the cells were monitored to ensure they maintained viability and functional
abilities throughout the whole banking process from collection to thawing.
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ANCTC has different maternities collecting CB samples situated across the UK. Due to
transportation times there is a delay between the collection of a sample in the maternity
and its cryopreservation at the bank. To ensure the CB samples arrive at the bank with
the highest level of potency, Chapter 3 assessed the impact of two different storage tem-
peratures on fresh CB, the effects of time on cell potency and the effects of fresh storage
on the recovery of cells post-thaw after delaying cryopreservation. This section of the
study is of benefit to both the Biobank and the HSCT bank but also assessed the effects
of fresh storage prior to cryopreservation on two other sources of haematopoietic stem
cells (HSC): bone marrow (BM), and mobilised peripheral blood stem cells (PBSC). Due
to differences between studies in the storage temperatures tested and in the methods of
assessing cell potency, there is no consensus in the literature regarding the optimal fresh
storage conditions for the three sources of HSCs. For example, regarding fresh storage
temperature many studies indicate CB should be maintained at refrigerated tempera-
tures in order to avoid significant reductions in cell recoveries.441–446 In contrast there
are studies reporting that cell recovery is optimum at ambient temperatures,54,438,439
whereas other studies report no significant difference in cell recovery if cells are stored
at 4◦C or 25◦C, although losses are reported at 37◦C.19,440 Similarly for BM, most stud-
ies report higher recoveries whilst stored at refrigerated temperatures449,450,452 however,
Antonenas et al found no difference in CD34+ cells over 72 hours between storage at 4◦C
or room temperature.453 PBSC samples are reported to have higher cell viabilities when
stored at cooler temperatures.453,455,457 As discussed in Chapter three the effects of two
different storage temperatures (refrigerated temperatures, 4-8◦C and room temperature,
19-22◦C) were assessed on fresh CB, PBSC and BM and the effects these temperatures
had prior to cryopreservation. Viable CD45+ (assessed by exclusion of 7AAD+ cells)
and CD34+ cell (assessed using 7AAD and Annexin V) in addition to CFU recoveries
were assessed. Higher recoveries were noted in samples maintained at refrigerated com-
pared to room temperature with significant differences observed in CD45+7AAD− cell
recovery after 72 hours in CB and PBSC; in CD34+7AAD− after 48 hours in CB and
72 hours in PBSC and BM; and significant differences in CFU recovery after 48 hours
in CB and BM.
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As refrigerated temperatures were found to be optimal for maintaining viable and func-
tional cells, the effect of fresh storage time and delaying cryopreservation was analysed
for samples stored at this temperature for up to 72 hours. Continuous reductions in
viable cell and CFU recoveries were observed in the HPC samples as time progressed.
Compared to t=0, pre-freeze analysis of CB samples showed significant reductions after
24 hours in CD34+7AAD− cells and after 48 hours in CFU recovery. Significant losses
in viable CD45+ and CD34+ cells were observed after 48 hours of fresh storage of PBSC.
BM samples also lost significant numbers of viable CD34+ and CFU after 48 hours.
Post-thaw analysis highlighted a loss in viable and functional cells when cryopreserva-
tion was delayed. For CB samples significant losses were observed, compared to cryop-
reservation at t=0, when freezing had been delayed for 48 hours in CFU recovery and
in CD34+7AAD− cells after 72 hours. This is in agreement with studies reported by
Campos et al438 and Hubel et al442–444 who report that cryopreservation of CB can be
delayed for 24 hours with minimal losses in progenitor cells but refutes other studies in
which no significant losses were observed for as long as 72 hours.441,446,447 Significant
post-thaw losses were observed in viable CD34+ cells and CFUs after 48 hours in PBSC
samples contradicting other groups who report PBSC samples maintained viable cell
and CFU recoveries for as long as 72 hours after collection.454,455 In the assessment of
BM samples, significant losses in post-thaw CFU recovery were observed after a 24 hour
delay to cryopreservation with viable CD45 and CD34 losses not observed until a delay
of 72 hours.
Based on these data, samples sent to the ANCTC are now maintained in a cooled
environment within the temperature range of 2◦C to 15◦C. If this temperature range
is not met during transportation, samples are processed as normal but with additional
viability tests post-thaw to ensure the cells maintained an acceptable level of potency.
The ANCTC aims to process and cryopreserve all CB units designated for HSCT banking
within 24 hours of collection. However, this is not always possible as samples are collected
24 hours a day but to avoid high costs, courier runs between the maternity and ANCTC
occur once a day. Therefore, to avoid the CFU losses observed after 48 hours ANCTC
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has set a maximum time for cryopreservation to 36 hours after collection; samples that
cannot be cryopreserved within this timeframe can still be stored in the Biobank.
The isolation of CBMCs is often the first step in many experiments and when isolating
pure cell populations. The Biobank aims to store some CB samples as CBMC frac-
tions, therefore, the second area of investigation was to optimise the CBMC isolation
protocol employed at ANCTC. A common procedure for isolating CBMCs is through
the Ficoll Density Gradient Method (ficoll).467–469 This involves layering blood over
ficoll, a polysaccharide with a specific density, followed by centrifugation resulting in
the separating of different fractions of the blood according to their density. This is a
time consuming process with low reproducibility and high user variability. Biosafe, the
company that produces the SEPAX machines routinely used at the ANCTC to reduce
the volume of CB samples designated for HSCT banking, developed a program (eMNC)
on the SEPAX device with the aim of isolating CBMCs and replacing the ficoll protocol.
This new protocol would separate the CBMC cells based on their density through cen-
trifugation without the need to add density gradient media. The eMNC protocol is fully
automated, therefore, the low reproducibility and high user variability associated with
ficoll should be reduced whilst freeing the technician to perform other duties. Another
potential advantage of this new method is a reduced risk of contamination as the sepa-
ration is performed within a sealed sterile tubing set without the need to add exogenous
material such as the density gradient media. As part of a collaboration with Biosafe
the cell fractions obtained from this new protocol were compared with ficoll-derived
CBMCs to assess if this method can be optimised and become a replacement for ficoll
based isolations. Three different versions of the eMNC program were assessed. Com-
pared to ficoll-derived CBMCs the cell products had similar mononuclear cell recoveries
but lower levels of granulocyte and erythrocyte depletion. Isolation using ficoll separates
cells due to their density with larger granulocytes and aggregated erythrocytes falling
below the layer of ficoll whilst the cells of interest remain above the density gradient me-
dia. As the eMNC does not have this layer of ficoll, the cells of interest remain directly
on top of the unwanted denser cells, this makes it difficult to remove the CBMCs whilst
avoiding contaminating cells. Low granulocyte depletion led to reduced post-thaw via-
bilities when cryopreserving the cell fractions isolated using eMNC. CBMC enrichment
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is often the first step taken when isolating pure cell populations, therefore, the ability to
isolate CD133+ cells from eMNC and ficoll products were compared. The CD133 frac-
tion isolated from the eMNC-derived CBMC samples had lower cell recoveries, purity
and viabilities. This was due to difficulties during the isolation such as formation of a
loose pellets after centrifugation and trapping other cells within the separation column
resulting from the contaminating erythrocytes. Therefore, despite attempts by Biosafe
to optimise the program, the eMNC cellular products were inferior to those using ficoll.
As the new protocol was not found to be a suitable replacement to the ficoll method,
Biosafe decided to discontinue the development of this program.
As the ficoll procedure remains the most efficient method of isolating CBMCs at the AN-
CTC, attempts were made to further optimise the process. The first of which assessed if
it was necessary to dilute the blood prior to layering over ficoll. This is often performed
to reduce the density of the blood and cell concentration facilitating the layering step and
preventing mononuclear cells from becoming trapped amongst the aggregating erythro-
cytes.469 Lower levels of granulocyte depletion were observed when samples were diluted
prior to separation. Therefore, leaving samples undiluted was beneficial to CBMC iso-
lation whilst also reducing the number of tubes required, making the process quicker to
perform and more economical. The ficoll process performed at ANCTC uses standard
50ml conical bottom tubes, specialised tubes have been developed to facilitate the ficoll
procedure such as the Leucosep and Sepmate tubes. These tubes have a physical barrier
separating the ficoll from the blood allowing easier layering and removal of the desired
cellular fraction post-centrifugation. The CBMC products obtained when using these
two tubes were tested against that from the standard tube without the barrier. The
CBMC product obtained from the standard tube had lower levels of granulocyte con-
tamination than the Leucosep tubes and higher mononuclear cell recoveries compared
to the SepMate tubes. Therefore, the optimal ficoll procedure for CBMC isolation from
involves undiluted CB with the use of the more economical standard tubes.
The Biobank involves cryopreservation and potentially long term storage of CB frac-
tions until they are required. Therefore, the third stage of the Biobank development,
as described in Chapter 5, was to improve on the methods used during the freezing
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and thawing of the cells. Cryopreservation of cells requires a cryoprotectant to prevent
damage to the membrane through the formation of ice crystals and changes in osmotic
pressure.101 Dimethyl sulphoxide (DMSO) is commonly used as a cryoprotectant when
freezing the different sources of HSCs and can be used at a range of concentrations from
2.2 to 20%.102 Higher concentrations may increase the cryoprotective effect,148 however,
there is conflicting evidence as to whether DMSO is toxic to cells122 or not.123,124 In
this study the toxicity of DMSO was assessed at three different stages of cryopreser-
vation: when added to fresh CB, if freezing is delayed after DMSO addition and in
post-thaw samples. A dose dependant toxicity of DMSO to fresh CB cells was observed
with the addition of 40% removing almost all viable and functional cells immediately
after addition. Possible mechanisms of DMSO toxicity include the denaturation of pro-
teins caused by hydrogen bond formation with the cryoprotectant127,128 or through the
induction of apoptosis by interacting with programmed cell death receptors and their
ligands.125,126 However, losses of viable cells may also be due to the exothermic reac-
tion between DMSO and water, a large increase in temperature was noted when high
concentrations were added despite attempts to maintain cells at 4◦C. The addition of
DMSO to a final concentration of 10% (v/v) was not found to have any significant ef-
fects on cell viability or functional abilities for up to 2 hours in fresh CBMC samples
or post-thaw when freezing had been delayed for up to 1 hour after addition of the
cryoprotectant. This furthers the studies by Rowley et al who report HPCs can tolerate
10% (v/v) DMSO for up to an hour123 but disagrees with Douay et al who found signif-
icantly reduced CFU recoveries after 30 minutes of exposure.122 In order to reduce any
toxic effects of DMSO, it has been suggested to maintain samples at refrigerated tem-
peratures.55,122 However, in this study no significant differences were observed between
CBMC samples with 10% (v/v) DMSO stored at refrigerated or room temperature for
up to 24 hours. Post-thaw DMSO is commonly washed from samples to avoid its toxic
effects to cells already weakened by the cryopreservation process.55,105–107,161 However,
washing cells can be time consuming and can result in poor cell recoveries as clumping
can occur during centrifugation.55,155,159 To prevent this, DNase is often added to the
wash buffers.148,160,161 Within this study washing CBMC samples post-thaw resulted
in an average loss of 13.7% CD45+ cells. Once these losses had been taken into account,
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CBMC samples that were un-manipulated post-thaw and remained in 10% (v/v) DMSO,
resulted in significant reductions in CFUs after one hour. These losses occurred at a
faster rate than reported by Regan et al who observe the recovery of CFUs to be stable
for up to 2 hours after thawing.510 However, a recent study by Huang et al reports
significant CFU losses occurred as soon as 30 minutes post-thaw.511 Dilution of thawed
CBMC samples, reducing the DMSO concentration to 5% prevented significant CFU
losses until 24 hours whereas the complete removal of DMSO delayed the observation of
significant CFU losses until 48 hours post-thaw.
A wide range of DMSO concentrations are used to cryopreserved HSCs for transplanta-
tion (from 2.2 to 20%) with 10% the most commonly used.102 As DMSO has been shown
to be toxic to cells as well as patients105–107 in a dose related manner, various studies
suggest lowering the concentrations to 5%.140–142 However, lowering concentrations will
also have an effect on the ability to cryopreserve viable cells and CFUs. Despite minimal
cell toxicity observed at DMSO concentrations of 10%, the effect of further reducing the
concentration was assessed. Although 5% has been reported to be an alternative concen-
tration when cryopreserving CB,140 significantly reduced viable CD45+ and CD34+ cell
recoveries were observed in this study. The optimum DMSO concentration was found
to be within the range of 7.5% to 10%. This range of DMSO concentrations has also
been reported to be optimal for the cryopreservation of PBSC samples.147
Previously, only an observation from preliminary experiments had been reported stating
that 1% (w/v) dextran-40 in combination with 10% (v/v) DMSO results in a moder-
ate improvement in post-thaw leucocyte viability,55 however this data has never been
published. Based on this statement, many CB banks have added dextran-40 to their
cryoprotective solutions. This study is the first to show that the presence of dextran-
40 not only results in an increase in leucocyte viability but also better preserves the
viability and potency of CD34+ HPCs. This study has also confirmed that 1% (w/v)
dextran-40 is the optimal concentration when cryopreserving CB cells in 10% DMSO.
The Biobank requires the ability to store pure cell fractions isolated from CB. For
the purposes of this study regulatory T cells (Tregs) were chosen. These cells play
a vital role in maintaining homeostasis of the immune system through the promotion
Chapter 7 Discussion 184
of immunological tolerance.243–247 Due to their immuno-suppressive capabilities, these
cells have the potential to be used therapeutically to prevent unwanted immunological
reactions such as in autoimmune diseases389 and allogeneic transplants.404,417
Isolation strategies for Tregs are often based on their expression of the α chain of the
IL-2 receptor (CD25). This marker is also upregulated in activated and memory T cell
populations. Therefore, adult peripheral blood (PB) samples contain a high frequency
of CD25+ cells but only those expressing the highest levels co-express FoxP3 and can
be considered regulatory. This leads to a practical problem when isolating Tregs from
PB as further isolation steps are required to remove the non-regulatory contaminating
CD25int cells. CB cells have been shown, in this study and others,483,512 to have a more
defined CD25+ regulatory population due to the decreased opportunity for CB T cells
to become activated through encountering antigens. This allows for easier isolation of
these cells however, it has been suggested that CB-derived Tregs are not mature enough
to be suppressive.513 Therefore, when assessing the feasibility of banking CB Tregs at
ANCTC, the first aim is to compare these cells against their adult counterparts to ensure
they possess a regulatory phenotype and function.
The frequency of Tregs (identified with the phenotype CD25+FoxP3+CD127low) within
CD4+ T cells was compared between CB and PB samples. Higher levels of 5.67% of CB
CD4+ cells co-expressed the Treg markers compared to 2.33% in PB. This is in agreement
with Wing et al and Godfreyet al who also observed higher frequencies within CB.483,512
CB and PB Tregs were compared for expression of antigens associated with suppressive
cell function. Differences were observed in the expression of CCR4, which is involved
with homing of cells to non-lymphoid tissues. Higher levels of CCR4 expression were
observed in PB Tregs compared to CB cells (p=0.0002). Expression of this marker has
been linked to the activation status of a cell and memory cells, expressing CD45RO+,
tend to have higher levels of this homing marker.319,321 Since PB Tregs have been shown
to be predominantly CD45RO+514 this could account for their increased levels of CCR4
compared to CB cells which instead possess a na¨ıve CD45RA+ phenotype.483
Differences in CD39 expression were also observed between CB and PB Tregs with higher
levels found in adult cells (p=0.0015). This marker has been linked to the suppressive
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function of Tregs through the conversion of pro-inflammatory extracellular ATP into
AMP.290,295 As with CCR4 this marker has been linked to a memory phenotype of
CD45RO, CCR6 and HLA-DR299 which could explain why lower levels were observed
in CB Tregs. In order to assess if this marker played a regulatory role in CB Tregs,
the CD39+ and CD39− subpopulations were isolated from CD25+ CB samples. Higher
intensity of FoxP3 expression was observed in the CD39+ subpopulation along with
higher levels of suppression (p=0.0341 at a Treg:CD25− ratio of 1:1). This confirms
that CD39 is linked to the suppressive function of CB Tregs.
The immuno-suppressive capabilities of Tregs isolated from CB and PB sources were
compared. Cells from both sources were found to be anergic when stimulated with anti-
CD3 and anti-CD28, confirming the observations made by other groups.236,359 When
co-cultured with stimulated CD25− cells, PB Tregs were found to be more efficient
at suppressing proliferation (although differences were not found to be significant). As
previously mentioned, lower intensity of FoxP3 and lower levels of CD39 expression were
observed in CB Tregs. These two markers are linked with regulatory function and could,
in part, explain why CB Tregs showed lower levels of suppression.
Despite their lower levels of suppression compared to PB Tregs, CB cells are still an at-
tractive cellular population for the Biobank due to their higher frequency within CD4+
cells and more defined CD25 population. As Tregs are isolated based on CD25 ex-
pression, separation from CBMCs can be achieved in a single CD25 enrichment step429
as opposed to the problems with contaminating activated and memory CD25+ cells
when isolating from adult sources which require further isolation steps to be removed.419
Within this study, three different isolation techniques were compared; flow cytometric
cell sorting and two MACS methods (MBio and SCT). A comparison of the two MACS
methods resulted in lower yields for MBio (p=0.0087) however, the cells isolated had
higher levels of purity (p=0.03) and suppressive capabilities (p=0.0028). Isolation of
CD25 using flow cytometric cell sorting resulted in cells with equally high levels of pu-
rity compared to the MBio protocol but these cells had higher suppressive capabilities
despite lower viabilities. To avoid extended sorting times which can reduce viabilities
further, CD4+ cells were isolated from CBMCs prior to flow cytometric cell sorting
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CD25+ cell separation. Therefore, although these isolated Tregs had higher levels of
suppression than those isolated using MBio, it was decided that this MACS method was
the most efficient. An alternative Treg isolation approach is through the depletion of
CD49d+ and CD127+ cells from a CD4+ enriched population.515 This leads to the isola-
tion of ‘untouched’ Tregs which would be desirable for immunotherapeutic applications.
This isolation strategy was not assessed during this study but should be considered in
future investigations at ANCTC.
Two strategies for banking Tregs were assessed; cryopreservation and banking of isolated
pure population or banking of CBMCs with a view to isolate the cells of interest post-
thaw. Cryopreserving isolated Tregs resulted in high cell recovery post-thaw. However,
a reduction in viability led to reduced suppressive ability compared to pre-freeze assess-
ment (p=0.0313). The assessment of the effects of cryopreservation on Tregs could be
furthered by assessing if the mechanism of suppression changes post-thaw through tran-
swell assays or blocking cytokines. The cryopreservation of adult mononuclear cells has
been shown to result in a significant reduction of Treg frequency in CD4+ T cells post-
thaw.425 However, only a slight reduction was observed when cryopreserving CBMCs
(reduced from 3.94% pre-freeze to 3.01% post-thaw). As the loss during CBMC cryop-
reservation was low, the ability to isolate Tregs post-thaw was assessed. CD25+ cells
were isolated from thawed CBMCs with similar purities to those observed during fresh
isolations. Higher viabilities and suppressive capabilities were observed compared to
post-thaw pure CD25+ pops (p=0.0012 at a Treg:CD25− ratio of 1:2). Therefore, the
most efficient banking procedure for Tregs was found to be through the cryopreservation
and storage of CBMCs with the cells of interest isolated post-thaw.
For their use in therapeutic applications Tregs would need to be isolated under GMP
grade conditions. Therefore, the two banking options were assessed using CE marked
reagents and a CliniMACS cell separation device. The fresh isolation of Tregs using
the CliniMACS resulted in product with lower levels of purity compared to research
grade MBio protocol but these cells were found to be equally suppressive. As observed
in the research grade isolations, cryopreservation of these cells led to lower post-thaw
viabilities and suppressive capabilities compared to cells isolated from thawed CBMCs.
Chapter 7 Discussion 187
Therefore, Tregs can be stored within the CBMC fraction in the Biobank and isolated
post-thaw using research or GMP grade protocols resulting in a cell product with high
purity, viability and suppressive abilities.
For their use therapeutically, large numbers of Tregs would be required. As only a
small number can be obtained from an individual CB unit, to reach the doses required
these cells are often expanded using anti-CD3, anti-CD28 and high doses of IL-2. Tregs
are capable of expansion after cryopreservation, as demonstrated by Peters et al who
restored the suppressive activity of post-thaw PB cells.419 Therefore, assessing the
ability to expand post-thaw CB-derived Tregs or to cryopreserve expanded cells whilst
ensuring the cells maintain suppressive phenotype and activity could be assessed at
ANCTC.
7.1 Further work
In this study Tregs were focussed upon when considering banking of specific cell pop-
ulation. However, the Biobank would require the storage of different cell populations
found within CB, for instance HPCs and natural killer (NK) cells.
The potential to bank HPCs was touched upon in Chapter 4 when CD133 cells were iso-
lated from CBMCs resulting in purities of 88.98%. However, the effect of cryopreserving
these cells was not assessed in this study.
NK cells are cytotoxic lymphocytes, which form part of the innate immune system,
responding rapidly to virally infected and tumour cells. These cells are defined as
CD3−CD56+ cells and comprise 15-30% of lymphocytes in CB.516,517 These cells were
named natural killer as it was initially believed that they did not require activation
to become functional.518 These cells recognise tumour and infected cells through dif-
ferent mechanisms such as the down regulation of MHC class I molecules on target
cells519 or the upregulation of NKG2D ligands on distressed cells.520 NK cells mediate
their cytotoxic effects through the release of cytoplasmic granules, such as perforin and
granzymes521 or are able to mediate apoptosis through the death receptor.522 NK cells
also recruit other immune cells through the secretion of cytokines such as IFN-γ and
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TNF-α.523 Due to the increase in incidence of tumour resistance to drugs and radiation
therapy, investigations into the use of immunotherapies are increasing. NK cells have
been shown to kill leukaemia cells ex vivo524 and are believed to be the main effector cell
of the graft-versus-leukaemia (GvL) effect observed post-HSCT. Current clinical trials
involving NK cells are assessing the tolerable does (from 1×106 to 1×108 cells) that can
be administered after HSCT525,526 whilst assessing any improvement in the GvL and
graft-versus-host-disease (GvHD) effect.527 These cells can be isolated through positive
selection of CD56 cells or preferentially untouched NK cells can be obtained through
the depletion of T cells, B cells, dendritic cells, stem cells, monocytes, granulocytes and
erythroid cells using a cocktail of magnetic bead-labelled antibodies.
7.2 Concluding remarks
In summary, this study has laid the foundations for the creation of a Biobank at AN-
CTC. This has been achieved by optimising the different stages of the banking process,
starting with the effects of transport conditions and delaying cryopreservation. No other
study has evaluated all three sources of HPCs in the same lab, with the same quality
variables. This is becoming increasingly important as more centralised facilities for cell
processing are being developed. Within this study, it was observed that HPC products
are better maintained at refrigerated temperatures prior to cryopreservation, as well as
highlighting the importance of minimising delays to freezing in order to avoid losses in
cell potency. Cryopreservation is an important part of biobanking and allows the long
term storage of cells. However, suboptimal cryopreservation techniques can result in
a loss of cell viability and functionality. This study assessed the toxic effects of the
cryoprotectant DMSO at different stages of cryopreservation and it was observed that
when handled correctly the detrimental effects of DMSO to the cells can be minimised
allowing high post-thaw recovery of potent cells. In addition, this is the first study to
show that the presence of 1% (w/v) dextran-40 in the cryoprotectant solution is crucial
to maintaining CB cell potency post-thaw. Finally, Tregs were chosen to assess the
ability of the Biobank to store specific cell populations. Comparing CB Tregs to their
adult counterparts, a reduced suppressive ability was observed in CB cells which also
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exhibited decreased FoxP3 intensity and lower levels of CD39 expression. However, a
higher frequency of Tregs was noted in CB samples with fewer contaminating CD25+
non-Treg cells facilitating the isolation process. Two banking strategies were assessed,
the more efficient protocol was found to be isolating Tregs from banked CBMCs rather
than banking pure Treg populations. These banking processes were adapted to be-
come GMP compliant allowing distribution of these cell products not only for research
purposes but also potentially for their use in immunotherapeutic interventions.
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